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There is a considerable body of evidence to suggest that osteoporosis is the index 
disease of calcium deficiency, in both humans and animals. In addition, menopause 
or oophorectomy has been shown to affect bone metabolism such that a rise in the 
rate of bone resorption leads to post-menopausal osteoporosis. If this is the case 
then increasing dietary calcium intake or supplementation with calcium will result 
in reducing the incidence of osteoporosis in post-menopausal women. The current 
study was conducted to investigate the relationship between habitual calcium intake 
and the rate of bone loss in post-menopausal women.  
 
Volunteers were recruited from the community to participate in a 2 year prospective 
study. A validated self-administered questionnaire was used to estimate total daily 
calcium intake in the subjects. Subjects were divided into tertiles according to 
calcium intakes. Six monthly bone density scans were performed of the lumbar 
spine, hip and forearm and the rate of decline in bone density for each site was 
calculated. Biochemical markers of bone metabolism at baseline were measured. 
 
The mean calcium intake was 1114 mg/d (300 – 2589mg/d). Only 10% of the 
women met their recommended daily intake (RDI) of calcium from their diet alone. 
When calcium supplements were considered (42% were taking supplements) 31% 
of women met their RDI. About 84% had serum 25OHD levels >50 nmol/L. Serum 
PTH was related to calcium intake, C-terminal telopeptides (CTX) and age. 
Although the relationship between serum PTH and 25OHD was not significant, 
PTH and CTX tended to be higher in those with low serum 25OHD within each 
tertile of calcium intake. In addition, women with lower calcium intake were 
heavier, while an inverse relationship was observed between 25OHD and fasting 
glucose. 
 
The prevalence of osteoporosis in the study group was much lower than that reported 
in previous surveys in Australian post-menopausal women, however, is consistent 
with the prevalence reported in health statistics for the wider community. The rate of 
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loss of bone density at the ultradistal forearm fell significantly in women on lower 
calcium diets compared to higher calcium diets although no significant relationship 
was demonstrated between the rate of bone loss at the lumbar spine or the hip and 
calcium intake. This significant relationship at the ultradistal forearm site may be 
because of the greater proportion of trabecular bone at this site. 
 
Feedback on the bone density result was given to the subjects immediately after the 
baseline bone density measurement. The change in calcium intake after 12 months 
for women with osteoporosis or osteopenia was not significant suggesting that the 
feedback on bone density did not have an impact on dietary intakes or habits. 
 
The acute biochemical effects of calcium supplementation with or without vitamin D 
were examined in a group of vitamin D deficient women (serum 25OHD <50 
nmol/L). Suppression of PTH and CTX was more effective when calcium was given 
with vitamin D. When the acute biochemical effects of calcium carbonate and citrate 
supplements were compared, citrate was found to be more effective than carbonate in 
suppressing bone resorption markers. 
 
Women with metabolic syndrome appear to be able to respond more favourably to a 
higher dietary calcium content that those without the metabolic syndrome.  
 
The findings of this study confirm that calcium intake, even in a relatively healthy 
and health conscious cohort of postmenopausal women is linked to the rate of bone 
loss, at least in trabecular bone (ultradistal forearm). However the influence of 
calcium intake on the bone density at other sites may be influenced by a myriad of 
other metabolic and endocrine factors, including metabolic syndrome. Data from this 
study confirm a probable link between energy and bone mineral metabolism. This 
knowledge may be harnessed to exploit the potential of adequate dietary calcium to 
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Osteoporosis is the most prevalent metabolic bone disease in the developed world. 
With an aging population, the impact of osteoporosis and resultant fractures is 
expected to rise throughout the world. Osteoporotic fractures increase with age with 
at least a two-fold higher incidence among women compared to men for all age-
related fracture sites.  
 
1.1 The costs and burden of osteoporosis 
 
The social and economic burden of osteoporosis and consequent fractures is 
increasing worldwide. In the USA, it was estimated that in 2004 more than 10 million 
individuals suffered from osteoporosis (1). This number is expected to rise with each 
year. There were 692,000 Australians, 3.4% of the population, diagnosed with 
osteoporosis in 2007-08, and 89% of these were women (2). However, osteoporosis 
remains the most undetected and under treated national health priority in Australia 
accounting for only 0.6% of conditions managed by general practitioners (GPs) (3). 
Between the periods 1998-99 to 2007-08, the rate of advice from GPs for over the 
counter medication increased from 1% of osteoporosis related problems to 10% (3). 
This is likely to be due to the availability and promotion of calcium and vitamin D 
supplements. 
 
According to Osteoporosis Australia’s latest report, an estimated 4.7 million 
Australians over the age of 50 currently have osteoporosis or osteopenia, with 
associated 144,000 fragility fractures in 2013 (4) This has been equated to one 
fracture every 3.6 minutes in Australia. Although the rate of osteoporotic fractures 
were estimated to rise by another 30% by 2022 (equating to one fracture every 2.9 
minutes) with an estimated cost of $33 billion (4) more recent data suggest that the 
rate of hip fractures is decreasing in the developed world (5,6,7) and this is likely to 
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reduce the estimated future fracture rates and associated costs, however, no such data 
is available for fractures at other sites. 
 
Re-fracture following an initial osteoporotic fracture, especially in the first 5 to 10 
years has been recognised as an important contributing factor to excess mortality 
observed in both men and women with osteoporosis (8). Of men and women 
followed up for over 20 years by the Dubbo Osteoporosis Study, the rates of re-
fracture within the initial 5 years of a fragility fracture were 24% for women and 
20% for men. Mortality rates were higher for those who re-fractured (50% for 
women and 75% for men) compared to those fracture-free (26% for women and 37% 
for men) (8). Therefore prevention of osteoporosis and fractures will have a 
significant impact not only on the quality of life but on reducing premature death in 
both men and women.  
 
It is clear that while primary prevention of osteoporosis and fracture is an important 
aspect of community and public health, the secondary prevention of fracture deserves 
equal if not more attention. All fracture patients present to tertiary hospitals, and 
elderly patients especially with hip fractures require surgery and hospitalisation, 
providing an opportunity to enrol them in a falls and future fracture prevention 
program. To this end, the International Osteoporosis Federation has implemented a 
program to prevent secondary fractures worldwide (‘Capture the Fracture’) (9). The 
program facilitates the implementation of Fracture Liaison Services within local 
health networks. The program has been well received globally, including the 
Australia. The Australian and New Zealand Hip Fracture Registry produced Hip 
Fracture Guidelines for the initial care as well as post-discharge implementation of 
strategies aimed at secondary prevention of fractures (10). The Royal Adelaide 
Hospital and Flinders Medical Centre uses a Falls Risk Assessment Tool on all 
patients admitted with hip and other fractures and a Post-Discharge Assessment is 
performed to implement a multidisciplinary care plan and community involvement in 
future fracture prevention, via a Fracture Liaison Service run by the Statewide 
Orthopaedic Clinical Network (11).  Other examples of local care models include the 
NSW Model of Care (12) and WA Osteoporosis Model of Care (13).   
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In addition, the education of the public and raising awareness of adequate calcium 
intake is likely to contribute to preventing osteoporosis and fractures. The recently 
launched Calcium Calculator by the International Osteoporosis Foundation is an 
application that can be downloaded to a smart phone or used on the website to 
calculate daily calcium intake based on a typical weekly intake (14). The application 
is user-friendly, takes only a few minutes to complete and includes several ethnic and 
‘new’ food items (kale, naan bread, rice milk, almond milk) that are not mentioned in 
traditional questionnaires. Globally, recent publications bear evidence for the success 
of secondary fracture prevention programs (15,16). 
 
In addition to the disease burden and the cost on quality of life, the economic burden 
due to osteoporotic fractures is a significant proportion of the National Health 
Budget. In 2012 the total of osteoporosis and related fractures was $2.75 billion and 
the total cost from 2013 to 2022 is estimated to be $33 billion (4). Therefore the 
prevention of osteoporosis and its consequent fractures is a major public health 
priority. 
 
1.2 Aetiology of osteoporosis 
 
Osteoporosis is a heterogeneous disorder with a multifactorial aetiology.  Age and 
oestrogen deficiency at the menopause have been shown to play major etiologic 
roles. Other factors include hereditary predisposition, nutrition, medication such as 
glucocorticoids, age-associated oxidative stress (17) and limited physical activity or 
mechanical loading as well as chronic inflammatory status (18,19). This review will 
be restricted to age, oestrogen deficiency and nutritional factors in the causation of 
osteoporosis. However, the multiple aetiologies of osteoporosis are acknowledged, 
but a discussion of all factors is beyond the scope of this review.  
 
1.2.1. Nutritional factors 
Nutrition plays a central role in the pathogenesis, prevention and treatment of 
osteoporosis (20). Calcium homeostasis is the major nutritional factor in maintaining 
the skeleton; however, numerous other nutrients that contribute to bone health have 
come to light. Food and Nutrition Board of the Institutes of Medicine have nominated 
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calcium, phosphorous, vitamin D, magnesium and fluoride as bone-related nutrients. 
The index disease associated with the deficiency in any of these nutrients is primarily 
a bone disease (21). Although in the past the recommended intakes of these nutrients 
were calculated on the basis of the minimum amount needed to prevent the index 
disease, the reference intakes took into account the amounts needed to prevent 
chronic disease and promote public health benefit (22). 
 
The fact that numerous other nutrients are involved in maintaining bone health has 
been used to explain the inconsistencies between results of calcium and vitamin D 
intervention trials (23). Other nutrients that have been emphasised are vitamins C, K 
and B, potassium and carotenoids. The role of protein has been contentious, with 
proponents arguing the need for greater protein intakes in the elderly to maintain 
bone structure (23), and opponents arguing the fact that the greater acidic load 
introduced through animal protein may lead to a loss of calcium (24) and in turn, loss 
of bone mass. However a more recent longitudinal population bases study suggests 
that a high level of dietary protein intake, within the range commonly consumed does 
not result in bone loss in older people (25).   
 
Bone loss has been attributed to regular intakes of caffeine and cola drinks (26) while 
consumption of alcoholic beverages may have an inconsistent effect on bone (27).  
Chronic alcoholism has been identified as an independent risk factor for osteoporosis, 
associated with a 2.8-fold increase in the risk of hip fractures (28,29) and lower bone 
density (30,31,32) but these conclusions were drawn from small studies on men 
whose regular intake of alcohol was more than 27 units/day for up to 24 years. Other 
studies suggest that moderate alcohol use may decrease fracture rates and increase 
bone density (33,34). In the Framingham cohort, women who consumed 7 oz (207 
ml) per week or more had higher BMD at all sites compared to those who drank less 
than 1 oz (30 ml) per week, when averaged over 20 years (34). However, re-analysis 
of the data failed to show this relationship with current rates of alcohol consumption 
(35). A more recent meta-analysis suggests that those who consume 0.5 to 1.0 
standard drinks per day have a lower risk of hip fracture; however a precise range of 




1.2.1.1 Calcium and bone health 
 
Bone acts as a reserve store of calcium which can be given up when needed. 
Insufficient dietary calcium intakes can lead to bone resorption to provide calcium 
resulting in a fall in bone mass and density. Any fall in extracellular calcium 
concentration leads to the secretion of parathyroid hormone, which increases bone 
resorption to release calcium. External calcium balance is determined by the relation 
between calcium intake and absorption and the losses of calcium through the skin, 
kidney and bowel.  
 
Therefore the calcium economy is a dynamic state influenced by fluxes in dietary 
calcium intake, intestinal calcium absorption, renal calcium reabsorption and bone 
resorption. Other nutrients interact with calcium and affect the calcium economy in a 
positive or a negative manner.  
 
1.2.1.2 Vitamin D 
 
Vitamin D is considered an important nutritional factor in the prevention of 
osteoporosis by consumer groups such as Osteoporosis Australia (AO) (37) and 
professional groups such as International Osteoporosis Federation (IOF) (38). One in 
four (23%, 4 million) Australians are reported to be vitamin D deficient (serum 
25OHD <50 nmol/L) in the National Health Measures Survey 2011-2012, report 
released in April 2014 (39). Seasonal variation in the level of sunlight exposure 
results in a variation of serum 25OHD. In South Australia, the rate of vitamin D 
deficiency is 15% in summer and 42% in winter (39).  
 
Vitamin D has a clear and established effect on calcium and phosphate homeostasis 
(40). It appears that vitamin D can be implicated not only in bone health but muscle 
function (41). Evidence suggests that vitamin D is an independent predictor of falls in 
the elderly (41,42,43) presumably due to impaired balance and muscle weakness as a 




In older adults, supplementation of vitamin D has been shown to attenuate secondary 
hyperparathyroidism (44,45). The lower PTH is associated with reduced bone 
turnover (45,46) and increased BMD (47). When calcium was added to vitamin D 
supplementation the reduction in PTH was greater than with vitamin D alone (44). To 
suppress bone resorption, as demonstrated by a significant reduction in bone 
resorption markers, however, supplemental calcium is required in addition to vitamin 
D, in both vitamin D sufficient (47) and vitamin D deficient (48) postmenopausal 
women.  Furthermore supplementation of calcium with vitamin D reduces the 
incidence of fractures in the elderly (49,50,51,52). In a study in 1586 community 
dwelling subjects 65 to 71 years of age, supplementation with 800 IU of 
cholecalciferol and 1000 mg of calcium carbonate over 3 years reduced the rate of 
any fracture by 17%, non-vertebral fracture by 13% and distal forearm fracture by 
30% but did not reduce the rate of lower extremity fractures (52). None of the 
fracture reduction rates in this study reached statistical significance.  However in a 
meta-analysis of 29 studies, calcium supplementation significantly reduced fracture 
rates but adding at least 800 IU of vitamin D to the supplement reduced the fracture 
rates even further (51).   
 
The DIPART study also showed a significant reduction in hip fracture risk when 
vitamin D was added (53).  In this study, pooled data from 68,500 patients 
demonstrated that when 10ug of vitamin D was added to the calcium supplement, the 
hazard ratios for any facture and hip fracture were 0.92 (0.86 – 0.99) and 0.84 (0.70 – 
1.01) respectively. Doubling the vitamin D dose had no significant effect on the 
fracture rates. Their analysis also showed that supplementation with vitamin D alone 
was not effective in fracture reduction further validating the need for both calcium 
and vitamin D to prevent fractures (53,54). 
 
While there has been no demonstrable benefit from vitamin D supplementation alone, 
using calcium and vitamin D together has been shown to reduce the fracture risk over 
and above that provided by calcium alone. The variable or inconsistent results 
obtained by various studies may be partly due to the pooling of data of heterogeneous 
groups of patients.  It appears that, individuals with documented osteoporosis, at risk 
of osteoporosis or vitamin D deficiency may benefit more from supplementation with 
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calcium with or without vitamin D than community dwelling individuals without 
these characteristics (55). The recommended serum 25OHD level in Australian adults 
is ≥ 50 nmol/L at the end of winter and 10 – 20 nmol/L higher at the end of summer 
(54) for optimal musculoskeletal health.  
 
1.2.2. Age 
After the age of 60 years in men and after the menopause in women, there is 
progressive loss of bone, at the rate of about 0.5% pa in men and 1% pa in women. 
This is due to a rise in bone resorption in women and a fall in bone formation in men 
possibly secondary to a fall in androgens. The different mechanisms involved in the 
bone loss in men and women are reflected by histomorphomotric features of 
trabecular bone. In older men, the trabeculae are generally thinner, while in older 
women the trabeculae are less in number, suggesting a total removal of trabeculae 
(56). However, the proposed ‘unitary model of estrogen deficiency’ suggests that, in 
both men and women, the mechanism underlying osteoporosis is estrogen deficiency 
(57). 
 
The age related component of bone loss is associated with a decline in the number of 
osteoblasts present in the bone multicellular unit (BMU) (58). The number of 
osteoblasts in the BMU is a function of the generation of new osteoblasts from local 
progenitor cells and the life span of mature osteoblasts. Osteoblasts are generated 
from multipotential mesenchymal stem cells. With age, the self- renewal capacity of 
mesenchymal stem cells decline,  leading to reduced numbers of osteoblasts, and 
more mesenchymal cells being diverted to the adipocyte lineage (59). 
 
There is both a menopausal and age related decline in intestinal calcium absorption. 
It has been reported that Ca absorption decreases at the menopause with further 
decline with advancing age (60). This is not related to vitamin D status; there is an 
apparent decrease in gastrointestinal responsiveness to 1,25(OH)2D in these subjects 
(61). In aged rats (24 months), immunofluorescence and Western blot studies have 
demonstrated a diminished number of vitamin D receptors (VDR) compared to 
young rats (3 months) (62). In addition, competition binding assays using 3H-1α 
25(OH)2D3 and 1α 25(OH)2D3 demonstrated an age related decline in ligand binding 
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to VDR in rats (62). Although this model may explain at least partly, the age related 
decline in calcium absorption, the decline in VDR numbers or ligand binding has not 
been demonstrated in human enterocytes.  
  
1.2.3. Menopause 
Bone loss in post menopausal women was thought to occur in 2 phases (63,64). Both 
these phases were shown to occur in association with a falling estrogen level (65). 
Revision of the accepted involutional theory of osteoporosis suggests that estrogen 
deficiency is the underlying cause of bone loss in all phases in menopausal women 
and the continuous phase of bone loss in aging men (57). During the first 5 to 10 
years after the menopause there is a phase of rapid bone loss (about 3% per year in 
the lumbar vertebrae) after which the loss of bone slows to about 0.5% per year (66). 
The rapid phase of bone loss may account for up to 50% of loss of spinal bone mass 
across life in women (67). This accelerated phase of bone loss during which a 
disproportionate loss of trabecular bone is demonstrated, has been attributed to the 
loss of direct effects of oestrogen on bone cell function (57). During the slow phase 
that follows, proportionate losses of trabecular and cortical bone occurs (57).   
 
There are 3 proposed mechanisms to explain bone loss in menopause. One proposes 
that oestrogen and androgens influence the lifespan of osteoblasts and osteocytes by 
altering the redox balance, and reducing oxidative stress (68). Studies in animal 
models have demonstrated a steady increase in oxidative stress in the skeleton (69). 
Reactive oxygen species (ROS) have been shown to attenuate osteoblastogenesis and 
shorten the lifespan of osteocytes, while generating functional osteoclasts, with 
resultant net bone resorption (68). Oestrogen and androgen deficiency with 
menopause and advancing age has been proposed to lead to increased ROS 
generation. Evidence proving this theory has been published in the oestrogen or 
androgen deficient murine model, whose bone resorption was reversed by the 
administration of antioxidants (68). 
 
The second proposed theory is an inflammatory milieu leading to an increased rate of 
bone resorption after the menopause (70). Oestrogen withdrawal results in an 
increase in inflammatory cytokines (IL-7 and TNF).  These cytokines inhibit the 
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activity of mature osteoblasts and increase bone resorption. The features of the 
resultant bone are those described in the rapid phase of bone loss in early menopause 
(trabecular thinning, perforation, loss of connectivity between trabeculae) (71). The 
slower phase of bone loss that follows is attributed, at least in part, to apoptosis of 
osteoblasts (70).  
 
Within the inflammatory mileu, NF-κB ligand (RANKL), a membrane protein and a 
member of the tumor necrosis factor superfamily has been recognised as a key 
osteoclastogenic cytokine and the final downstream activator that drives 
osteoclastognenesis leading to bone resorption. Osteoprotegerin (OPG) is a decoy 
receptor for RANKL and modulates its activity. Both RANKL and OPG are 
synthesised by osteoblasts. More recent data suggests that there are other sources of 
RANKL. Cells of B cell lineage isolated from postmenopausal women were shown 
to express RANKL (72). B-cell lineage cells were found to be more abundant in 
ovariectomised mice compared to sham-operated littermates (73) which suggests that 
RANKL expression may be upreguated in the absence of estrogen. Cytokines IL-7 
and TNF are proposed to induce bone loss via stimulating B and T cells to express 
RANKL, directly inducing osteoclasts and inhibition of osteoblasts generation 
(74,75).  All these mechanisms have been shown to be enhanced in ovariectomised 
mice and in gene knock-out mouse models. This may explain the inflammatory mileu 
created by estrogen deficiency in post-,menopausal women leading to net bone 
resorption.  
 
The third theory suggests that the calcium economy is disrupted in menopause, 
without the involvement of PTH. In postmenopausal women, oestrogen 
administration has been shown to lower urinary calcium excretion, lower urinary 
excretion of products of bone collagen metabolism (hydroxyproline), and lower 
serum alkaline phosphatase activity (76). These may be direct effects of oestrogen 
via bone specific oestrogen receptors on bone (discussed below) (77). Furthermore, 
oestrogen has long since thought to modulate the sensitivity of bone to PTH (78,79) 




The discovery of oestrogen receptors in the kidney (82) gave rise to the hypothesis 
that oestrogen may play a direct role in calcium reabsorption in the renal tubules. 
Thus, with oestrogen deficiency, such as following menopause, more calcium is lost 
in the urine due to inefficient reabsorption of calcium in the tubules as demonstrated 
by previous studies (83,84). 
 
Evidence suggests that calcium absorption declines at the menopause and is 
reversible with replacement of oestrogen suggesting a direct role of oestrogen in 
intestinal calcium absorption (85). Calcium absorption is regarded as the main 
determinant of calcium balance, accounting for nearly 60% of the variance in 
calcium balance (86). The oestrogen deficiency caused by menopause then in effect, 
leads to a negative calcium balance and affects the calcium economy increasing the 
risk of osteoporosis. Furthermore, the rate of calcium absorption mainly via active 
transport, when adjusted for age, was shown to be significantly reduced in 
postmenopausal women with prevalent fractures (87). 
 
1.2.3.1 The Role of Oestrogen in bone 
Oestrogen has been shown to have 3 fundamental roles in bone metabolism. 
Oestrogen inhibits bone remodelling and the initiation of new BMUs, it inhibits 
differentiation and promotes apoptosis of osteoclasts, and promotes the 
differentiation of osteoblasts (57). Oestrogen receptors (ER) are members of the 
superfamily of ligand-regulated nuclear transcription factors. There are 2 isoforms of 
ER, α and β, both expressed in osteoclasts, osteoblasts and their precursors (88). At a 
cellular level, oestrogen acts via ERα, to activate endothelial nitric oxide synthase 
(eNOS) to produce  nitric oxide (NO) (89). NO has been shown to regulate 
osteoclastic activity resulting in osteoclast apoptosis (90). Furthermore, oestrogen 
directly modifies osteoblast synthesis of osteoclast regulatory cytokines including 
osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANKL) as well as 
up regulation of both α and β oestrogen receptors (91). The direct effect of oestrogen 
on osteoclast formation may be mediated via non genomic mechanisms (89). 
Oestrogen may exert an anti-resorptive effect on bone by stimulating oestrogen 
receptor, OPG and RANKL expression in osteoblasts.  In addition there is evidence 
that oestrogen may exert its effects on bone metabolism via Dlk1/FA1 (Delta-like 
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1/Fetal Antigen 1). Soluble Dlk1/FA1 (sDlk1/FA1) is an endocrine factor that 
regulates bone mass, and higher circulating levels were reported in ovariectomised 
mice demonstrating enhanced bone resorption and inhibited bone formation (92). In 
postmenopausal women, replacement of oestrogen led to a fall in serum sDlk1/FA1 
and bone turnover markers (93). 
 
Androgens such as testosterone may be converted to oestrogen before they affect 
skeletal tissue. Therefore when there is a lack of androgens as in gonadal failure in 
males there is also a deficiency of oestrogen. This results in an up regulation of 
follicle stimulating hormone (FSH). FSH has been shown to have a direct effect on 
bone metabolism mediated via non gonadal FSH receptors and TNF α production 
(94,95). 
 
1.2.4 Negative calcium balance in postmenopausal women 
There is evidence for a negative calcium balance during and after menopause 
resulting from a fall in intestinal calcium absorption and an increase in the urinary 
calcium loss (96). Urinary losses of calcium were shown to be higher in 
postmenopausal women compared to premenopausal women (97,98). Together with 
the lowered calcium absorption in the gut (99) this leads to a negative calcium 
balance. Therefore it is reasonable to postulate that bone resorption occurs in these 
women to maintain the physiological calcium status (60,99). In addition, a high 
calcium intake has been shown to slow the rate of bone loss (100,101,102,103,104). 
 
A review of 32 clinical trials of calcium supplementation in over 3000 
postmenopausal women showed a significant loss of bone (>1% per annum) in the 
controls with no significant loss of bone in the calcium treated subjects (105). 
Twenty eight of these studies reported diet histories, which showed that, when the 
total calcium intake was less than 1300 mg a day the mean loss was 0.9% per annum 
(P<0.001) and when the intake was greater than 1300 mg a day the loss was 0.2% per 






1.3 Calcium requirements 
 
Calcium requirements are the intakes above which no further calcium can be retained 
(106). Calcium requirements are determined by balance studies, factorial estimates of 
requirements or assessment of changes in bone mineral density and bone mineral 
content. Balance studies estimate calcium requirement as the intake at which the 
excreted calcium equals the net absorbed calcium, adding an allowance for insensible 
skin losses (107). The rise in the calcium requirement after the menopause is likely to 
be at least an extra 200 mg a day (60). 
 
The recommended daily allowance (RDA) of a nutrient is a value which is the 
estimated intake to meet the needs of 95% of the population. Intakes below the RDA 
will be adequate for some individuals but an intake less than two thirds of the RDA is 
considered to be inadequate. The National Institute of Health (NIH) Consensus 
Conference estimated the daily requirement of calcium to be 800 mg to 1000 mg in 
childhood, 1200 to 1500 mg from ages 12 to 24 years and 1000 mg from age 25 years 
to menopause and 1500 mg thereafter. (108). Taking into consideration the National 
Academy of Science recommendations to compensate for calcium losses in sweat, 
composite RDAs were estimated to be 600 mg for ages 1 to 3 years; 1000 mg for 
ages 4 to 8 years; 1600 mg for ages 9 to 18 years; 1200 mg for ages 19 to 50 years; 
1400 mg for ages over 50 years and 1200mg during pregnancy and lactation (108).   
This revision of American RDAs and the FAO/WHO recommendations (109) 
resulted in a revision of the Australian/New Zealand recommendations. The 
recommended daily intakes (RDI) for the Australian and New Zealand population 
were estimated to be 500 mg for ages 1 to 3 years; 700 mg for ages 4 to 7 years; 1000 
mg for ages 9 to 11 years; 1300 mg for ages 12 to 18 years; 1000 mg for ages 19 to 
50 years; 1300 mg for women over 50 years; 1000 mg for men 50 to 70 years and 
1300 mg for men over 70 years (110).  
 
The position statement published by the Australian and New Zealand Bone and 
Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia states 
that, in people with baseline calcium intakes between 500 and 900 mg a day, 
increasing the intake by a further 500 to 1000 mg a day has beneficial effects on bone 
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mineral density. However calcium intakes significantly above this recommended 
level is unlikely to lead to additional benefit for bone health (111). The Institute of 
Medicine recommended intake for postmenopausal women is 1200 mg a day with the 
upper level of intake set at 2000 mg a day (106). The US Preventive Services Task 
Force recommendation states that while there is insufficient evidence to assess the 
balance of benefits and harms of daily calcium supplementation greater than 1000 mg 
for the primary prevention of fractures in noninstitutionalised postmenopausal 
women, a daily supplementation of 1000 mg or less of calcium is not beneficial 
(112). This implies that to demonstrate  the benefit of calcium on bone, at least 
1000mg/day is required but current evidence is insufficient to delineate the possible 
adverse effects of calcium at this dose. 
 
1.3.1 Factors affecting optimal calcium intakes 
 
1.3.1.1 Content of calcium in dietary sources and type of diet 
Dietary calcium is predominantly obtained from dairy products, with smaller 
amounts in bony fish, legumes, nuts, fortified soy products and cereals. Thus, the 
type and variety of diet will determine the content of calcium in the diet. Elimination 
of dairy from the diet as in lactose intolerance and veganism, severely curtails the 
amount of available dietary calcium but ovo-lacto-vegetarians appear to have similar 
calcium intakes to omnivores (113) suggesting that both ovo-lacto-vegetarians and 
ominovores obtain their calcium from dairy..  
 
1.3.1.2 Bioavailability of calcium 
Typically a vegetarian diet contains high amounts of phytates and oxalates which 
may bind to calcium in the intestine and reduce the efficacy of calcium absorption. 
This may increase the individual requirement for calcium. Foods rich in oxalic acid 
are spinach, rhubarb and beans. Seeds, nuts, grains and some beans including soy 
beans contain high levels of phytates. Although it is estimated that the bioavailability 
of calcium in soy milk is comparable to that of cows’ milk, this is not always the 
case. Compared to cows’ milk, the bioavailability of calcium in beans is 50% and 




Bioavailability of calcium from supplements depends on the dosage and the stomach 
contents at the time of ingestion. It has been shown that 250 mg calcium carbonate 
given with breakfast had a bioavailability comparable to that of calcium in milk 
(99,114). The proportion of calcium absorbed is an inverse function of load (115). At 
high intakes, the active transport mechanism becomes saturated and passive diffusion 
only accounts for about 5 – 10 % of additional absorbed calcium (115,116). 
 
1.3.1.3 Sodium intake 
Calcium requirement increases in proportion to sodium in the diet because the 
excretion of calcium in the urine is influenced by the sodium output (97,117). Every 
100 mmol of sodium was shown to cause a loss of about 1 mmol of calcium in the 
urine. Salt loading in animals has been shown to result in bone loss (118). 
Restricting dietary sodium lowers bone turnover markers, suggesting a bone 
protective effect (119). 
 
1.3.1.4 Dietary protein 
Each gram of dietary protein has been shown to increase the urinary calcium 
excretion by 1 mg (120) but the benefit of additional calcium in dairy products 
outweighs the possible deleterious effects of extra protein (121). However a diet 
very low in protein has been shown to lower intestinal absorption of calcium 
(35,122,123) and the role of protein in calcium balance is controversial.  
 
1.3.2 Average calcium intakes 
 
Average Australian and New Zealand adult intake of calcium is estimated to be about 
850 mg a day, and 40% of this calcium is obtained from non-dairy sources (110).  
The reported dietary calcium intakes for various cohorts in the United Kingdom, Italy 
and the United States show that it varies from as little as 198 mg a day to over 1000 
mg a day in adults (124,125,126). In these studies, the majority of subjects had 
calcium intakes that fell below the RDA. In Australia the average habitual dietary 
calcium intake in over a 1000 randomly selected women was 631 mg with a range 
between 170 and 2071 mg (127). Less than 7% of this cohort used calcium 
supplementation. Dairy food provided up to 80% of the calcium. Seventy six percent 
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of the women aged 20 to 54 years and 87% of the women older than 54 years had 
calcium intakes below the recommended daily intake. These data suggests that in the 
general population, an average adult may obtain 60% of his or her calcium from 
dairy sources but some women may obtain up to 80% of their calcium from dairy. 
 
1.3.3 Toxic effects of high calcium in the diet 
There exists an inverse relationship between dietary calcium and fractional intestinal 
absorption of calcium. Therefore additional intakes of calcium to a typical diet would 
only marginally increase the urinary excreted calcium. It follows that the risk of 
developing nephrolithiasis from increased urinary calcium is very small. However 
milk alkali syndrome (MAS) is a well defined syndrome where hypercalcaemia and 
alkalosis can follow excessive intake of milk. Using MAS as the end point of toxicity 
the lowest observed adverse effect level is about 5 g of calcium in adult humans 
(128). The hypercalcuria of male stone formers has been shown to be due to 
hyperabsorption of calcium and less related to intake (129) and there is little danger 
of hypercalcuria from calcium supplements because intestinal fractional calcium 
absorption is an inverse function of intake (114)   However, excess dietary calcium 
has been implicated in interfering with the absorption of zinc and iron in susceptible 
individuals. Therefore the upper level of intake for calcium has been set at 2500 mg a 
day for both men and women of all ages (109). 
 
There has been considerable interest in the effect of calcium supplementation on the 
cardiovascular system. There is evidence that Ca supplementation exerts beneficial 
effects on systolic blood pressure (130) and serum lipids (131). The latter may be 
explained by the hypothesis that lowers circulating calcitrophic hormones secondary 
to high calcium intakes favouring lipolysis (132). However a meta-analysis of Ca 
supplementation in postmenopausal women with cardiovascular events as secondary 
endpoints demonstrated a 27% increased risk of myocardial infarction (MI), a non-
significant increase in stroke and death in those receiving supplements (133). The 
Women’s Health Initiative investigators however reported no effect of calcium 
supplement on cardiovascular risk (134). Meta-analysis of studies using either Ca or 
vitamin D reported a 26% increased risk of MI and a 19% increase in risk of stroke 
(135). More recent studies have also demonstrated a higher risk of coronary heart 
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disease/MI (136,137). The mechanism proposed to explain this phenomenon is that a 
high Ca milieu may result in extracellular deposition of Ca in vascular smooth 
muscle leading to calcified plaque (138,139). However the Canadian Multicentre 
Osteoporosis Study (CaMos) demonstrated that in both men and women, calcium 
supplementation up to 1000mg/d and higher intakes of calcium from dietary sources 
reduced the risk of all-cause mortality (140). The Melbourne Collaborative Cohort 
Study demonstrated that daily dietary Ca intakes up to 1348mg reduced the hazard 
ratio of fracture, non-fatal MI, stroke and all-cause mortality (141). 
 
It appears that while Ca supplements cause serum Ca levels to spike to supra-
physiological levels (when taken in 600 – 1200mg doses at once), dietary Ca may 
lead to a slower rise in serum Ca preventing the high Ca milieu that promotes 
vascular calcification. It is also possible that, other nutrients (including fibre) has an 
effect on the absorption of dietary Ca. Phytates, phosphates, fibre and fats may bind 
to Ca either preventing or slowing absorption. Therefore the actual absorbed Ca may 
be much less than estimated dietary intakes, while supplemented elemental Ca may 
be more readily absorbed. 
 
1.3.4 Effects of calcium on bone mineral density 
 
Ensuring adequate calcium intake, with supplementation when the diet is deficient, 
has been suggested as an inexpensive strategy to prevent osteoporosis and 
consequent fractures (142). The fact that calcium and oestrogen deficiency are 
important factors in the causation of post menopausal osteoporosis has long been 
accepted. An oophorectomised animal model using histomorphometric data and bone 
turnover markers showed that bone loss was maximum in those that were oestrogen 
and calcium deficient (143). In this study, dietary calcium deficiency induced bone 
loss in both cancellous and cortical bones, while the bone loss in oestrogen 
deficiency was confined to cancellous bone. This suggests that there may be additive 
effects of oestrogen and calcium deficiency, and the resultant bone loss from calcium 




 There have been a number of observational and interventional studies of calcium 
intake and its effects on bone density in post-menopausal women. One of these 
studies was a 2 year longitudinal study in postmenopausal women which showed that 
increasing dietary calcium protected against bone loss at the hip and ankle sites 
(117). The change in calcium intake was positively correlated with the change in 
bone density at the hip and ankle, suggesting that a lower calcium intake was 
associated with a greater rate of bone loss. Stable hip densities were reported at an 
intake of 1700 mg a day. However the amount of daily calcium intake to achieve 
calcium balance was also shown to be dependent on the sodium intake (117) such 
that, lower calcium intakes would achieve a balance if the sodium intakes were 
lower.  This then leads to the concept that, the bone protective dose of calcium 
should be tailored for each individual. Another study conducted in Italy showed that 
post menopausal women with lower calcium intakes were more likely to have 
osteoporosis demonstrable by Dual Energy X ray Absorptiometry (DXA) scanning, 
with a T score below -2.5 when the measurements were corrected for body weight 
(144). This and other such studies suggest that on a population basis, the prevalence 
of osteoporosis will be higher in populations that have lower dietary calcium intakes, 
unless calcium is supplemented. 
 
In a more comprehensive study, albeit in a smaller number of post- menopausal 
women Dawson-Hughes et al showed that those who had a calcium intake below 
one-half of the RDA appeared to lose bone more rapidly in their lumbar spine than 
those whose intake exceeded the RDA, when corrected for baseline bone density, 
years since menopause and body weight (126). They projected the annual rate of 
bone loss for post menopausal women to be 1.1%. Those on lower calcium intakes 
suffered a loss of bone up to 4% per annum while those whose calcium intake 
exceeded the RDA had a gain of bone of up to 6%. The results of this small study are 
encouraging because it demonstrates that, in post-menopausal women, calcium 
supplementation alone may be sufficient to increase their bone density. However a 2 
year prospective non-interventional study failed to demonstrate a rise in BMD with 
increasing total calcium intake (dietary and supplemental) during the early 
postmenopausal period in women up to 60 years of age (145). The early phase of 
rapid bone loss after the menopause may not be amenable to calcium 
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supplementation alone and may require oestrogen replacement. In this study, on a 
calcium supplement of 500 mg, those in early menopause showed a statistically 
significant loss of bone regardless of the form of calcium taken. The placebo arm of 
this group also showed a significant rate of bone loss. In the late menopausal group, 
those who ingested the calcium in the form of citrate malate showed no bone loss in 
the lumbar spine during the study period of 2 years. In contrast, those who used 
calcium in the form of carbonate or those who were on the placebo showed a 
significant decline in bone density (101). A more recent study showed that 500 mg of 
calcium citrate is as effective as 1000 mg of calcium carbonate in suppressing bone 
markers (146) and other studies have demonstrated that calcium citrate has greater 
bioavailability and better absorbed than calcium carbonate (147,148,149) which may 
explain the bone protective effect of calcium citrate.  
 
The variable, often conflicting results of calcium intake with or without supplements 
on bone density may be due to the heterogeneity of the cohort, other uncontrolled 
dietary factors such as high sodium intake, the form of calcium supplemented and 
other uncontrolled but important factors impacting on bone density such as physical 
activity. 
 
In general, randomized controlled trials assessing bone mineral density show 
beneficial effects of calcium in both men and women (103,150,151,152,153). On 
average these studies showed that adequate calcium intake can result in a sustained 
reduction in bone loss of 50 – 60% (103,150,151,152). Furthermore in women who 
had a high calcium intake through their diet, a transient increase in BMD was 
observed when calcium was supplemented, an effect attributed to the suppression of 
parathyroid hormone (153,154). The effect on cortical bone is more sustained and 
cumulative than that on cancellous bone, which may be explained by the slower 
turnover of cortical bone.   
 
1.3.5 Calcium and fracture reduction 
 
With the information provided by studies such as those mentioned above, that 
showed preservation or a rise in bone density with high calcium intake, the next step 
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was to ascertain if a high calcium intake prevented or at least reduced the risk of 
fractures. Therefore randomised controlled trials were designed with fracture as the 
end point. An example of a study in this category is a randomised double blind study 
of 930 subjects of both sexes over 4 years which showed that the overall risk of a 
minimal trauma fracture was significantly lower in those who received 1200 mg of 
elemental calcium when compared to those who received the placebo (155). (hazard 
ratio 0.28 (95% CI: 0.09, 0.85).  However the hazard ratio reverted to 1.10 (95% CI: 
0.71, 1.69) during the post treatment 10 year follow up when the subjects were 
informed about the type of treatment they received and had the choice to take or not 
to take calcium.  
 
A meta-analysis of 29 randomised controlled trials showed that the use of calcium, 
either alone or in combination with vitamin D in people over 50 years of age was 
associated with a significant reduction in  fractures of all types (risk ratio 0.88; 95% 
CI: 0.83, 0.95; p= 0.0004) (51). Randomised controlled trials show that the rate of 
fracture risk reduction is significant even when the absolute differences in BMD 
change between the placebo and calcium supplemented groups are modest 
(153,156,157). This is now thought to be due to the beneficial effects of suppressing 
bone turnover. 
 
A landmark study was conducted over 3 years on more than 3000 institutionalised 
women between the ages of 69 and 106 years who were randomly allocated to 
receive 1200 mg calcium with added vitamin D or placebo over a period of 18 
months. (49). Women with vitamin D deficiency were normalised before the 
commencement of calcium. The number of hip fractures was shown to be 43% lower 
(P = 0.043) and the total number of non vertebral fractures were 32% (P = 0.015) 
lower in those who received calcium and vitamin D. A further 18 months of 
treatment resulted in a fall in the incidence of non-vertebral fractures by 24% and hip 
fractures by 29% (P < 0.001) in those who received calcium. (49) Other studies have 
shown results consistent with this study (158, 159,160,161). Some studies have not 
been successful in showing a significant effect of calcium on the rate of fractures 
(162,163,164) which may be explained by the heterogeneity of patient populations 
and their various baseline vitamin D status. A per-protocol analysis of 1500 older 
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women suggested that 1200 mg of calcium daily reduced the risk of fracture by 34% 
where an Intention to Treat analysis failed to show a significant effect (165). Pooled 
results from prospective cohort studies show that calcium intake is not associated 
with hip fracture risk in men and women while randomised controlled trials show no 
reduction in hip fracture risk when calcium supplements are given, and a possible 
increase in the risk, with a neutral effect on vertebral fracture risk (163). A 
longitudinal prospective study of 61,433 women followed up for 19 years showed 
that the relationship between the incidence of osteoporosis and minimal trauma 
fractures with dietary calcium intake was nonlinear (166). Vitamin D deficiency in 
women in the lowest quintile of calcium intake exacerbated the rate of fracture. The 
highest quintile of calcium intake did not reduce the incidence of osteoporosis or 
fracture. 
 
Overall, the current evidence points to a beneficial effect of calcium on fracture 
prevention in both men and women. A meta analysis of 29 randomised controlled 
trials supports the use of calcium with or without vitamin D in the prevention of 
osteoporosis and subsequent fractures in women over the age of 50 (51). 
 
1.3.6 Calcium supplementation in the community 
 
In almost all long term studies subject compliance with taking calcium was reported 
as moderate to low, defined as 80% of the tablets taken by 50 to 58% of subjects 
(103,150,151,152,156,165). According to this observation, the effectiveness of any 
intervention with daily calcium doses will be limited by non-compliance (51,165). 
However, according to current consensus, even with anti resorptive therapy, calcium 
supplementation is regarded as an integral component in the treatment regime of 
osteoporosis (111). Whether calcium should be used as a preventative agent is still 
controversial (167). 
 
1.3.7 Estimation of dietary calcium intake 
 
Nutrient intake can be estimated by a retrospective assessment using a food 
frequency questionnaire (FFQ) or by a prospective method, by tracking intakes 
32 
 
longitudinally using a food diary. Some questionnaires evaluate a single nutrient, 
while others assess the intake of energy and other nutrients (168).  
 
Nutrient intake estimation is useful for research as well as in the clinical setting. 
FFQs have been the method of choice for dietary intake data for epidemiological 
studies (168). They have been adapted for use in the clinical and research setting. For 
calcium intake data, FFQs have been designed to be completed independently by 
subjects and considered to be relatively inexpensive (169). 
 
However, FFQs need to be updated every few years because the pattern of dietary 
intakes changes over time (170). The other potential problem with FFQs is the 
inability to include all types of available fortified products on the market (171) or 
may not be appropriate for the gender or the age (172) or the geographic and 
socioeconomic characteristics of the cohort studied (173). Some validated total diet 
estimate questionnaires are lengthy and may not be accurate when used to assess a 
single nutrient (168). 
 
1.3.8 The link between energy metabolism and bone metabolism 
 
When studying the effects of dietary calcium intake on bone density and bone 
metabolism, other components of the diet and their metabolism on bone should be 
considered. The concept that bone remodelling and energy metabolism may be 
regulated by the same hormones under the influence of the hypothalamus was 
proposed in 2000 (174). This section will discuss the link between bone and calcium 
metabolism and energy metabolism, the proposed hormones involved in linking these 
processes and the role of nutrients. 
 
The net calcium absorbed via the gastrointestinal tract on a Western diet is about 150 
mg per day. This regular influx of calcium into the extracellular space is balanced by 
renal excretion and exchange with the bone calcium pool. Calcium homeostasis is 
maintained by 3 hormones, parathyroid hormone (PTH), calcitonin and 1,25 
dihydroxyvitamin D (1,25(OH)2 D). PTH, an 84 amino acid peptide is synthesised 
and secreted by the parathyroid gland and is in turn, regulated by extracellular 
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ionised calcium concentration. The biological actions of PTH include stimulation of 
osteoclastic bone resorption, stimulation of calcium reabsorption and inhibition of 
phosphate reabsorption in the renal tubules and stimulation of renal synthesis of 1,25 
(OH)2 D, all aimed at raising the serum calcium level.  
 
Increases in ionised calcium in extracellular fluid results in the release of calcitonin, a 
32 amino acid peptide synthesised and secreted by the parafollicular cells of the 
thyroid. The precise biological role of calcitonin in humans is yet to be delineated, 
and debated (175) but its role in fish and reptiles appear to be significant in calcium 
homeostasis (176). Although at pharmacological doses, calcitonin has been shown to 
decrease osteoclastic bone resorption (177) and decrease calcium reabsorption at the 
renal tubule with resultant calciuria, at physiological concentrations these effects 
have not been observed. In vitro observations also suggest that calcitonin may induce 
the formation of 1,25 (OH)2 vitamin D and enhance calcium absorption in the gut 
(178). Furthermore, clinical observations support the concept that calcitonin has little 
chronic effect because neither calcitonin deficient patients (post total thyroidectomy) 
nor patients with medullary thyroid carcinoma and excess calcitonin are reported to 
suffer altered calcium homeostasis (176).  
 
More recent evidence arising from in vitro cell and organ cultures and in vivo studies 
suggest that calcitonin may arrest bone resorption by inhibiting RANKL (179). The 
calcitonic effect of calcitonin is partly due to increased renal excretion of calcium 
secondary to a decline in renal reabsorption (180). Note-worthy is the inhibitory 
action on bone formation, demonstrated in mice and investigated extensively in 
various gene knockout mice (175). This phenomenon has been seen especially during 
growth when bone mineral accrual is highest (181). The proposed mechanism is the 
modulation of production of sclerostin, an osteocyte-derived negative regulator of 
bone formation (182). Another potential mechanism is the regulation of bone 
formation via the brain, proposed following the demonstration of calcitonin receptor 
expression and calcitonin binding in the arcuate nucleus of the hypothalamus (183). 
It is possible that the inhibitory effects of calcitonin on bone formation may 
ultimately be mediated via efferent neural pathways and neural regulators such as 
leptin and neuropeptide Y (184,185).  Given that calcitonin acting via CNS is known 
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to regulate appetite and gastric secretion, this may be another link between bone 
metabolism and energy metabolism. 
 
The concept of gut-brain-bone axis has opened up avenues exploring the effect of 
nutrients on enteroendocrine cells, and the effect of their secretions (incretins or gut 
derived hormones) on bone and other tissue. The major functions of incretins are to 
regulate gut secretions (acid, bicarbonate in the stomach), food intake (satiety), 
insulin secretion, lipoprotein lipase activity in fat cells, contraction of the gall 
bladder, pancreatic secretions and gut motility, in response to nutrient content in the 
gut lumen (186). The sophisticated sensory mechanisms of these cells are able to 
differentiate between different types of nutrients within the lumen.  
 
The proposed link between incretins and bone is an evolving concept in nutrient-
dependent regulation of bone turnover. The postprandial fall in bone resorption 
markers and the rise in bone formation markers (albeit to a lesser extent) has been 
attributed to the effects of incretins GLP–1 mainly, with GLP-2 playing a minor role 
(187,188). 
 
An adipocyte derived hormone, leptin was shown to be a major regulator of 
osteoblast function, and inhibits bone formation in vivo cultured cells (189) and in 
mice (190). Leptin-deficient and obese ob/ob mice and leptin receptor-deficient 
db/db mice display an osteopetrotic skeletal phenotype at an early age with high 
trabecular bone volume (191). Deficiency of leptin or its receptor in these mice 
resulted in a decreased rate of bone formation (BFR) but also decreased the rate of 
bone resorption (BRR) with a consequent high bone mass. Subcutaneous injection of 
leptin in these mice corrected the low bone formation and low bone resorption 
phenotype (191) demonstrating that peripherally administered leptin (as opposed to 
hypothalamic centrally regulated leptin) has an effect on BFR and BRR. However in 
humans, low circulating levels of leptin is associated with low bone density (192). 
 
 As in any other endocrine pathway adipocytes and leptin production in turn, may be 
under a feedback regulatory control of bone metabolism. Osteocalcin, an osteoblast-
specific protein, was nominated as the candidate hormone involved in the regulation 
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of energy metabolism. Indeed, glucose intolerance and greater amounts of visceral fat 
were noted in osteocalcin knockout mice (Osteocalcin-/-) (193). Deletion of other 
genes in osteoblasts (ie: Esp or Ptprv coding for a receptor- like protein tyrosine 
phosphatase OST-PTP) in mice was shown to increase pancreatic β cell proliferation, 
insulin secretion and sensitivity that protects against obesity and diabetes (193). This 
suggests that osteocalcin and other osteoblast-derived factors may influence insulin 
secretion and energy metabolism. 
 
Another important factor in the link between energy metabolism and skeletal 
physiology is cortisol. Evidence suggests that in human and rat bone. glucocorticoids 
(GC) are essential for the differentiation of osteoblasts and formation of mineralized 
extracellular matrix (194). GC, particularly cortisol plays a major role in energy 
metabolism. While acting as an integral component of the stress response, making 
energy available by increasing glycolysis and lipolysis, chronic excess cortisol leads 
to impaired peripheral glucose uptake, insulin resistance, increased lipogenesis both 
in the liver (non-alcoholic steatohepatitis) and in the trunk (central abdominal obesity 
or Cushingoid phenotype) (195). Indeed, patients with Cushing’s syndrome have a 2 
to 5 fold increase in subcutaneous and visceral fat compared to healthy controls 
(196).  Furthermore, several features of Cushing’s syndrome overlap with the 
metabolic syndrome. Central or visceral obesity, insulin resistance and 
hyperglycaemia are both common to the 2 syndromes. Given their role in fat and 
carbohydrate metabolism, and the common features of Cushing’s and metabolic 
syndrome, it is reasonable to postulate that glucocorticoids play a role in the 
development of the metabolic syndrome.  Current evidence indeed, points to subtle 
abnormalities in the hypothalamic-pituitary- adrenal axis (HPA axis) in metabolic 
syndrome, rather than a simple elevation of circulating cortisol (197). 
 
The role of cortisol in the differentiation of osteoblasts has been investigated 
extensively. It appears that precursor cells are directed towards differentiation by GC, 
during which genes stimulating and inhibiting bone formation are activated. The 
essential role of cortisol in this process has been demonstrated by the fact that, when 
cells are deprived of cortisol, they convert inactive cortisone to cortisol by expressing 
11β-hydroxy steroid dehydrogenase (198). However when administered at 
36 
 
pharmacological doses GC lead to well characterised adverse effects on bone, namely 
suppression of bone formation and increased rate of bone resorption. It is accepted 
that osteoblasts, osteoclasts and osteocytes are affected by GC.  
 
It is clear that cortisol or GC have a central and pivotal role in energy metabolism. It 
is also clear that GC is essential for skeletal health and metabolism. Therefore it is 
possible that energy metabolism and bone metabolism are linked via GC, mediated 
by intermediary metabolites or mediators. Osteocalcin has been proposed as a likely 
candidate produced by osteoblasts, that regulates energy metabolism and may have a 
role in modulating effects of GC. Osteocalcin has been shown to regulate glucose 
metabolism by influencing insulin secretion and sensitivity, and pancreatic β cell 
proliferation (199).  Treatment with GC has shown to significantly suppress 
circulating levels of osteocalcin and increase circulating insulin (200). Experiments 
using transgenic mice have shown that the disruption of GC signalling pathway of 
osteoblasts attenuates several features of Cushing’s and metabolic syndromes such as 
obesity, hyperlipidemia, insulin resistance and hyperglycaemia (200) leading to the 
conclusion that GC-induced suppression of osteoblast activity plays a major role in 
mediating the adverse effects of GC on energy metabolism.   More interestingly, 
when GC treated mice displaying features of metabolic syndrome were treated with 
osteocalcin, fat/lean mass ratio, hyperlipidemia, hyperglycaemia, insulin resistance 
and steatohepatitis were reversed. Furthermore when osteocalcin vectors were 
transfected in to the mice insulin signalling in target tissues were protected from 
disruption by GC (200). 
 
The actions of GC on osteoblasts, evidence that GC-induced derangement of 
carbohydrate and fat metabolism may be reversed by osteocalcin and the potential 
protection afforded by osteocalcin to target tissues of insulin from disruption by GC 
suggests that osteoblasts are intimately associated with energy metabolism. Therefore 
by extension, patients with metabolic syndrome and obesity, or a predisposition (ie 
genetic) to metabolic syndrome or obesity, may carry either acquired or inherited 
gene activation or deletion within osteoblasts. It is possible that even in individuals 
that have not inherited genes that predispose to metabolic syndrome or obesity, 
various acquired or environmental factors may modify cellular and genetic 
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components. These individuals therefore, may also display variant phenotypes in 
bone metabolism. For decades, obesity was accepted as a factor that protects against 
osteoporosis (201). Furthermore a meta-analysis showed that there was an inverse 
relationship between BMI and fracture risk (202,203). It was thought that in obesity 
the mechanical stimulation of bone due to greater body weight lead to higher bone 
density. 
 
Inconsistent results were reported on the association between fat distribution and 
BMD, and at least in some studies this was because no adjustment was made for BMI 
(204,205).  A cross sectional study of over 500 postmenopausal women however, 
reported a positive correlation between bone mass and BMI, total body fat mass and 
abdominal fat mass measured by DXA (206). The close link between bone and 
energy metabolism may at least in part, explain this finding. It appears that the 
deranged energy metabolism in these individuals leading to fat accumulation factors 
associated with this may stimulate osteoblasts to attain greater bone mass. It should 
be noted, however, that the relationship between bone mass, fat mass and lean mass 
are complex and numerous as yet unidentified factors may be at play. 
 
1.4 Assessment of bone loss 
 
Osteoporosis is defined by the WHO as a systemic skeletal disease characterised by 
compromised bone strength predisposing to increased risk of fracture, where bone 
strength reflects the integration of bone density and bone quality. Bone quality 
reflects bone architecture, bone turnover, accumulation of micro-fracture and bone 
mineralisation. A simpler definition would be that it reflects “too little bone in the 
bone” (207). Osteoporosis results from loss of bone due to the imbalance between the 
rates of formation and resorption, also described as uncoupling of formation and 








1.4.1 Bone mineral density and fracture risk 
 
Bone mineral density (BMD) is measured by dual energy x-ray absorptiometry 
(DXA) and is currently the most effective measure of bone density and estimation of 
fracture risk. It is a two-dimensional areal density rather than a volumetric density. It 
combines the trabecular and cortical measurements and is often affected by 
degenerative artefacts in the spine. Therefore, the total hip measurement is used for 
fracture risk assessment. It provides the reference standard for the diagnosis of 
osteoporosis. The measurements are reasonably precise, with a reproducibility of 
about 1% so changes over 2.8% are significant for a given population and 4% for 
individuals (208). It is easy and quick to perform. Skeletal assessment using DXA is 
typically made in the lumbar vertebrae and total hip. BMD is expressed by its 
relationship to two norms: the expected BMD for young normal adults of the same 
sex (standard deviations from the young normal mean; T score); and the expected 
BMD for the patient’s age and sex (Z score).  The difference between the patient’s 
score and the norm is expressed in terms of standard deviations (SD) above or below 
the mean. In general 1SD represents about 12% of the bone density value. With age, 
the T scores decline in parallel to the loss of bone density. According to the World 
Health Organization definition, osteoporosis is a BMD T score of less than or equal 
to -2.5 when measured using DXA (208) 
 
Quantitative ultrasound (qUS) and quantitative computed tomography (qCT) are 
other techniques used for assessing bone quality. Although qUS can be used to 
predict fracture risk it cannot be used to diagnose osteoporosis or to monitor effects 
of therapy because of poor precision. Common sites measured are the calcaneus, 
patella and the tibia. Quantitative US correlates only weakly with BMD 
measurements obtained from DXA and no population-based standards exist (209) so 
its effectiveness in predicting fracture risk is uncertain. Quantitative CT is mainly 
used in research. It provides a volumetric density measurement, and remains the best 
technique for assessing trabecular and cortical volumetric densities. This allows the 
detection of early bone loss in the vertebral body because CT is more sensitive to 
small changes than DXA. It is not used in the clinical setting because the emitted 




A landmark study showed that elderly women with low hip BMD (T < -3.5) had a 
two fold higher risk of hip fracture than the average risk for age matched women and 
the  hip bone density measured by DXA was inversely related to low trauma fracture 
risk at any site (210). The population-based reference interval provides a more 
reliable basis for the diagnosis of osteoporosis if derived from the same geographical 
region or ethnic community. BMD fracture prediction is to some extent site specific; 
BMD at the hip is a better predictor of hip fractures than of fractures elsewhere (211).  
However the total hip density has the highest predictive value for fractures in general 
probably because it is least affected by degenerative changes and has been proposed 
as the standard site (212).  A peripheral measurement of BMD (phalanx, forearm) 
together with a good clinical evaluation of the osteoporosis risk profile of the patient 
has been proposed for the diagnosis of osteoporosis when central DXA is not 
available (213). 
 
Using DXA it is generally accepted that the fracture risk rises by a factor of 1.5 – 2 
for every standard deviation reduction in BMD (211). However, the bone densities of 
those who develop low trauma or osteoporotic fractures overlap with those who do 
not. In other words, not all individuals with a low trauma fracture have a T score 
below -2.5, and the majority of people with a T score below -2.5 will not suffer 
osteoporotic fractures (211). Furthermore, the proportion of women with osteopenia 
is about 6 fold that of osteoporosis, therefore the absolute number of fractures will be 
greater in those with osteopenia (214,215). Although “risk” is widely used in this 
context it is generally odds ratio that is cited. The relation between odds and risk is 
given by the equation:  
 
Risk = odds / (1 + odds)   (216,217) 
 
A nomogram published in 2007 used femoral neck BMD T score with other clinical 
risk factors such as prior fracture, history of falls, postural sway and quadriceps 
strength to predict the 5 and 10 year hip fracture risk in men and women in the 
primary care setting (218). Evidently the incorporation of clinical risk factors 
enhanced the performance of BMD in the prediction of osteoporotic risk factors in 
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both men and women. A 10 year absolute risk estimating algorithm has been 
developed by University of Sheffield, UK (FRAX) which takes well known risk 
factors (age, race, sex, T score, prior fractures, current fracture, current smoking, 
glucocorticoid use, rheumatoid arthritis) as well as risk factors less utilised in the 
clinical setting (alcohol, body mass index or BMI) into account. This algorithm has 
been validated for several countries. It does not take biochemical markers into 
account due to lack of data so bone turnover rate is not considered in the risk 
calculation. This risk calculation model has gained general acceptance worldwide 
and the risk calculator can be freely accessed on the web for use on individual 
patients by clinicians (219).  
 
1.4.2 Bone turnover markers 
If bone quality is to be assessed, bone turnover markers (BTM) provide a more 
dynamic measurement than bone density. While bone density measurements are 
slower to change, BTM can be used as surrogate measures of acute changes in 
cellular activity.  However, longitudinal data of bone markers can be used to predict 
structural change in bone. In addition BTM provide an important tool in the clinical 
and preclinical assessment of response to interventions. 
 
BTM are proteins or enzymes released by osteoclasts and osteoblasts due to 
increased synthesis or metabolism or substances released during the formation or 
degradation of type I collagen. Smaller peptides are excreted in urine unchanged, 
while larger peptides may circulate in the serum with a longer half life. These 
markers provide a qualitative and a quantitative assessment of the rate of bone 
turnover or remodelling at any particular point in time but can be affected by a 
variety of physiological and pathological factors. Therefore bone turnover markers 
may provide a measure of bone quality and can be used to identify individuals with 
high bone turnover, which occurs in some metabolic bone diseases. In osteoporosis 
of postmenopausal women where bone resorption occurs at a greater rate than bone 
formation, bone resorption markers are expected to be high.  In addition, BTM may 
be used to monitor treatment response in metabolic bone diseases (220) and 
prediction of fracture risk (221,222,223).  BTM are particularly useful for the 
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assessment of efficacy of antiresorptive therapy in osteoporosis and also to identify 
non responders and non compliant patients to therapy (224,225).  
 
Numerous studies link the usefulness of BTM in fracture risk prediction as well as 
monitoring progression of bone disease and treatment response. However BTM are 
measured using various immunoassay methods, which clearly lacks standardisation.  
Therefore the position of the International Osteoporosis Foundation (IOF) and the 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) is 
that current knowledge is inadequate to make consensus statements or clinical 
guidelines for the use of BTM in the clinical arena (226,227).  They recommend 
using serum procollagan type 1 N propeptide (s-P1NP) as a marker of bone 
formation and serum C-terminal telopeptide type 1 collagen (s-CTX) as reference 
markers of bone resorption in clinical trials in order to collect sufficient data on these 
markers in the context of their contribution to estimation of relative risk of fracture. It 
is hoped that the uncertainties with regards to their use in fracture prediction and 
monitoring therapy may be resolved with further evidence from observational and 
interventional studies measuring these markers using standardised analytical 
procedures.  
 
1.4.2.1 Markers of bone formation 
 
These are direct or indirect products of active osteoblasts that circulate in the serum. 
 
1.4.2.1.1 Propeptides of type I procollagen 
 
Osteoblasts play a major role in bone formation. They synthesize type I collagen 
which forms 90% of bone matrix, and is the most abundant structural protein in 
vertebrates. Collagen synthesis commences with the formation of the pre-pro-peptide 
which undergoes post translational modifications within the endoplasmic reticulum 
(ER) and then the Golgi apparatus. During post-translational modification within the 
ER lysine and proline residues are hydroxylated and hydroxyl groups on lysine are 
glycolsylated with glucose or galactose monomers, resulting in a pro-peptide. Each 
pro-peptide folds to the left. Three such pro-peptides produce a triple helix forming a 
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procollagen molecule, which consists of α helical regions and non-helical regions. 
Proline hydroxylation is critical for the stabilisation of the triple helix. It is then 
transported into the Golgi apparatus for the addition of oligosaccharides, and the 
secreted into the extracellular matrix. Here the N- and C- terminal propeptides (the 
non-helical ends) are cleaved by ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) and BMP 1 (bone morphogenic protein 1)/Tolloid-like 
proteinases respectively, resulting in mature type 1 collagen (228) and releasing 
amino terminal (P1NP) and C- terminal propeptide of type I collagen (P1CP) in a 
steoichiometric fashion. Circulating levels are considered quantitative measures of 
newly formed type I collagen. P1CP is a globular protein but P1NP can be found in 
the circulation as a trimeric molecule or a monomeric linear form (229). Mature type 
1 collagen undergoes racemisation and isomerisation via spontaneous non-enzymatic 
reactions within the bone matrix yielding 4 isomers of C-terminal peptides that is 
released during degradation. Isomerised C-terminal peptides were therefore proposed 
as a marker of bone turnover (230). Indeed, the current assay for C-terminal 
telopeptide (CTX) detects the β isomerised C-terminal telopeptide, thereby 
quantifying the telopeptide released during degradation of mature type I collagen 
rather than the telopeptides released during collagen formation. 
 
P1NP has been recommended as the reference analyte for bone formation in clinical 
studies by the IOF and International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) (227). Additionally P1NP has wider global acceptance and is more 
convenient to use as a marker of bone formation that P1CP because of the following 
reasons. P1NP release kinetics are not affected by food intake or diurnal variation. In 
addition, the intraindividual variability of P1NP is small and it is more stable at room 
temperature than P1CP (225,231). 
 
Although early assays used antibodies raised against a synthetic peptide that 
recognised trimeric and monomeric fragments, the automated immunoassays 
(Elecsys 2010 system, Roche Professional Diagnostics, Rotkreutz, Switzerland; IDS-
iSYS, Immunodiagnostic Systems, UniQ P1NP RIA Orion Diagnostica, Epsoo, 
Finland) all identify the trimeric form (intact molecule) (225,231). The automated 
assays may also measure various fragments and thermal degradation products (total 
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P1NP). While the Elecsys (Roche Diagnostics) assay measures total P1NP (trimeric 
form and the monomeric form) the ID-iSYS and UniQ P1NP RIA assays measure 
only the intact trimeric molecule. 
 
Some studies have reported that the monomeric fragment may accumulate in chronic 
renal failure (232) and in metastatic bone disease (233), suggesting the use of current 
assays that measure the trimeric form should not be affected by this phenomenon. A 
recent study comparing the intact trimeric P1NP assay (IDS iSYS) with the total 
P1NP assay (Roche) in patients with chronic kidney disease showed that when using 
the total P1NP assay, measured P1NP was markedly elevated in patients with 
KDIGO (kidney disease improving global outcome) stage 3 or worse (below an 
eGFR of 30mL/min/1.73m2), but levels remained within the reference interval when 
measured using the intact P1NP assay (234). These findings suggest that in later 
stages of kidney disease, the monomeric forms accumulate in the circulation. 
Therefore in renal disease patients, the trimeric form needs to be measured in order to 
assess bone resorption. 
 
A meta-analysis of prospective studies demonstrated a significant association 
between serum P1NP and bone mineral density (223) suggesting that P1NP may 
reflect existing bone content and rate of bone formation in the bone remodelling 
cycle. In earlier studies, P1CP was shown not to rise after the menopause thus may 
not reflect bone formation in osteoporosis (235) but moderate correlations between 
elevations of serum P1CP and the rate of bone formation have been reported (236). 
 
However the association between circulating intact P1NP and fracture risk 
independent of BMD was found not to be significant in one study (237). The 
practical and widely acceptable use for serum P1NP is to identify patients who 
respond to anti resorptive and anabolic treatment in osteoporosis (238) but is not 
routinely recommended for clinical practice. 
 
1.4.2.1.2 Alkaline phosphatase 
The total serum alkaline phosphatase (ALP) consists of several dimeric isoforms 
originating from liver, bone, intestine, spleen, kidney and placenta. In healthy adults 
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about 50% of the total ALP in the serum is regarded to be of hepatic origin and the 
rest of bone origin (239). ALP plays a role in osteoid formation and mineralization 
and thus reflects bone formation. 
Liver and bone ALP isoforms can be differentiated on the basis of their physical 
properties (heat denaturation, electrophoresis, precipitation) or chemical properties 
(selective inhibition and immunoassay).  
 
The OFELY study showed that the bone specific ALP (bALP) level was significantly 
associated with fracture risk regardless of BMD in postmenopausal women (239). 
Few centres measure bALP due to labour intensive time consuming procedures 
and/or the cost (in Australia, Medicare Benefits Schedule does not pay a rebate for 
bALP as a bone formation marker), while most measure total serum ALP as part of 
the liver function test panel. However, due to the low index of individuality of serum 
total ALP and the poor correlation with bone histomorphometric indices total ALP 
measurement may not reflect metabolic changes in bone (240). The use of 
immunoassay to more specifically measure bALP (Alkphae-B kit, Metra Biosytems, 
USA; Ostase, Beckman Access, Beckman-Coulter Inc, USA) (241) has been shown 




Osteocalcin (Oc) is a protein synthesised by osteoblasts, and to a lesser extent by 
odontoblasts and hypertrophic chondrocytes. It binds to hydroxyapatite in the bone 
matrix. It contains 3 gamma carboxy glutamic acid (Gla) residues which confers Ca 
binding properties. Serum Oc is a specific marker of bone formation and a marker of 
osteoblastic activity (243). 
 
Serum Oc is rapidly degraded resulting in several circulating fragments (244) 
yielding variable results from different immunoassays (245). Furthermore, smaller 
serum Oc fragment levels may rise in renal failure due to the impaired renal 
clearance. Therefore assays that detect the intact molecule and the N-mid fragment 
are more robust (N-MID Osteocalcin One Step enzyme linked immunosorbent assay 




There is evidence that lower circulating levels of Oc are associated with an increased 
risk in all types of fractures in retrospective trials (246,247).  However, this 
relationship was not found to be significant in prospective trials (for review see 222). 
 
1.4.2.2 Bone resorption markers 
These are type I collagen degradation products or substances secreted by active 
osteoclasts and reflect the rate of resorption of the collagen matrix or the number and 
activity of osteoclasts depending on the specific marker measured. In general these 
markers are stable in vitro. 
 
1.4.2.2.1 Hydroxyproline 
The amino acid proline is hydroxylated in collagen. It constitutes 12 – 14% of the 
total amino acid content of mature collagen. However this is not specific to bone and 
is found in skin, CIq complement component and connective tissue. In addition 
dietary intake of proteins containing hydroxyproline (OHP) influences the amount 
excreted in urine. The majority of OHP in urine occurs as part of small peptides. 
Some of the OHP may be within larger peptides and proteins and need to be 
hydrolysed before analysis.  A significant proportion of urinary OHP can result from 
bone formation rather than resorption (248) and from the degradation of elastin and 
CIq (249).  Therefore, the specificity of OHP for bone resorption is poor. 
Furthermore colourimetric assays are cumbersome and nonspecific. An improved 
HPLC assay can be used to monitor post menopausal osteoporosis. The urinary OHP 
concentration cannot be used to diagnose metabolic bone disease because of the lack 
of a cut point that differentiates between healthy and diseased individuals. Although 
a decrease in the excretion rate of OHP can be used as an indicator of response to 
therapy the significant biological variation needs to be borne in mind (250).  Owing 
to these reasons urinary OHP measurement has been replaced by more specific 
markers and only mentioned here as a historical oddity. 
 
1.4.2.2.2 Pyridinoline crosslinks 
Pyridinoline (PYD) and deoxypyridinoline (DPD) are accepted as more specific 
markers of bone resorption compared to hydroxyproline. These are crosslinks formed 
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between peptide chains of different collagen molecules during maturation of bone 
and cartilage to provide mechanical stability. DPD is more specific to bone while 
PYD is also released from the degradation of cartilage. They are found in both free 
(40%) and protein bound forms in the urine. The advantages of measuring DPD and 
PYD in the urine is that these molecules result from degradation of mature collagen, 
excreted without further degradation, the urinary levels are not influenced by diet 
(251) and correlates with radio-isotopic measurement of bone resorption (252) as 
well as histomorphometric and dynamic parameters of bone resorption (253,254).   
However the diurnal variation in the rate of excretion prevents the use of random 
urine samples.  
 
The free fraction of PYD and DPD are measured using immunoassays and has been 
automated (Pyrilinks-D, Metra Biosystems USA; DPC Immulite, Siemens, USA). 
HPLC methods for total PYD and DPD have also been introduced (255). Although 
pre- fractionation and hydrolysis has been used prior to HPLC assay for total PYD 
and DPD, the measurement of the free fraction alone is likely to be adequate since 
the proportion of free fraction does not change significantly (256).  
 
1.4.2.2.3 Telopeptides 
The mature triple helix of collagen forms cross link at specific.  Lysyl and 
hydroxylysyl residues of the collagen molecule are oxidised to form aldehyde groups 
during ‘maturation’ which aids in the formation of crosslinks at specific sites in the 
tropocollagen molecule. Once cross linked, the polymers of tropocollagen are 
referred to as collagen fibrils. Fragments of the fibrils with intact cross-linked 
peptides are released to the circulation during proteolytic degradation of collagen 
such as during bone resorption. The cross linking process is demonstrated in figure 
1.1. N- and C- terminal telopeptides and their involvement in pyridinium crosslinks 
are shown in figure 1.2. 
 
The early radioimmunassays for C-terminal cross-linked telopeptide of type I 
collagen used antibodies raised against collagen isolated from human bone and 
degraded using metalloproteinase (MMP) (257). This assay (CTX-MMP) also cross 
reacted with DYP, PYD or pyrrole crosslinks. Furthermore, cathepsin K cleaves the 
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telopeptide structure and may abolish immunoreactivity in metabolic bone diseases 
such as osteoporosis. However this assay is useful in pathological bone resorption as 
seen in multiple myeloma and metastatic bone disease (258).     
 
 






Figure 1.2. Cross linking between telopeptides and collagen fibrils 
 
 A monoclonal antibody against the C terminal telopeptide or α 1 region of type I 
collagen (EKAHDGGR) allowed the development of assays for another bone 
resorption marker, the C-terminal cross-linking telopeptide of type I collagen (CTX). 
This octapeptide was originally purified from human urine. This antibody is specific 
for degradation products of type I collagen because it recognises the β isomer of 
aspartate, preceding glycine. The β isomerised Asp-Gly sequence increases the 
specificity of the assay for bone resorption (259).  The most widely used assay in 
Australia is an automated assay (Beta-CrossLaps Roche Elecsys, Roche Diagnostics, 
Mannheim, Germany) which uses a monoclonal  antibody against a synthetic 
polypeptide resembling the C terminal telopeptide or α 1 region of type I collagen 
(EKAHD-β-GGR). IDS iSYS CTX-1 (CrossLaps) CLIA automated assay, also using 
a monoclonal antibody, has recently entered the market, produced by 
Immunodiagnostic Systems Nordic, Denmark. 
 
Similarly, immunoassays have been developed to detect and quantify N-terminal 
telopeptides of type I collagen (NTX) (QYDGKGVG). The assays use a monoclonal 
antibody raised against the cross-linked N- terminal of α 2 chain of type I collagen 
and use serum or urine (Osteomark Serum ELISA, Osteomark Urine ELISA, Alere; 
Ostex International, Seattle, Washington, USA), which has been automated. Dry 
chemistry systems (Vitros ECi Immunodiagnostic Systems, Ortho-Clinical 
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Diagnostics, New Jersey, USA) are also available. However these assays measure 
total NTX and are not specific for isomerised forms thus may reflect resorption as 
well as formation.  
 
Both CTX and NTX have been shown to rise significantly with the menopause 
(260,261).   In addition urinary CTX levels above the premenopausal range (mean + 
2SD) were shown to be associated with a 2 fold higher risk of hip fracture while 
urinary NTX levels were not associated with fracture risk (235,262).  However these 
analytes show a high intra- and inter- individual variability, susceptible to change due 
to food intake and show a marked diurnal variation (263) requiring standardization of 
patient preparation, sample collection and handling.   
 
The clinical utility of serum CTX and P1NP was emphasised in a recent publication 
with consensus reference intervals and treatment targets (264). In addition, a meta-
analysis of prospective studies found a significant association between serum CTX 
and risk of fracture (223) although the use of serum CTX for this purpose has not 
been validated. 
 
1.4.2.2.4 Tartrate resistant acid phosphatase 
Tartrate resistant acid phosphatase (TRAP) belongs to the family of ubiquitously 
occurring acid phosphatases. Different isoforms are expressed in bone, prostate, 
spleen, liver and erythrocytes. The tartrate resistant isoform occurs in 2 subforms, 5a 
and 5b, and 5b is characteristic of osteoclasts possibly originating from macrophages 
(265). Although immunoassays have been developed to measure TRAP 5b in serum 
(266) the utility of this assay is limited due to the instability of TRAP in vitro (267).      
 
1.4.2.3 Novel markers 
 
Osteoprotegerin (OPG) and its ligand OPGL are cytokines regulating 
osteoclastogenesis.  OPGL is better known as RANKL (Receptor Activator of 
Nuclear factor κB Ligand). In addition to being an osteoclast differentiation factor 
(268), RANKL also has a role in T cell- dendritic cell communication and dendritic 




OPG is a soluble decoy receptor for RANKL (OPGL), and can neutralise its ability to 
bind to RANK. OPG is produced by osteoblasts. Although a large proportion of 
circulation OPG is derived from vascular smooth muscle and endothelial cells (270) 
it may have significant potential to inhibit bone resorption by suppressing 
differentiation of osteoclasts (271). Deficiency of OPG has been reported in juvenile 
Paget’s disease (272). 
 
RANKL, a member of TNF superfamily of ligands has been recognised as a critical 
second messenger in T cell activation and subsequent differentiation of osteoclasts, 
resulting in bone loss (273). RANKL is produced by osteoblast lineage cells which 
are thought to facilitate osteoclastogenesis in a paracrine manner (274). Expression of 
RANKL mRNA and OPG mRNA vary depending on the maturation stage of 
osteoblasts. In primary calvarial osteoblast cultures treated with 1,25(OH)2D3 
RANKL mRNA expression rose during all differentiation stages except in mature 
osteoblasts (275). RANKL from activated T cells (276) may be responsible for focal 
bone erosions in inflammatory arthritis (277). Circulating RANKL has been shown to 
increase with stimulated bone resorption (277) and soluble recombinant RANKL 
administration lead to severe catabolic events in bone of rodents (278). 
 
The receptor that mediates osteoclastogenic properties of RANKL is RANK 
(receptor activator of nuclear factor κB) and belongs to the TNF superfamily. The 
role of RANK in bone resorption was demonstrated by the high bone mass phenotype 
of RANK knockout mice which were devoid of mature osteoclasts (279).  Binding of 
RANK to RANKL leads to the activation of a second messenger TRAF 6 (TNF 
receptor associated factor 6) which in turn activates various protein kinase pathways 
and transcription factors (280). 
 
While OPG and RANKL play important roles in normal bone remodelling and 
maintenance of bone mass, bone resorptive properties of IL-1, IL-7, TNF-α, TGF-β, 
estrogen, PTH, PTHrP and vitamin D are now thought to be mediated via the 
regulation of OPG and/ or RANKL (280). In vitro studies demonstrate that calcitonin 
may exert its inhibitory effects on bone resorption by enhancing OPG mRNA 
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expression (281). OPG has been shown to rise with the menopause (282), but studies 
examining the relationship between estrogen and OPG report conflicting results 
(283).  The evidence for a relationship between OPG and bone density, OPG and 
fracture (prevalent or future) or OPG and markers of bone turnover are conflicting 
(282). Therefore there is not yet evidence that OPG has any role in the clinical 
assessment in post menopausal osteoporosis.  
 
Studies of serum RANKL in postmenopausal osteoporosis reported variable results, 
which raises the issue of the suitability of the currently available assay and the fact 
that circulating RANKL levels may not reflect those in the bone. Furthermore the 
changes in OPG and RANKL in response to various modes of anti-resorptive 
treatment have been inconsistent (282). For a comprehensive review of osteoblast 
physiology in normal and pathological conditions please see Ref 281. 
 
1.4.2.4 General considerations of bone markers 
 
Various bone markers detected in serum, plasma or urine are classified according to 
the metabolic process they are considered to reflect ie: bone formation or bone 
resorption. However some markers may be released during bone formation and 
resorption and these reflect the rate of bone turnover. Another classification reflects 
the biological location of the markers, ie: osteoblastic origin, osteoclastic origin or 
the organic matrix. But the fact that these markers are also present and released from 
tissue other than bone should be born in mind. Furthermore the rise in a particular 
marker may occur during non- skeletal pathological events as well as during normal 
physiological phenomena. The patterns of rise in bone markers are not disease 
specific. Therefore in a clinical sense, although bone markers reflect the rate of bone 
turnover, on their own, they cannot be used as diagnostic markers. However, bone 
marker concentrations and patterns can be used effectively to monitor treatment 
response and disease progression. 
 
Available evidence for an association between risk of fracture and BTM are variable, 
which may be in part due to variable methodologies used to measure BTM and the 
heterogeneity in reporting fractures and fracture outcome (ie: hazard ratio for fracture 
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per SD rise in BTM, hazard ratio for fracture in the highest BTM tertile/quartile or in 
2SD above reference population (284). 
 
In an analytical sense, many of the bone markers are subject to biological variation 
(both within subject and inter – subject). Therefore the identification of a definitive 
cut-off point or an acceptable reference interval is difficult. Current cut off points are 
recommendations reflecting a desirable range, and these should be further refined 
using age and gender specific ranges. Secondly, most bone markers are susceptible to 
pre analytical factors such as time of collection, fasting status, physical activity, renal 
and liver function, haemolysis which necessitate the standardisation of collection 
practices.  Following collection most markers need to be frozen because they are 
thermo labile even at room temperature (285). UV irradiation and other ambient 
influences have also been known to cause degradation. In addition they are also 
susceptible to freeze-thaw cycles. These issues necessitate strict standardisation of 
sample handling, storage and analysis. The currently available assays lack 
standardisation and external proficiency testing programs. 
 
In order to address these vagaries, the IOF and IFCC Working Group on Bone 
Marker Standards have recommended reference markers for bone formation and 
resorption, respectively as discussed above. They are working together with 
manufacturers of assays to standardise the assays for the reference BTM (284). 
Furthermore it is anticipated that the harmonisation of methods for the reference 
markers will aid in the development of globally acceptable decision limits and 
treatment goals. Reference intervals for the nominated reference BTM for the 
Australian population have been published (286). 
 
1.5    Conclusions and proposal for the current study 
 
It is clear that with the menopause, there is an increased requirement for dietary 
calcium and a consequence of inadequate calcium intake may be - osteoporosis. 
Published studies to date suggest that adequate calcium intake, mainly in the form of 
supplemental intake, in institutionalised postmenopausal women lead to a reduction 
in bone loss, demonstrated by a fall in bone resorption markers. However 
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observational studies of community dwelling women on self-selected diets and bone 
loss have not been published. The current study proposes to ascertain if a higher 
calcium intake, through a self-selected diet leads to a reduced rate of bone loss 
compared to a lower calcium intake in community dwelling postmenopausal women.  
 
1.6 The aims and Protocol of the current study  
 
The following research project aims to establish if there is a difference between the 
rates of bone loss in post-menopausal women on self-selected low or high calcium 
diets. The rate of bone loss was assessed by serial bone density measurements. 
Baseline biochemistry allows the identification of any existing bone disease or other 
chronic disease and to investigate any relationships between these variables and 
dietary intake of calcium, as well as any relationship between these variables and the 
annual percentage bone loss. In addition, any relationship between the rate of 
fractional calcium absorption and biochemical variables in the serum and urine, and 
rate of bone loss were investigated.  
 
1.7  Hypothesis 
Self-selected diets high in calcium will prevent bone loss in community dwelling 
post-menopausal women, as demonstrated by a lower rate of fall in the bone density 
and lower levels of bone resorption markers 
1.8 Aims 
1.8.1. Validate a calcium intake questionnaire suitable for community dwelling 
women 
1.8.2. Determine the baseline total calcium intakes, bone densities and biochemistry 
in the subjects  
1.8.3. Determine any relationships between baseline measurements and dietary 
calcium 
1.8.4. Determine rate of bone loss over 2 years using 6 monthly bone densities and 
compare the rates between quartiles of calcium intakes 
1.8.5. Determine the acute effects of a calcium load on bone resorption and the 
effects of adding vitamin D to the calcium load (published papers) 
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1.8.6. Determine if metabolic syndrome as demonstrated by a greater amount of 
visceral fat influences a dietary calcium load (The influence of metabolic syndrome 
on acute effects of a dietary calcium load on bone resorption markers)  

































Materials and Methods 
 
2.1 Subject recruitment 
Ethics approval for the present study was obtained from the Royal Adelaide Hospital 
Human Research Ethics Committee (RAH protocol number 090715a, b and c).  
 
Advertisements (figure 2.1) were placed in the free community newspaper 
Messenger circulated in the Northern and North Eastern suburbs of Adelaide, 
encouraging postmenopausal women to participate in a study investigating the link 
between diet and bone density. In addition, messages were added to radio programs 
on Australian Broadcasting Cooperation on health and wellbeing, encouraging 
postmenopausal women to participate. All interested women were asked to contact a 
telephone message service and leave their name, address and telephone number. The 
messaging service then faxed these details each morning to the Clinical Chemistry 
office at IMVS/SA Pathology.  
 
The selection criteria for the subjects were: 
1. Postmenopausal women 
2. Healthy and living in the community 
 
Once the contact details of interested women were obtained, they were sent an 
information sheet (appendix 1), an accompanying letter (appendix 2), general health 
questionnaire including contact details and email address (appendix 3) and a dietary 
calcium questionnaire (appendix 4) via mail, with a stamped envelope so that the two 
questionnaires can be returned. Upon receipt of these surveys, some women were 
excluded from the study based on the following criteria: 
1. Current hormone replacement therapy or hormone replacement therapy within the 
previous 6 months 
2. Current anti-resorptive therapy or anti-resorptive therapy within the previous 6 
months 





Figure 2.1. Advertisement as it appeared in the Messenger community newspaper in 
September 2009. 
 
Of the selected women, those who had an email address were emailed the web link 
for the CSIRO diet survey at: (http://calciumstudy.ofq.csiro.au/faces/Register.jsp) 
with a username and a password created for individual subjects. The completed 
online surveys for each subject were accessed from the server and saved as Excel 
spreadsheets. 
 
When the baseline dietary data were completed the subjects were invited via letter to 
visit the Endocrine Test Unit in the Royal Adelaide Hospital for baseline blood tests 
and urine tests including a calcium absorption test (appendix 5). At this visit, the 
investigator met with the subject, and answered any questions the subject may have. 
Informed consent was also obtained at this visit (appendix 6). 
 
2.2 Baseline Blood and Urine Tests 
 
The subjects were instructed via a letter (appendix 5) to fast for 8 – 10 hours prior to 
the blood and urine tests. Upon arrival, they were given a sterile 50ml container to 




All blood specimens were obtained from the anti-cubital vein, after a minimal period 
of tourniquet application. Two serum specimens (plain gel tubes, 8 ml each) were 
collected for biochemistry, vitamin D, parathyroid hormone (PTH) and C-terminal 
telopeptides (β crosslaps, CTX). A single plasma specimen (into a lithium heparin 
tube, 8ml) was collected as the baseline specimen for the calcium absorption study 
(detailed below). All specimens were promptly sent to the laboratory. 
 
2.3 Analysis of Specimens 
 
Routine biochemical parameters were assayed on an automated Olympus AU 5700 
instrument as per the manufacturer’s instructions. 
The specific methods used are given in table 2.1 below. 
 
Table 2.1. Details of assay methods used in the biochemical analysis 
 
A Analyte Assay method 
Sodium, potassium and 
chloride 
indirect ion selective electrodes 
Bicarbonate Enzymatic method using phosphenol 
pyruvate carboxylase to convert HCO3- and 
PEP and malate dehydrogenase as 
secondary enzyme 
Glucose Hexokinase and glucose 6 phosphate 
dehydrogenase 
Urea urease reaction with glutamate 
dehydrogenase as secondary enzyme 
Creatinine Jaffe reaction (yellow-orange compound 
with alkaline picrate) 
Urate Enzymatic method using uricase and 
peroxidase 




Total calcium Arsenazo III reaction to produce a purple 
complex 
Albumin Bromocresol purple complex formation 
Total protein cupric ions in alkaline solution to produce a 
blue violet complex 
Total bilirubin Diazo reagent in the presence of caffeine 
and surfactant 
Gamma glutamyle transferase 
(GGT) 
Szasz procedure – activity using gamma-
glutamyl-3 carboxy 4-nitroanilide 
Alkaline phosphatase (total) 
(ALP) 
rate of conversion of pNPP to p-nitrophenol 
Alanine amino transferase 
(ALT) 
 
Enzyme activity using 2-oxoglutarate and 
L-alanine as substrates and lactate 
dehydrogenase as the secondary enzyme 
Aspartate amino transferase 
(AST) 
 
Enzyme activity using 2-oxaloacetate and 
L-aspartate with malate dehydrogenase as 
the secondary enzyme 
Lactate dehydrogenase Enzyme activity using lactate as substrate 
Total cholesterol cholesterol esterase and cholesterol oxidase 
High density lipoprotein-
cholesterol (HDL) 
Anti-human β lipoprotein antibody is used 
to bind to lipoproteins other than HDL 
(LDL, VLDL and chylomicrons). HDL then 
reacts with cholesterol esterase and 
cholesterol oxidase 
Triglycerides lipase, glycerokinase, glycerol PO4 oxidase 
and peroxidase 
CRP (C reactive protein) Immunoturbidimetric assay 
 
Calculated parameters: 
Some of the biochemical variables were calculated using measured values and these 
with the equations are shown below. 














= total Ca – {(0.01257[Ca] albumin)/(1+0.01257[Ca])} – 
{(0.0049[Ca]globulin)/(1+0.0049[Ca])} – {(0.0835[Ca]anion gap)/(1+0.0835[Ca])} 
– {(0.0759[Ca]bicarbonate)/(1+0.0759[Ca])} 
Where [Ca] = ionised Ca (287) 
 
Globulins (g/L) = total protein (g/L) – albumin (g/L)  
 
The estimated glomerular filtrations rate was also available, calculated using the 
MDRD formula (288). 
 
eGFR (mL/min/1.73 m2) = 175 × (Scr)
-1.154 × (Age)-0.203 × 0.742  
 
LDL (low density lipoprotein) was calculated using the Friedeweld formula (289): 
 
LDL = total cholesterol – (HDL–cholesterol) – triglyceride/ 2.2 
 
25 hydroxyvitamin D (25OHD) 
The assay for 25OHD uses an automated competitive binding chemiluminescence 
method. Samples in duplicate are pre-treated to denature vitamin D binding protein 
then neutralised with assay buffer. Anti 25OHD antibody labelled acridinium is then 
added to the samples. After incubation magnetic particles bound to 25OHD are added 
to each sample followed by a further incubation step. The magnetic particles are 
captured using a magnet which removes unbound anti-25OHD antibody. A trigger 
reagent is added to catalyse the light emission from acridinium, which is inversely 
proportional to the concentration of 25OHD in the original sample. All reagents are 
supplied by Immunodiagnositics (IDS Inc, USA) and the assay is run on the IDS-
iSYS Multi-Discipline Automated Analyser. 
 
1, 25 dihydroxyvitamin D (1,25(OH)2D) 
Serum 1,25(OH)2 D was measured using a radioimmunoassay using reagents 
supplied by Immunodiagnostics (IDS Inc, USA) according to manufacturer’s 
60 
 
instructions. The radioactivity was read on a Perkin Elmer 2470 gamma counter and 
the concentrations were calculated. 
    
Parathyroid hormone (PTH) 
PTH was measured using a heterogeneous sandwich immunoassay using biotinylated 
antibodies and ruthenium labelled antibodies. The automated assay is run on Roche 
Modular Analytics E170 using Roche reagents (Roche Diagnostics GmbH, 
Mannheim). 
 
β Crosslaps (CTX) 
Serum CTX was measured using a 2 step electrochemiluminescence immunoassay 
using biotinylated monoclonal antibodies, streptavidin coated microparticles and anti 
CTX antibody labelled ruthenium complex. All reagents were supplied by Roche 
Diagnostics and the assay was run on Roche Modular Analytics E170 (Roche 
Diagnostics GmbH, Mannheim). 
 
Calcium absorption 
Active intestinal absorption of calcium was assessed using radiocalcium (45Ca) with 
20 mg CaCl2 as carrier using the following protocol (290). 
After an overnight fast, 2 x 10 ml of non-stasis venous plasma samples (into a Li 
heparin tube) were collected. The patient was then given a 250mL dose of distilled 
water with 5µCi (in 3 mL of working solution prepared by diluting stock solution 
with an activity of 26.53mCi/mL) of 45Ca isotope and 20mg of stable calcium. (3 mL 
of this solution was retained by the laboratory for the subsequent steps in the 
analysis). Another 10ml non stasis venous sample was collected one hour after 
drinking the dose. 
Following centrifugation, 2mL of plasma from each of the samples were added to 
12mL of scintillation fluid. 100µL of the retained dose was added to one of the pre-
dose plasma samples.  The 3 vials were counted on a Packard Tri-Carb Scintillation 
Counter. Radiocalcium absorption was automatically calculated by the laboratory 
computer. 
The fractional Ca absorption was calculated as follows: 
Fraction of radioactive Ca dose per L of plasma = Fx/L 
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Fx/L = 0.01117 + 1.54 X (1/body weight) 
Fractional Ca absorption = FC 
FC = Fx in 10 L – [15.4 X (1/body weight) – 0.0154] 
 
The baseline blood test included electrolytes (sodium, potassium, chloride, 
bicarbonate), anion gap, glucose, urea, creatinine, estimated glomerular filtration 
rate, total cholesterol, urate, phosphate, total and ionised calcium, albumin, globulin, 
total protein, total bilirubin, GGT, ALP, ALT, AST, lactate dehydrogenase, 25 OH 
vitamin D, CTX, PTH and radiocalcium absorption. These tests were repeated at 12 
months with the addition of CRP and cortisol. 
 
2.4 Bone density measurement 
When the subject had completed the blood and urine tests, they were given 
appointments to attend the Endocrine and Metabolic Unit Bone Densitometry Service 
(Norland, Cooper Surgical Company) at the Royal Adelaide Hospital for assessment 
of bone density at three sites. Lumbar spine (L1 to L4), femoral neck, total hip, 
proximal and ultradistal forearm were measured. The bone density was reported in 
g/cm2. T and Z scores were included in the reports. Body weight (kg) was obtained 
using digital scales, with the subjects wearing light clothing and no shoes. Height 
(cm) was assessed using a stadiometer and the body mass index (BMI) calculated as 
weight in kilograms divided by the square of height in meters. 
 
2.5 Visceral fat measurement 
The fat mass in the lumbar region was measured using DXA as a separate measure 
using Research Mode on the instrument (Norland, Cooper Surgical Company). Bone 
mineral density (g/cm2), bone mineral content (g), lean mass (g) and fat mass (g) 
were obtained. The waist circumference of the subjects was also obtained during this 
measurement using a centimetre tape, placed around the smallest circumference in 
the torso. 
 
Upon the completion of the baseline bone density measurement, 6 monthly 
appointments for repeat bone density measurements were made for each subject (5 in 
total). At the 12 months’ bone density appointment they were given the paper based 
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dairy food frequency questionnaire to complete. They were also sent emails with the 
link for the CSIRO online FFQ and a blood test request form was mailed out to the 
subjects at this point.  
 
The 12 month blood test included the baseline blood tests except radiocalcium 
absorption. In addition to these, triglycerides, HDL, LDL, Cortisol and 1,25 (OH)2 
vitamin D were measured. 
 
 
2.6 Validation of the Dietary Ca Questionnaire 
The short calcium intake questionnaire was validated by using a 3 day weighed food 
records for 26 subjects who agreed to participate in the validation following baseline 
blood sample collection and bone density measurements. The short calcium 
questionnaire was compared with the previously validated online food frequency 
questionnaire for the same 26 subjects as further validation.  
 
2.6.1 Introduction 
Despite nation-wide attempts at estimating nutritional intakes of Australians, there is 
currently a gap in the knowledge of intakes of specific nutrients, especially calcium. 
The latest National Health Measures Survey (39) published extensive data on fruit 
and vegetable intakes and vitamin D intakes but calcium intakes were not estimated. 
Previously published data suggest that calcium intakes among both male and female 
Australians are, on average, well below the recommended daily intakes (RDI) (103). 
Particularly in postmenopausal women, the intakes appear to fall well short of the 
RDI. After the menopause, calcium absorption decreases with age (291) while 
urinary calcium losses rise (292) increasing the RDI. However an individual’s dietary 
habits may not change to accommodate the increase in RDI to maintain calcium 
balance. The Geelong Osteoporosis Study demonstrated that 87% of older Australian 
women had intakes below the RDI (127).  
 
The lack of data on nutrient intakes is partly due to the lack of validated and easy-to-
use tools for the estimation of intakes. Food-Frequency Questionnaires (FFQ) are 
widely used in epidemiological studies to gather data on a variety of nutrients. They 
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are inexpensive and self-administered. However they are by nature, extensive and 
lengthy in order to include all consumed food items. This leads to inaccurate results 
due to subject boredom and lack of time. There is also inaccuracy introduced to the 
estimate due to cognitive challenges in estimating usual intakes over a period of 
months to a year. In addition, although validated for multiple nutrients, they are 
inadequate and less accurate in estimating the intake of a single nutrient (168). They 
may not be appropriate for all age groups, as many are only available online. Some 
may require analysis using a computer, therefore the result is not readily available. 
These are not suitable for use in the clinical setting where estimates need to be made 
during consultation, or in the research setting, where estimates need to be made 
during subject enrolment (293) particularly when subjects are screened based on their 
dietary intakes. 
 
Various FFQs have been validated for estimating calcium intakes but these have been 
developed decades ago (127,294) although still in use (295), they may not be relevant 
today (296). Most studies published prior to 2000 do not include dietary supplements 
(168) and for a nutrient such as calcium, supplements may make up a significant 
proportion of intake. Due to various campaigns promoting supplementary calcium, a 
significant contribution from dietary supplements to total daily calcium is expected. 
In addition, the reproducibility of FFQs for calcium has not been assessed in the 
published validation studies. Despite weighed food records (WFR) being the method 
of choice for validating FFQs, only 2 (127,296) out of 4 validation studies of calcium 
FFQs used WFR. The other 2 used food records only (297,298).  None of these 
published validation studies assessed reproducibility of the questionnaire.  
 
Accurate, reproducible results obtained using an easy – to –use questionnaire for 
estimating calcium intake would contribute to the clinical and research fields. In 
addition, Australian dietary intakes have undergone considerable change with more 
multicultural food items becoming available and the high consumption of dietary 
supplements. The aims of the current study are to validate a short quiestionnaire of 






2.6.2.1 Participant Recruitment and Data Collection 
Volunteer postmenopausal women participating in an observational, non-
interventional prospective study of bone density were invited to participate in the 
short calcium questionnaire (SQ) validation study. Ethics approval was granted by 
the Royal Adelaide Human Research Ethics Committee (Protocol number 09071; 
29th July 2009) and informed consent was obtained from each subjects. Demographic 
data, medical history and medication were recorded. Each subject met with a 
researcher, who gave them verbal instructions on how to complete the 3-day WFR, 
provided them with electronic kitchen scales (Homemaker Slimline Electronic Scale, 
China) and demonstrated how to use it. The SQ consisted of food items high in 
calcium (mainly dairy). A baseline intake of 300mg calcium was added to the total 
obtained from the SQ to account for non-dairy calcium intake derived from dietary 
modelling based on daily food intake of a 60 year old female (Appendix 4). After 
completing the baseline SQ on paper they were given access for an online FFQ (298) 
at home or when they revisited the dietician to submit the WFR. SQs which were 
completed by the subjects 24 and 12 months prior to this study as part of the 
observational study, were used to assess reproducibility. Calcium added to the daily 
intake by supplements was added to the intakes obtained from all methods. 
 
2.6.2.2 Nutrient Analysis and Statistical Analysis 
Dietary data were analyzed using a database of Australian foods (Foodworks, Xyris 
Software, Australia) for the SQ and WFR. The online FFQ was based on a previously 
published FFQ (298). Mean difference and standard deviation of differences were 
calculated for calcium intakes assessed by SQ and WFR, SQ and FFQ and FFQ and 
WFR. In order to ensure robustness of the validation, a range of statistical techniques 
were used. Wilcoxon paired samples tests were used to determine whether the 
estimates of intakes were significantly different between methods. Bland-Altman 
plots were used to assess the agreement between the 3 methods. A cross classification 
method was used to further assess the agreement between the methods, as follows: 
Subjects were ranked into tertiles according to calcium intakes for each method. The 
degree of agreement between the methods was determined using linear weighted 
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kappa (κ) statistic with 95% confidence intervals. The percentage of subjects 
classified as meeting or not meeting the RDI (1300 mg per day for postmenopausal 
women) by each method were determined. A Student’s t test was used to determine if 
the current estimates of Ca intake using SQ was significantly different from estimates 
24 and 12 months prior (reproducibility), collected as part of the observational study. 
Only dietary Ca intakes were considered for the reproducibility study because 
subjects may have started, ceased or changed calcium supplements.  Statistical 
analysis was performed using Analyse-it for Microsoft Excel 3.60.5, 1997-2015 
(Analyse-it Software Ltd, Leeds, UK). 
2.6.3 Results  
Twenty six women completed the validation study. Demographic data and Ca intakes 
from the 3 methods for the 26 subjects who completed the study are presented in 
table 26.1.  
 
Table 2.6.1. Demographic data and Ca intakes by the 3 methods. 
 Mean SD Range 
Age(years) 62 4 55 - 68 
Height (m) 1.61 0.04 1.53 – 1.69 
Weight (kg) 66 14 47 - 106 
BMI 25.5 4.9 19.1 – 38.2 
Ca intakes (mg/day) 
FFQ 1180 488 460 - 2225 
SQ 1080 488 360 - 2125 
WFR 1034 517 383 - 2306 
 
There were no significant differences between the WFR and SQ (P=0.38), WFR and 
FFQ (P=0.186) or SQ and FFQ (P=0.36) estimates of mean calcium intakes.  The 
degree of agreement between these methods in ranking subjects to tertiles of intakes 




Table 2.6.2. The degree of agreement between methods in ranking subjects 
into tertiles of intakes and classifying into meeting or not meeting RDI. 
 Degree of agreement in linear weighted kappa 
 Ranking of subjects into 
tertiles of    Ca intake 
Classifying whether 
meeting  RDI  
WFR vs SQ 0.38 (fair) 0.54(moderate) 
WFR vs FFQ 0.38 (fair) 0.39 (fair) 
SQ vs FFQ 0.66 (substantial) 0.59(moderate) 
 
Bland Altman plots (figures 6.2.1, 6.2.2 and 6.2.3) depict the mean bias for calcium 













(WFR + SQ) / 2
 
Figure 6.2.1. Bland-Altman plot, WFR (weighed food record) against SQ 
(short questionnaire). The mean bias was 46.2 mg/d (95% CI -783.5 to 





















Figure 6.2.2. Bland-Altman plot, SQ against FFQ (online). Mean bias -130 mg/d 





















Figure 6.2.3. Bland-Altman plot, WFR against FFQ. Mean bias 176.3 mg/d 




There was considerable bias or disagreement between WFR and FFQ (mean 176.3 
mg; 95% CI -1149.7 to 1502.2; 1.96SD) and between SQ and FFQ (mean -130.0 mg; 
95% CI -1187.6 to 927.5). The bias between WFR and SQ was much less at 46.2 mg 
(95% CI -783.5 to 876.0 mg/d).  However none of these biases were statistically 
significant. 
 
With regards to the reproducibility of the SQ there was no significant difference 
between the current estimates and 24 months prior (P=0.97) and 12 months prior 
(P=0.66). 
2.6.4  Discussion and conclusions 
Despite substantial agreement between SQ and FFQ in ranking subjects into tertiles 
of intake, there was considerable overall bias, although not statistically significant, 
between the 2 methods of estimating Ca intakes. SQ showed moderate agreement 
with WFR for classifying subjects into meeting or not meeting RDI, and also showed 
the least bias. SQ was reproducible, as shown by yearly estimates over 3 years.  
  
Generally the subjects in this study had a high intake of calcium perhaps due to the 
awareness of the study’s objectives in terms of validating a questionnaire of calcium 
intakes and the observational study on bone density.  
 
When estimating Ca intakes in a clinical or research setting, it is important to have a 
brief but accurate tool, to save time. The FFQ used here was developed for the 
estimation of multiple nutrients and was considerably biased when compared to 
WFR, generally overestimating intakes while SQ showed minimal bias and better 
agreement with WFR.  The ability to complete the dietary questionnaire while 
waiting for or during consultation is an added advantage of an SQ. Immediate 
feedback given to the patient is of value because this is an effective strategy to 
increase Ca intakes in individuals with inadequate intakes (297). Amongst the 
subjects recruited for this study some 69% did not meet the RDI of calcium, 
consistent with previously published figures of up to 76% falling short of the RDI 
(127). Whether a patient meets RDI or not is important when advising them on their 
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requirement of Ca supplements and SQ may be used in the clinical setting for this 
purpose. 
The reproducibility of the SQ in this study suggests that it is suitable to be used in the 
2 year prospective observational trial the women were initially recruited to, and can 
be used to determine if their calcium intake varied significantly during the study. 
 
The background or base intake of calcium was considered to be 300 mg/d from all 
non-dairy sources, derived from dietary modelling based on daily food intake of a 60 
year old woman. Further refinement of the short questionnaire may be required in 
terms of including food items that contain dairy such as cheese toppings in pizza and 
Mexican food (nachos, tacos etc). 
 
2.7 Statistical Analysis 
2.7.1 Relationship between baseline biochemistry and habitual calcium intake 
The correlation between baseline biochemistry (CTX, PTH, 25 OH vitamin D, ALP, 
radiocalcium absorption, rate of urinary Ca excretion) and habitual total Ca intake 
were assessed using linear regression. Additionally, maintenance of habitual calcium 
intake was assessed by re-administering SQ and FFQ at 12 months and 24 months to 
identify any significant change from baseline calcium intakes. 
 
2.7.2 Relationship between baseline biochemistry and bone density 
The relationship between baseline biochemical variables and baseline bone density of 
the proximal and ultradistal forearm, lumbar spine, femoral neck and total hip were 
analysed using linear regression and Pearson’s correlation. 
2.7.3 Rate of change in bone density 
The subjects were divided into 3 groups using the tertiles of daily total Ca intake. The 
rate of change in bone density for each measured site for each quintile of daily total 
Ca intake was calculated by subtracting the latest value from the previous value. The 
rates of change in bone density for the 3 tertiles of Ca intakes were compared against 
each other. 
The rate of change in bone density was correlated to baseline bone density of each 
site and to baseline biochemistry (CTX, PTH, 25 OH vitamin D, ALP, radiocalcium 
absorption, rate of urinary Ca excretion). 
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2.7.4 Relationship between visceral fat and other measured parameters 
Visceral fat measurement was correlated with baseline biochemistry (CTX, PTH, 25 
OH vitamin D, ALP, radiocalcium absorption, rate of urinary Ca excretion), baseline 
bone density of measured regions, daily total Ca intake and daily dietary Ca intake 
linear regression and multivariate ANOVA.   
 
2.7.5 Relationship between metabolic syndrome and bone metabolism 
Metabolic syndrome was defined as a waist circumference greater than or equal to 
88cm (ATP criteria). The subjects were divided to 2 groups, those with metabolic 
syndrome and those without, based on the waist circumference. The waist 
circumference was correlated with the visceral fat measurement to confirm that a 
greater waist circumference was due to higher amounts of visceral fat. Baseline 
biochemistry (CTX, PTH, 25 OH vitamin D, ALP, radiocalcium absorption, rate of 
urinary Ca excretion), baseline bone density of measured sites, the rate of change in 
bone density and daily total and dietary Ca intake were compared between the 
groups. 
The influence of overweight/obesity (ow/ob) on bone density, and the relationship 



















Recruitment and progression of subjects, baseline biochemistry, the 
prevalence of osteoporosis and osteopenia and calcium intakes  
 
In order to evaluate the effects of calcium intake on changes in bone density in 
community – dwelling post-menopausal women, subjects were recruited to a 2 year 
observational prospective study.  The methodology is given in detail in chapter 2 
(2.1). Briefly, ethics approval was obtained to recruit community-dwelling post-
menopausal women to participate in a prospective observational study of calcium 
intakes and bone densities.  A detailed account of recruitment and progression of 
subjects during the 2 years of the study is described below. This chapter also contains 
the baseline biochemistry and the prevalence of osteoporosis and osteopenia in the 
subjects.  
 
3.1 Recruitment of subjects 
In response to the advertising, 273 women contacted the nominated call centre 
telephone number and provided their contact details. Out of these 12 women were 
excluded because they were pre or peri-menopausal. The remaining 261 (95.6%) 
women were mailed the basic health questionnaire (Appendix 3), the FFQ (Appendix 
4), information for subjects (Appendix 1) and a letter (Appendix 2) inviting them to 
participate in the study. Only 180 (69%) were returned, out of which 5 were excluded 
(n=1 on a bisphosphonate; n=2 malignancy, n=2 chronic renal failure). 
 
3.1.1 Progression of subjects 
The remaining 175 women were then contacted and appointments were given for 
fasting blood tests and baseline bone density measurements. Figure 3.1 depicts the 






Figure 3.1. Progression of subjects 
 
 
3.1.2 Number of subjects completing each stage of the study 
Only 132 women arrived for their blood tests and 129 out of these for the baseline 
bone densities. All subjects received a copy of the bone density report, and those who 
had osteoporosis at least in one site were given the option of being referred for 
specialist treatment (n=16). All but 1 declined this invitation and continued to 










Table 3.1. The number of subjects completing each stage 
    Number  percentage  
Enquired   273    
Invited to participate  261    
Completed FFQ   180    
Recruited   175       100 
Baseline biochemistry  132   75 
Baseline BMD   129   74 
2nd BMD (6 months)  120     69 
2nd Biochemistry (12 months) 97   55 
 
3.2 Baseline data  
3.2.1 Demographic data 
Demographic data are presented in table 2 for the 129 subjects that attended for their 
baseline bone density, where their height and weight were measured. 
 
Table 3.2 Demographic data. 
     Mean range  SD 
Age years   61 51 – 73 5 
Height m   1.62 1.48–1.81 0.06 
Weight kg   66 45 – 108 12 
BMI kg/m2   25 18 – 42 4 
YSM years   10 1 – 39  7 
YSM = years since menopause 
 
3.2.2 The prevalence of osteoporosis and osteopenia in the subjects enrolled 
 
Table 3.3 below lists the number of subjects who were diagnosed with osteopenia or 
osteoporosis at each measured site on the first (baseline) bone density scan, 
according to WHO criteria (bone density for each site below 2.5 standard deviations 
from the young normal average for Australian women classified as osteoporosis, and 
bone density between 1 and 2.5 standard deviations below the young normal average 




Table 3.3   The numbers of subjects with osteopenia and osteoporosis at specific 
anatomical sites. 
 
Site  Number Osteopenia Osteoporosis 
   scanned No % No % 
LS  L2 – 4 129  39 30 11 9  
FN  129  74 57 7 5 
TH  129  45 35 4 3 
PFA  48  45 37 12 10 
UDFA  48  31 25 0 0  
LS = lumbar spine, FN = femoral neck, TH =  total hip, PFA = proximal 
forearm, UDFA = ultradistal forearm. 
 
The prevalence of osteoporosis at any site in this group was 12% (n=16) and the 
prevalence of osteopenia at least at one site is 56% (n=72). The estimated prevalence 
of osteoporosis in community dwelling Australian adults aged 50 years and over is 
9% (15% among women and 3% among men) based on self-reported surveys 2011-
2012 (299).   
 
The following histograms (figures 3.2 to 3.7) depict the overall prevalence of 
osteoporosis and osteopenia at each site measured in the subjects compared to that in 
the community as reported in Australian postmenopausal women in a previous study 
investigating calcium intakes and bone density, the Geelong Osteoporosis Study 
(GOS) (127). In addition the histograms also indicate the prevalence of each 
condition in the subjects of the present study with a total calcium intake that met the 
daily requirement of 1300mg (adequate Ca intake), in those who did not meet the 
requirement (low Ca intake) and in subjects that took a calcium supplement and those 
who did not. While the GOS reported a more than 20% prevalence of osteoporosis in 
females over the age of 50 years (127) which exceeds the AIHW 2014 reported 
prevalence (299), the prevalence of osteoporosis in the subjects of this study was 9% 
at the lumbar spine, 7% at the femoral neck and 4% at the hip. Osteopenia was 
reported in more than 70% of females over the age of 50 years (127). The prevalence 
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of osteopenia in the subjects of the present study was 30% at the lumbar spine, 74% 
at the femoral neck and 45% at the hip. The prevalence of osteoporosis in the 
subjects was much less than the reported prevalence in Australian community 
dwelling post-menopausal women at all sites measured while the prevalence of 
osteopenia at the femoral neck in the study group was consistent with that reported 
by GOS (127).  
 








Figure 3.2. Prevalence of osteoporosis in the lumbar spine in the participants of the 
present study (blue bars); reported prevalence for the Australian female population 
over 50 years (red bar, Geelong Osteoporosis Study 2011, Ref 127).  All participants 
= all subjects in the current study; High Ca intake = intakes >/= 1300mg, low Ca 














Figure 3.3 Prevalence of osteoporosis in the femoral neck in the participants of the 
current study (blue bars); prevalence for the Australian female population over 50 
years (red bar, Geelong Osteoporosis Study 2011, Ref 127). All participants = all 
subjects in the current study; High Ca intake = intakes >/= 1300mg, low Ca intake = 
intakes <1300mg/d. 
 








Figure 3.4 Prevalence of osteoporosis in the total hip in the participants of the current 
study (blue bars); prevalence for the Australian female population over 50 years (red 
bar, Geelong Osteoporosis Study 2011, Ref 127). All participants = all subjects in the 






Figure 3.5. Prevalence of osteopenia in the lumbar spine in the participants of the 
current study (blue bars); prevalence for the Australian female population over 50 
years (red bar, Geelong Osteoporosis Study 2011, Ref 127). All participants = all 




Figure 3.6. Prevalence of osteopenia in the femoral neck in the participants of the 
current study (blue bars); prevalence for the Australian female population over 50 
years (red bar, Geelong Osteoporosis Study 2011, Ref 127). All participants = all 






 Figure 3.7. Prevalence of osteopenia in total hip in the participants of the study (blue 
bars); prevalence for the Australian female population over 50 years (red bar, 
Geelong Osteoporosis Study 2011, Ref 127) All participants = all subjects in the 
current study; High Ca intake = intakes >/= 1300mg, low Ca intake = intakes 
<1300mg/d. 
 
3.3 Baseline calcium intakes in the subjects 
3.3.1 Baseline Calcium intakes as per validated short questionnaire  
A self- administered short questionnaire (SQ) was validated in a subset of the 
subjects, against weighed in food records (WFR) (see 2.6; Chapter 2 Material and 
Methods for details of the validation process). A total of 175 women completed the 
SQ.  SQ considers dairy and other calcium rich food and an extra 300mg/day was 
added to the total to account for dietary items not listed. This baseline intake of 
300mg/day was determined by dietary modelling of the daily intakes of a 60 year old 
woman with a sedentary lifestyle. The mean age of this group was 60.6 (SD 5, range 
51 – 78). Total daily Ca intake on average was 1114 mg (SD 498, range 300 – 2589) 
and the Ca obtained daily from diet alone on average was 860mg (SD 299, range 300 
– 1790). Out of this 175, 73 subjects were taking Ca supplements (42%). When 
considering the total intake of Ca, only 31% of the women met their recommended 
daily intake of Ca of 1300mg. When dietary Ca only was considered (without 
supplements) only 9.7% met their daily requirement. Of those who were taking 
supplements, 59% took a daily dose between 500 and 999mg, 17% were on >1000mg 
and 24% were on a dose <500mg. The most commonly consumed supplement was 
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CaCO3 with added vitamin D (Caltrate, Pfizer Inc, NC, USA).  Figure 3.7 depicts the 


























Percentage women taking calcium 
supplements
 
Figure 3.8. Types of Ca supplements and percentage of women consuming them. 
 
3.3.2 Baseline Calcium intakes as per online questionnaire  
The online CSIRO questionnaire is a food frequency questionnaire (FFQ) designed to 
estimate all nutrients using average intakes recalled from a period of 12 months, 
therefore includes seasonal fruit and vegetables. However it did not include any 
supplemental intakes. All 175 women invited to participate in the study were sent log 
in information (web link, log in name and a password) to complete the FFQ. Out of 
these 131 women completed it. The comparison between SQ with and without Ca 











Table 3.4. Comparison between SQ total intake (including supplements), SQ diet 
only intake and online FFQ dietary Ca intake 
 
 SQ total intake mg/d SQ diet mg/d FFQ mg/d 
number 175 175 131 
Age, mean(SD) y 60.6 (5) 60.6 (5) 60.6 (5) 
range 51 - 78 51 - 78 51 - 78 
Intake, mean(SD) 1114 (498) 860 (299) 1180 (478) 
range 300-2589 300-1790 400 - 2552 
% meeting RDI 31 9.7 30 
 
 
Figure 3.9. Linear regression between SQ and FFQ daily Ca intakes.  
 
Linear regression between the SQ and the online FFQ showed a poor correlation with 
an R2 of 0.22. The lack of agreement between these 2 questionnaires may be because 
the online FFQ was more extensive and included all food items consumed (estimated 
over a period of 1 year) whereas the SQ included dairy and fish. Although a 
‘background’ calcium intake of 300mg/d was added to the SQ to account for non-
dairy and non-fish calcium sources (modelled on a 60 year old women with a 
sedentary lifestyle by a senior dietician) this may not apply to the subjects of our 
study who appear to be more ‘health conscious’ and active. Therefore the SQ may 
81 
 
have underestimated their calcium intake. On the other hand, because the online FFQ 
was very extensive and the subjects were able to log in and complete the 
questionnaire over several days the intakes may not be estimated accurately, and may 
have overestimated their intakes. however it did not account for any supplements. 
Overall, the agreement between SQ and FFQ was low. 
.  
3.4 Baseline biochemistry  
Fasting baseline biochemistry of serum including fractional calcium absorption and 
urine were completed by 131 subjects in order to identify any renal or hepatic disease 
or electrolyte imbalances including abnormal calcium homeostasis. The results are 
given in table 6 below. 
 
Table 3.5 Baseline fasting serum and urine biochemistry 
 
Analyte   mean SD range  RI 
HCO3- (mmol/L) 27 3 20 – 35 22 – 32  
AG (mmol/L)  14 3 7 – 22  7 – 17  
Creatinine(umol/L) 61 10 38 – 92 50 – 100  
iCa (mmol/L)  1.22 0.04 1.15 – 1.40 1.10–1.30  
tCa (mmol/L)  2.38 0.08 2.19 – 2.68 2.10–2.55  
PO4 (mmol/L)  1.15 0.13 0.86 – 1.46 0.65–1.45  
ALP (IU/L)  83 25 27 – 175 30 – 110  
CTX (ng/L)  451 183 70 – 1064 <400  
PTH (pmol/L)  4.4 1.7 0.6 – 11.2 0.8 – 5.5  
25OHD (nmol/L) 73 25 21 – 157 60 – 160  
UCa:Cr   0.27 0.21 0.03 – 1.40 0.03–0.40 
UNa:Cr   10.5 7.5 1 – 48 
Ca abs   0.60 0.22 0.15 – 1.34 >0.5 
 
There were no subjects with renal impairment or hepatic disease. Most other analytes 
including electrolytes were within the reference interval.  The desirable range for 
bone resorption marker, C-terminal telopeptide (βCTX) was set at <400 ng/L by the 
local laboratory (Institute of Medical and Veterinary Science / SA Pathology) 
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following a survey of βCTX levels in healthy premenopausal women. When this cut 
point is used, 58% of the subjects had a greater than desirable level of bone 
resorption. The current Australian consensus reference interval for postmenopausal 
women on fasting morning serum βCTX (aged 50 to 70 years) is 50 – 800 ng/L.  
Based on this criterion, only 4% had an increased rate of bone turnover. CTX 
however is subject to acute changes in response to various factors therefore raised 
CTX was not included as in the exclusion criteria. There were 3 subjects with PTH 
above the upper limit of the reference interval, but all 3 had normal total and ionised 
calcium suggesting secondary hyperparathyroidism. A more detailed description of 
cross-sectional biochemistry data is presented in Chapter 4. 
 
3.4.1 Vitamin D status 
The proportion of subjects in each category of deficiency and the ABS reported 
proportions for the general population are given in table 3.6. The majority of this 
group of women were vitamin D sufficient (85% >50 nmol/L). Three subjects had 
levels below 30nmol/L but none were below 13nmol/L. According to NHMS 23% of 
Australian adults are vitamin D deficient but only 15% of adults aged 65 – 74 years 
are deficient (39). The mean serum 25OHD level in the subjects was slightly higher 
than average at 73nmol/L (SD 25).  In the South Australian population 55 to 64 years 
and 65 to 74 years are 68.9 nmol/L (IQR 55.0, 81.0) and 69.8nmol/L (IQRI 56.4, 
82.0) respectively. In South Australia, 15% of adults are vitamin D deficient in 
summer and the rate rises to 42% in winter (39).  
 
Table 3.6 Serum 25OHD in the subjects of the current study and 25OHD levels 
reported for the Australian population (39) 
Deficiency category serum 25OHD Australian population  
 25OHD nmol/L  Subjects (%) (male and female) % 
    51 – 73 years 55 – 64 years 65 – 74 years 
Sufficient  ≥ 50  111 (85) 81.6  83.4 
Mild deficiency 30 – 49 17 (13)  15.1  13.0 
Moderate/severe <30 3 (2)  2.4  2.4  




Vitamin D status determined by serum 25OHD levels in the subjects of the current 
study are comparable to those reported by the NHMS (39) for the Australian 
population over the age of 55. Blood samples in the subjects for this study were 
collected as they were recruited throughout the year, therefore a distinction between 
winter and summer levels were not made.  
 
3.4.2 Parathyroid hormone and its relationship to other analytes 
The relationship of PTH to other analytes for the 129 subjects recruited for the study 
was examined using regression analysis and ANOVA (table 3.9). 
 
Table 3.7. Relationship between baseline serum PTH and other analytes 
Analyte iCa tCa PO4 25OHD ALP CTX Ca abs# Ca:Cr* 
Multiple R 0.063 0.069 0.109 0.077 0.109 0.303 0.147 0.109 
R2  0.004 0.005 0.012 0.006 0.012 0.092 0.022 0.012 
Adjusted R2-0.004 -0.003 0.004 -0.002 0.004 0.085 0.014 0.004 
SE  0.039 0.085 0.129 25.202 24.61 175.81 0.209 0.219 
n  127 130 130 130 130 130 128 124 
ANOVA   
F  0.505 0.604 1.553 0.769 1.528 12.918 2.796 1.483 
P  0.478 0.439 0.215 0.382 0.219 0.004 0.097 0.226 
# fractional Ca absorption; * urinary calcium excretion rate  
 
Baseline serum PTH was significantly related to baseline CTX suggesting that a 
higher serum PTH may lead to a higher rate of bone turnover. No other measured 
analyte was related to serum PTH. PTH may be determined by dietary Ca intake and 
may not be explained by 25OHD status alone. It is possible that in those with low 
25OHD, serum PTH may remain within the normal range if dietary Ca was adequate. 
The effects of PTH on other biochemical variables and the effect of Ca intake on 
PTH will be discussed in detail in Chapter 4. 
 
3.5 Discussion 
This is a cross sectional analysis of calcium intakes, prevalence of osteoporosis and 
biochemical parameters relating to calcium metabolism in a sample of community 
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dwelling post-menopausal women. Only 50% of eligible subjects enrolled in the 
study and 37% attended at 6 months.  
 
The prevalence of osteoporosis and osteopenia of the subjects of the current study 
were comparable to those reported for healthy Australian older persons (over the age 
of 50) (299). A previous study (127) however reported higher rates of prevalence of 
osteoporosis in their subjects. In that study, all adults enrolled in the Commonwealth 
Electoral roll as a resident of the Geelong area fulfilled the criteria to participate. 
Therefore the women in the age categories of >50 years may have included residents 
of assisted-care living facilities, those with minimal mobility and those with chronic 
disease. This may have resulted in the higher prevalence of osteoporosis and 
osteopenia in their subjects compared to the reported prevalence for healthy 
Australian population reported by AIHW, where the prevalence was determined by 
general practitioner diagnosed osteoporosis in community dwelling otherwise healthy 
individuals, thus excluding people with chronic disease and other factors such as long 
term glucocorticoid treatment that may lead to osteoporosis (299). It is also relevant 
that this reported prevalence, while representative of ‘doctor-diagnosed’ 
osteoporosis, may underestimate the actual prevalence of osteoporosis in the 
community. This is because routine bone density screening for osteoporosis is not 
offered due to restricted funding by Health Insurance Commission (Medicare Benefit 
not available for screening of asymptomatic patients, and only available if there are 
signs and symptoms of conditions resulting in osteoporosis or if a minimal trauma 
fracture has occurred) (300) and diagnosis may only have been made in patients who 
may have suffered a minimal trauma fracture. The data of the current study however 
suggest that the prevalence of osteoporosis in this cohort is representative of that in 
the community dwelling healthy population. 
 
Two questionnaires for calcium intakes were compared. Only 30% of the women met 
the RDI for calcium intake according to both questionnaires. However the more 
extensive online FFQ may have overestimated intakes while the SQ may have 
underestimated intakes because the correlation between the 2 was poor. Biochemistry 
of bone related analytes in fasting blood samples for all subjects were acceptable and 
those that fell outside the reference interval set by the laboratory were not clinically 
85 
 
significant. The percentage of subjects in the current study with various levels of 
vitamin D deficiency as estimated by serum 25OHD levels were comparable to those 
reported for healthy community dwelling Australians (39).  
 
In this cross sectional data analysis, a significant relationship was seen between PTH 
and CTX. This by no means is a causative relationship but very probably is an 
association. It is likely that calcium intakes influence both CTX and PTH, and the 
expectation is that, both PTH and CTX will show an inverse relationship with 
calcium intake. The relationship between PTH, 25OHD and calcium intakes will be 



























Relationship between serum parathyroid hormone, vitamin 
D status and calcium intake 
 
4.1 Introduction 
Vitamin D has been recognised as an important factor in maintaining healthy bone. 
The position statement on vitamin D status in Australian and New Zealand adults 
suggests a serum 25OHD cut-point of 12.5nmol/L to define severe vitamin D 
deficiency. A cut-point of 13nmol/L has been used by the Australian Bureau of 
Statistics (ABS) in its National Health Measures Survey (NHMS) (2011-2012) 
because serum 25OHD levels are generally reported in whole numbers (39). Vitamin 
D deficiency and insufficiency are common in the community due to unavailability 
of vitamin D in food and the lack of exposure to sunlight. Pigmented skin types do 
not synthesise vitamin D in adequate amounts. These factors have led to vitamin D 
deficiency being recognised as a significant public health concern in Australia. 
Vitamin D deficiency or insufficiency has been reported in 31% of Australian adults 
(serum 25OHD levels <50 nmol/L). During winter, it is estimated that about 50% of 
women fall into the deficient or insufficient category (54).  
 
Low serum 25OHD has been associated with a rise in serum PTH, such that the point 
at which the parathyroid hormone (PTH) starts to rise has been suggested as the cut-
point for vitamin D insufficiency. Estimates of this inflection point has been reported 
as 50 nmol/L (301) and as high as 110 nmol/L (302). In South Australia, one study 
suggested a level of > 40 nmol/L to maintain bone health (303) while another 
demonstrated that in post-menopausal women, bone resorption markers rose 
significantly when serum 25OHD status fell below 60 nmol/L while PTH rose at a 
level of 50 nmol/L (304). The inflection point in serum 25OHD at which PTH rises 
may vary between populations due to the influence of calcium intake, although some 
argue that calcium intake does not influence serum PTH levels in subjects with a 
serum 25OHD above 25 nmol/L (305). A more recent study of post-menopausal 
women suggested that both serum 25OHD and calcium intake significantly 




The current study aims to ascertain the influence of Ca intake on PTH, relationship 
between calcium intake and serum 25OHD, PTH and the bone resorption marker C-
terminal telopeptide (CTX). The relationship between anthropometric measures and 
serum PTH is also explored. 
 
4.2 Materials and Methods 
Post-menopausal women from the community were recruited as described in Chapter 
2. Data from post-menopausal women recruited for 3 other studies of shorter duration 
(these studies are presented in detail in chapters 7, 8 and 10) are also included here. 
The baseline biochemistry results obtained from all subjects from these studies were 
combined in this cross-sectional study. All women resided in the South Australian 
community. Women with chronic disease, on regular prescription medication, 
previously diagnosed bone disease and malignancy were excluded. A total of 201 
women were included in this study. 
 
Each woman completed a basic health questionnaire (appendix 3) and a calcium 
intake questionnaire (appendix 4). They were then invited to attend the Endocrine 
Test Unit at the Royal Adelaide Hospital for fasting blood tests, following a 8 to 10 
hour fast. Blood was collected for biochemistry (electrolytes, creatinine, urea, liver 
function tests, calcium and phosphate), 25OHD, CTX and PTH. Calcium absorption 
was measured as detailed in Chapter 2. 
 
Calcium intakes were calculated using the validated questionnaire (see Chapter 2.6 
for validation study). When subjects were taking calcium supplements, the total 
intake (dietary and supplemental) was considered. The intakes were then divided into 
tertiles and within tertiles of intake, the subjects were further categorised according 
to serum 25OHD. The categories were serum 25OHD <30 nmol/L, 30 – 60 nmol/L 
and > 60 nmol/L. This provided an even distribution of subjects across the tertiles 
while retaining clinical significance. The serum variables between tertiles of calcium 
intake as well as for each level of 25OHD within tertiles were compared using a 
Student t test. Relationship between serum measures and calcium intake were 
explored using multiple regression and correlation using Analyse-It statistical 





Demographic and biochemistry data for all subjects are listed in table 4.1.   
 
Table 4.1. Demographic and biochemistry data for all subjects (n=201). 
 
Mean SD SE range n 
age (y) 61.4 5.3 0.4 50 – 75 201 
Height (m) 1.6 0.06 0 1.48–1.84 173 
Weight (kg) 68.3 16.7 1.3 45 – 210 172 
BMI (kg/m2) 25.9 5.7 0.3 17.8-70.1 172 
Ca intake (mg/d) 1016 450.9 32 300 – 2589 198 
total cholesterol (mmol/L) 5.5 1.0 0.8 2.6 – 8.5 189 
glucose (mmol/L) 4.7 0.8 0.1 2.8 – 7.0 172 
creatinine (umol/L) 62.4 10.3 0.7 38 – 110 197 
ionised Ca (mmol/L) 1.22 0.04 0 1.10 – 1.40 194 
Total Ca (mmol/L) 2.37 0.09 0 2.089– 2.68 197 
PO4 (mmol/L) 1.15 0.13 0.1 0.87 – 1.46 196 
ALP (U/L) 80.7 23.4 1.7 27 – 175 201 
CTX (ng/L) 439.1 170.2 12 70 – 1064 200 
PTH (pmol/L) 4.5 1.8 0.1 1.6 – 15.4 199 
25OHD (nmol/L) 71.6 24.9 1.8 21 – 167 201 
 
The range of values obtained for each analyte is given in table 4.1. The number of 
subjects with values outside the laboratory reference interval for each biochemical 
analyte is listed in table 4.2.  
 
The results outside the RI for total cholesterol, fasting glucose, creatinine, ionised 
and total Ca, PO4 and ALP were not clinically significant. More than half the 
subjects had serum CTX values above the desirable limit set by the laboratory. The 
current Australian consensus for CTX reference interval for post-menopausal women 
is 50 – 800 ng/L (264), and when these limits are used, only 3% of the subjects are 








Table 4.2. The number (percentage) of subjects outside the reference interval (RI) for 
measured analytes. 
analyte RI < lower limit > upper limit 
Total cholesterol <5.5 mmol/L NA 87 (46) 
Fasting glucose 3.3 – 5.5 mmol/L 4 (2) 24 (14) 
Creatinine 50 - 100 umol/L 15 (7) 1 (0.5) 
Ionised Ca 1.10-1.15 mmol/L 0 (0) 3 (1.5) 
Total Ca 2.10–2.55 mmol/L 1 (0.5) 6 (3) 
PO4 0.65-1.45 mmol/L 0 (0) 2 (1) 
ALP 30-110 U/L 1 (0.5) 19 (9) 
CTX <400 ng/L NA 112 (56) 
PTH 0.8-5.5 pmol/L 0 (0) 36 (18) 
25OHD  50 - 150 nmol/L 71 (36) 6 (3) 
 
Eighteen percent of the subjects had a serum PTH above the upper limit of RI, but 
they were included in the study because they all demonstrated normal total and 
ionised calcium levels. The elevated PTH therefore may reflect secondary 
hyperparathyroidism in these patients. More than a third of the subjects were vitamin 
D deficient or insufficient according to the laboratory RI. However vitamin D status 
as defined by the National Health Measurement Survey (NHMS) (39) places 84% of 
the subjects as adequate vitamin D (Table 4.3). 
 
Table 4.3. Serum 25OHD of the subjects as per NHMS (39). 
 
Serum 25OHD (nmol/L)  Number percentage 
Adequate 25OHD status (≥ 50)  169  84% 
Total deficiency (< 50)   33  16% 
Mild deficiency (30 – 49)  28  14% 
Moderate deficiency (13 – 29)  5  2% 




The majority of subjects were vitamin D sufficient with only 16% mild to moderately 
deficient. The tertiles of calcium intakes with mean serum 25OHD and PTH are 
presented in table 4.4 
 
Table 4.4. Tertiles of calcium intakes with mean serum 25OHD and PTH. 
 
Tertile Ca intake mean (SD) 
 mg/d 
25OHD mean (SD) 
nmol/L 
PTH mean (SD) 
pmol/L 
1 635.5 (28.5) 75.5 (27.3) 5.2 (2.3) 
2 1116.2 (20.2) 74.2 (28.3) 4.2 (1.3) 
3 1817.9 (51.1) 75.2 (22.9) 4.2 (1.6) 
 
Cross sectional analysis demonstrates no significant difference in serum 25OHD or 
PTH between the tertiles of calcium intake.  Within each tertile of calcium intake, 
subjects were further stratified into serum 25OHD levels of <30, 30 – 60 and >60 
nmol/L. The number of subjects in each of these strata is listed in table 4.5. 
 








T1 < 30  4 
 
30 – 60  24 
 
> 60  38 
T2 < 30  0 
 
30 – 60  27 
 
> 60  39 
T3 < 30  1 
 
30 – 60  15 
 
> 60  50 
 
Women with the lowest Ca intake and serum 25OHD below 30 nmol/L demonstrated 
significantly higher PTH levels than those with 25OHD over 30 nmol/L within the 
same tertile (T1) (P<0.01) (Figure 4.1). Serum PTH for the women with 25OHD 
between 31 and 60 nmol/L in the highest Ca intake tertile (T3) was significantly 
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higher than PTH in those with 25OHD >60 nmol/L within the same tertile (P<0.01). 
Serum PTH for 25OHD 30-60 nmol/L in T3 was also significantly higher than serum 
PTH for 25OHD <30 nmol/L however there was only 1 subject with 25OHD <30 



























*= P <0.05; ** = P < 0.01 
Figure 4.1. Serum PTH level within each 25OHD bracket for each tertile of Ca 
intake. 
 
Serum CTX for those in the lowest 25OHD bracket was significantly higher than for 
the other categories within the lowest Ca intake tertile (T1) (P<0.01) (Figure 4.2). This 
was not observed in tertiles of higher Ca intakes. There was no significant difference 
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Figure 4.2. Serum CTX and ALP within each 25OHD bracket for each tertile of Ca 
intake. 
 
Variables that showed a significant correlation between them on simple regression 
analyses are listed in table 4.5 together with the correlation coefficient. Serum PTH 
was positively related to age and BMI. Calcium intake declined with age in this 
group and lower BMI were observed with higher calcium intakes (P=0.01). The 
association between age and 25OHD was not significant. Calcium intake was 
positively related to serum total cholesterol, PO4 level and serum 25OHD. Serum 
glucose was higher in heavier individuals as was expected as both greater body 
weight and higher fasting glucose are features of the metabolic syndrome.  Fasting 
glucose also showed a significant negative relationship with serum 25OHD. 
Similarly, serum 25OHD was lower in women who were heavier. PTH was 










Table 4.5. Significant relationships as indicated by simple regression analyses (n = 
202; r = correlation coefficient; 95 CI=95% confidence interval). 
 
Pair of variables r 95% CI P 
Age, Ca intake -0.164 -0.327-0.009 0.05 
Age, PTH 0.226 0.055-0.383 0.008 
Ca intake, cholesterol 0.179 0.007-0.341 0.03 
Ca intake, PO4 0.178 0.006-0.340 0.03 
Ca intake, PTH -0.19 -0.354- (-0.021) 0.02 
Ca intake, 25OHD 0.238 0.068-0.394 0.005 
Ca intake, BMI -0.208 -0.368- (-0.037) 0.01 
Glucose, 25OHD -0.228 -0.385- (-0.057) 0.007 
Glucose, weight 0.205 0.033-0.364 0.016 
Glucose, BMI 0.260 0.091-0.414 0.002 
CTX, PTH 0.182 0.010-0.344 0.03 
PTH, 25OHD -0.198 -0.359-(-0.027) 0.02 
PTH, BMI 0.220 0.050-0.379 0.009 
25OHD, weight -0.213 -0.372- (-0.042) 0.01 
25OHD, BMI -0.235 -0.392- (-0.065) 0.005 
 
 
Age, calcium intake, PTH, 25OHD, weight and BMI were not normally distributed 
(Kolmogorow-Smirnov test, P values 0.008, 0.0002, <0.0001, <0.0001, <0.0001 and 
<0.0001 respectively).  Logarithmic transformation of these data was used to obtain 
Gaussian distributions. The adjusted correlation coefficients for the regression 









Table 4.6. Adjusted correlation coefficient (r) between natural logarithm of variables 
and level of significance (P), ln -  natural logarithm). 
 
 ln age ln PTH ln 25OHD 
ln Ca intake 0.003 (0.217) -0.061 (0.0003) 0.004  (0.18) 
ln PTH 0.058 (0.0004)   
ln 25OHD -0.005 (0.941) -0.02 (0.01)  
ln weight 0.020 (0.036) 0.015 (0.05) -0.054 (0.001) 
ln BMI 0.02 (0.01) 0.036 (0.007) -0.054 (0.001) 
 
Significant negative relationships were observed between Ca intake and PTH, and 
25OHD and PTH. Weight and BMI rose significantly with age. PTH rose with 
weight and BMI and 25OHD level fell significantly with increasing weight. PTH 
increased with age. 
 
CTX was found to be normally distributed. To explore the relationship between CTX 
and PTH, 25OHD, age, weight and BMI, multivariate Spearman’s rank correlation 
was performed (table 4.7) which demonstrated a strong relationship between age and 
PTH, confirming logarithmic transformed data above. The inverse relationships 
between serum PTH and Ca intake, and the positive relationship between PTH and 
CTX were significant.  
 
Table 4.7. Multivariate Spearman’s rank correlation coefficient, r and significance 
(P) 
 
  Age  Ca intake CTX  PTH  25OHD 
Age    -0.083  0.003  0.242  0.041 
    (0.246) (0.967) (0.0007) (0.567) 
Ca intake     -0.001  -0.197  0.142 
      (0.987) (0.0059) (0.0469) 
CTX        0.203  0.029 
        (0.0043) (0.684) 
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Multiple linear regression of serum PTH on age, BMI, calcium intake, CTX, 25OHD 
and calcium absorption (table 4.8) demonstrated significant positive relationships 
between serum PTH and age and BMI, when adjusted for calcium intake, 25OHD 
and calcium absorption. Age and BMI were the dominant determinants of PTH levels 
in this cohort although the relationship with calcium intake approached significance 
(P=0.08). Clearly the relationship between PTH and 25OHD was dependent on the 
effect of increasing weight but is lost when BMI is included in the regression 
presumably as a result of increased fat mass sequestering vitamin D (306). 
 
Table 4.8. Determinants of serum parathyroid hormone (PTH)  
       SE  P 
PTH =   +0.0729 X age  0.029  0.01 
   +0.0835 X BMI  0.034  0.01 
   -0.0004 X Ca intake  0.000  0.08 
   -0.003 X 25OHD  0.005  0.57 
   +0.0157 X Ca absorption 0.654  0.81 
   -1.505 pmol/L   -  - 
  R2 = 0.132; adjusted R2 = 0.095; P<0.005; n=125. 
 
Out of 202 subjects, only 48 (28%) met the recommended daily intake (RDI) of Ca of 
1300 mg/d (9).  There was no significant difference between the tertiles of Ca intake 
when the mean age, height, serum glucose, creatinine and ALP were compared. The 
analytes that showed a significant difference between at least 2 tertiles are listed with 











Table 4.9. Variables that showed a significant difference between at least 2 tertiles of 
Ca intake (difference between means and P values within brackets).  
 
     T2 – T1 T3 – T1 T3 – T2 
Weight (kg)  0.5 (0.43) -4.7 (0.03)  -5.2 (0.05) 
BMI (kg/m2)  -0.41 (0.3) -2.0 (0.01)  -1.7 (0.05) 
Total cholesterol  -0.39 (0.02) 0.24 (0.09)  -0.15 (0.19) 
(mmol/L) 
Ionised Ca (mmol/L) 0.01 (0.06) -0.01 (0.01) -0.0 (0.21) 
Total Ca (mmol/L) 0.03 (0.02) 0.04 (0.01) 0.01 (0.37) 
PO4 (mmol/L)  0.03 (0.12) 0.02 (0.04) 0.01 (0.29) 
PTH (pmol/L)  -0.94 (0.002) -0.96 (0.003) -0.02 (0.47) 
25OHD (nmol/L) 3.3 (0.22) 6.9 (0.04) 3.5 (0.19) 
CTX (ng/L)  -53 (0.02) -15 (0.31) 38 (0.10) 
T1=lowest intake, T3=highest intake.  
 
Total cholesterol was higher in the women in the middle tertile than the lowest. 
Serum total Ca tended to rise with increased dietary calcium intake, however ionised 
Ca appear to be greater in those with the lowest Ca intake. Likewise serum PO4 was 
higher in women with the highest Ca intake.  Serum CTX was highest in the lowest 
tertile of Ca intake.  Serum 25OHD was highest in women with the highest intake of 
Ca. 
 
Generally, women in the lowest and the middle tertile of Ca intake were heavier than 
those in the highest tertile. This is confirmed by correlation between variables for all 
subjects where there was a negative trend between calcium intake and weight (r = -
0.15; P=0.07) and a significant negative relationship between calcium intake and 
BMI (r=-0.2; P=0.01) (Table 4.5).  
 
4.4 Discussion 
The majority of the women in this study did not meet the total calcium intake RDI of 
1300mg/d for post-menopausal women. In contrast, the majority of the subjects were 
vitamin D sufficient, with levels above 50 nmol/L (84%). NHMS data demonstrated 
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that older adults were less likely to be vitamin D deficient than young adults (31% in 
those aged 18 – 34 years, and 15% in those aged 65 to 74 years)  (39) likely due to 
more widespread use of supplements in the older age group. As depicted in figure 3.8 
in Chapter 3, over 30% of women in this study were taking vitamin D with their 
calcium supplement. Some may have been taking vitamin D alone, and this may not 
be recorded because vitamin D intake was not specifically asked in the calcium 
intake questionnaire. The findings in our subjects with regards to vitamin D status are 
consistent with those of the NHMS (39).  
 
Several statistical analyses were performed in the cross-sectional analysis to explore 
the relationship between biochemical variables associated with calcium metabolism 
and other parameters (weight, age, BMI). In order to reduce type II statistical errors, 
only relationships with a physiological basis or those with a P value <0.01 are 
discussed further. 
 
The strong positive relationships between age and PTH and BMI and PTH are 
consistent with published data (125, 307,308). Lower than recommended calcium 
intakes appeared to be physiologically significant as indicated by the inverse 
relationship with PTH. However the major determinants of PTH in this group of 
women were age and BMI. Calcium intake was inversely related to PTH when the 
effects of age and BMI were adjusted for, but this relationship was not significant 
(P=0.8).  PTH was not related to intestinal calcium absorption in this group of 
women, confirming previously published data on post-menopausal women (304). 
  
While serum total Ca rose with increasing dietary calcium, ionised Ca appeared be 
significantly higher in the women with the lowest calcium intake compared to those 
with the highest intake. This may be because of other factors included in the 
calculation of ionised calcium (albumin, globulin, bicarbonate and anion gap) being 
different between these 2 groups. There is also evidence to suggest that ionised Ca is 
a more sensitive and earlier marker of hyperparathyroidism than total Ca (309). 
Therefore in women with lower calcium intakes, the high ionised Ca may be an early 
marker of hyperparathyroidism. Serum PTH in these women may be within the 
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laboratory reference interval, but may be physiologically higher than the optimal 
level for that individual.     
 
Importantly however, within each tertile of Ca intake, PTH and CTX tended to be 
higher in those with lower vitamin D. The serum PTH level in women with vitamin 
D deficiency (<30 nmol/L) within the lowest tertile of Ca intake was significantly 
higher than in women with sufficient vitamin D status. Even within the highest Ca 
intake tertile, those with insufficient vitamin D status (30 – 60 nmol/L) had a 
significantly higher PTH level than those with sufficient vitamin D.  This confirms 
the significant inverse relationship between PTH and 25OHD, as reported by other 
studies (304, 307,310). These findings support the concept that serum PTH is 
determined by both Ca intake and vitamin D status, and that, the effect of low 
25OHD level exerted on PTH is more important than that of inadequate calcium 
intake. Serum CTX only rose in women with vitamin D deficiency if their Ca intakes 
were in the lowest tertile, suggesting that bone resorption is highest when both 
calcium intake and serum 25OHD are low. Serum 25OHD declined as body weight 
increased, confirming that 25OHD is sequestered in adipocytes (306). 
 
Calcium intake appeared to be positively associated with serum 25OHD, which was 
also reported in previously with dietary calcium intake (306) and with calcium 
supplements (48). With increasing dietary calcium, a higher serum 25OHD has been 
attributed to a concomitant increase in vitamin D in the diet (306). With calcium 
supplementation, the rise in serum 25OHD was attributed to lower serum PTH and 
thus a lower rate of catabolism of 25OHD (48). 
 
Women with lower Ca intakes tended to be heavier than those with higher Ca 
intakes, perhaps reflecting a poorer diet high in energy or a less healthy lifestyle. The 
major dietary component containing calcium amongst these women was dairy 
products and therefore these data do not provide any evidence that consuming dairy 
products increases the risk of increasing BMI (see Chapter 9 for relationship between 
visceral fat and calcium intake). It has been suggested that higher calcium intakes 
will lead to lipolysis (132) and higher dietary calcium may reduce the absorption of 
fat in the gut (311). The inverse relationship between serum 25OHD and fasting 
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glucose suggests that low 25OHD may be a risk factor for metabolic syndrome 
(312,313,314). This relationship has been reported previously in postmenopausal 
women, with fasting glucose rising steadily when serum 25OHD fell below 40 
nmol/L (313). There is evidence that serum 25OHD may be inversely related to the 
prevalence of insulin resistance, hyperglycaemia (314,315) and diabetes (316). This 
phenomenon may be explained by beta cell dysfunction in hypovitaminosis D (317). 
In addition a higher BMI may be associated with a higher fasting glucose and a lower 
25OHD.  
 
Body weight, BMI and age were important determinants of PTH when adjusted for 
calcium intake, calcium absorption and 25OHD. Some report the rise in PTH with 
age to be independent of 25OHD economy or renal function (308) while others 
suggest that, when adjusted for body weight and 25OHD, there is little effect of age 
on PTH (304). Others suggest dissociation between the calcemic action and 
phosphoturic effect of PTH in older adults leading to a gradual rise in intact 
circulating PTH with age (318). Another hypothesis suggests a reduced calcemic 
response to PTH at the bone in older adults (319).  These hypotheses have been 
suggested to explain the relatively normal Ca levels in the elderly subjects with 
higher basal and maximal PTH values in response to induced hypocalcaemia 
suggesting a ‘PTH resistance’ state. 
 
The fall in 25OHD with increasing weight has been suggested as a cause of 
increasing PTH with weight (319) however later studies (307) and in the current 
study weight is a significant determinant of PTH after adjusting for serum 25OHD. 
There is evidence to suggest that higher levels of PTH may be associated with low 
grade inflammation and adipose tissue in patients with primary hyperparathyroidism 
demonstrated upregulation of inflammatory genes (320). Higher circulating 
proinflammatory cytokines were observed in rodents with induced secondary 
hyperparathyroidism (321) and in obese humans, serum PTH levels correlated with 
CRP levels and triglyceride:HDL ratio independent of serum 25OHD levels (322). 
NHANES data demonstrate a clear linear rise in CRP with rising PTH in US adults 
(323). These findings suggest a close relationship between adiposity, PTH and 
inflammation. In addition, PTH was shown to be an independent predictor of 
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metabolic syndrome, regardless of vitamin D status (324). It is likely that adipocytes 
play an inflammatory role due to their ability to produce proinflammatory cytokines, 
however the association between inflammation and PTH is, currently just that, with 
no clear explanation of the physiological or pathological role of PTH in the 
inflammatory process. Nevertheless, data from the current study and others as 
mentioned strongly suggest that PTH rises with age and with increasing weight. 
 
Although calcium intake and absorption are physiologically important factors 
affecting PTH, in this group of post-menopausal women, age and body weight were 
more important determinants of PTH. The rise in 25OHD and lower body weight 
with higher calcium intake may reflect a healthier lifestyle in these women. The 
higher fasting glucose with lower 25OHD may reflect a less active lifestyle and 
suboptimal nutritional choices. Furthermore, total calcium intake may have a 
significant effect on 25OHD and energy metabolism. 
 
The variable results in some of the studies in PTH may be due to the variability in 
assays and the fragments detected. Some second generation assays available now 
detect the intact PTH (iPTH, 1-84) using 2 antibodies that target epitopes in the NH2- 
terminal (amino acids 1 to 7) and the mid-region (amino acids 44 to 65). Therefore it 
can be argued that they may detect fragments of PTH that have lost the –COOH 
terminal beyond the 65th amino acid, and may not only measure iPTH (318, 325). 
This may result in higher PTH measurements when these fragments are also added to 
the result. The physiological significance of these fragments that lack the –COOH 
terminal is yet to be determined.   
 
Given the demonstrated associations between age and PTH and body weight and 
PTH, and the evidence for the positive linear relationship between PTH and 
proinflammatory markers, further investigations of the mechanism of PTH 
involvement in inflammation and the effect of suppression of PTH with vitamin D 
are needed. Modulating PTH may be a new method in the prevention of metabolic 
syndrome and obesity. Additionally, it may be concluded that the traditionally 
accepted simple relationship between calcium intake and PTH need to be revised to 









Post-menopausal women are said to be in negative calcium balance (96) with a 
higher rate of bone resorption to maintain physiological levels of Ca (99) resulting in 
higher requirements for calcium in order to prevent bone loss. A slower rate of bone 
resorption has been demonstrated in post-menopausal women with high calcium 
intakes compared to those with lower intakes (100,101,102,103,104)). A review of 
clinical trials shows that, with calcium supplementation, postmenopausal bone loss 
can be abrogated (105).  
 
Longitudinal observational studies have demonstrated that increased dietary calcium 
can lead to improvements in bone density (117,126) or prevention of age related bone 
loss as assessed by bone density (144).   
 
The current study was designed to ascertain if changes in bone density in 
postmenopausal women over a 2 year period were determined by calcium intake. 
 
5.2 Materials and Methods 
Community dwelling post-menopausal women were recruited to the current study as 
described in Chapter 2. Aerial bone density measurements (BMD) were made using a 
Norland (Cooper Surgical Company) densitometer. Measurements were obtained at 
the lumbar spine (L1 – L4), femoral neck, total or standard hip, proximal forearm and 
ultradistal forearm (33%) at baseline and at 6 monthly intervals. The Ca intake 
questionnaire was completed again at 12 months to ensure that the subjects have not 
changed their diet significantly during the study. The subjects who were on Ca or 
vitamin D supplements were allowed to continue, and the amount of Ca from 




Correlation between baseline bone density for each site and Ca intake was examined 
using a correlation matrix. Calcium intakes were divided to tertiles, and the mean 
change in BMD for each measured site within each tertile of Ca intake was calculated 
by subtracting the mean density at the final measurement from the mean baseline 
measurement.  The change in mean BMD for each site within each tertile of Ca 
intake at each time point was calculated by subtracting the latter from the baseline 
values. All changes were compared between each site and between tertiles using 
Student’s t tests. 
 
5.3 Results 
5.3.1 Completion of bone density scans by subjects 
Table 5.1 shows the number of forearm and hip/spine bone density scans completed 
by subjects. Most subjects completed all 5 hip/spine scans. Forearm scanning was 
added to the protocol later, when some of the subjects had already had the hip and 
spine scans.   
 






5 5 33 
 5 4 45 
 4 4 6 
 5 3 10 
 3 or 4 3 8 
 1 or 2 1 or 2 24 
  
 
5.3.2 Relationship between habitual calcium intake and baseline bone density 
Baseline calcium intake was divided into tertiles as listed in table 5.2. Included in this 







Table 5.2. Tertiles of calcium intakes, with mean (SD) of calcium intakes, age, 
weight and BMI for subjects in each tertile 
 
tertile Ca intake (mg) Age (years) Weight (kg) BMI (kg/m2) 
1 653.5 (28.5) 61 (4.6) 68.2 (13.5) 25.9 (4.8) 
2 1116.2 (20.0) 60.9 (5.1) 60.9 (5.1) 25.3 (3.8) 
3 1817.9 (51.1) 60.6 (5.4) 60.6 (5.4) 24.4 (3.8) 
 
There was no significant difference between the mean age of subjects between the 
tertiles. However subjects in the lowest tertile of Ca intake were heavier than those in 
the highest tertile of Ca intake. The mean (SD) of bone density for each measured 
site in each tertile are listed in table 5.3.   
 
Table 5.3. Mean g/cm2 (SD) bone density for each site in each tertile of calcium 
intake 
tertile LS FN TH PFA UDFA 































Student t tests indicate that the only anatomical site that showed a significant 
difference between tertiles at baseline is the ultradistal forearm, where the subjects 
with the lowest tertile of calcium intake had a higher bone density than the highest 
teritile (P=0.05). 
 
Cross-sectional analysis using a correlation matrix for baseline bone density at each 
site and baseline calcium intakes is presented in table 5.4. The ultradistal and proximal 
forearm bone densities were inversely related to age (P<0.0005 and P<0.005 
respectively).  Height was positively correlated to femoral neck and ultradistal forearm 
bone density (P<0.005). Weight and BMI were positively correlated to lumbar spine, 
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femoral neck, hip, proximal forearm and ultradistal forearm densities (all P<0.0005 
except BMI and femoral neck BMD, P<0.025). Bone density in each site was also 
significantly correlated to other sites (P<0.0005). Dietary calcium (but not total 
calcium) intake appeared to decline with age (P<0.01). Only the femoral neck BMD 
correlated with calcium intake (dietary calcium, not total calcium, P<0.01). 
 
When corrected for age, calcium intake and serum 25OHD, BMI was significantly 
positively associated with the baseline bone density at all sites (lumbar spine 
P=0.0002; femoral neck P=0.01; total hip P=0.0003; proximal forearm P=0.04; 
ultradistal forearm P=0.004). When corrected for BMI, calcium intake and serum 
25OHD, the ultradistal forearm is the only site where baseline bone density was 
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Table 5.4. Correlation matrix of measured anthropometric variables, calcium intake and bone density  
  
  age 
 
height weight BMI LS BMD FN BMD Hip BMD 
PFA 
BMD UDFA BMD Ca intake 
age 1  
         height -0.12465  1 
        weight -0.08139  0.343543 1 
       BMI -0.03298  -0.05915 0.915033 1 
      LS 
BMD -0.09049 
 
0.113009 0.352031 0.32135 1 
     FN 
BMD -0.13992 
 
0.285006 0.31425 0.20761 0.503959 1 
    Hip 
BMD -0.14755 
 
0.147364 0.375026 0.331238 0.56337 0.885372 1 
   PFA 
BMD -0.24447 
 
0.149005 0.362634 0.340032 0.529071 0.516451 0.567288 1 
  UDFA 
BMD -0.42856 
 




-0.03639 -0.13479 -0.12795 -0.06607 0.026116 -0.00472 -0.06606 -0.150306552 1 
 
Figure  6.3. Correlation matrix representing the correlation between biometric measures, baseline bone densities and baseline calcium intake. 








5.3.3 The effect of estimated baseline calcium intake on changes in bone density 
over 2 years 
 
5.3.3.1 Changes in the lumbar spine bone density 
The mean change in the lumbar spine density at 6 months, 12 months, 18 months and 
24 months from baseline values were calculated for subjects in each of the tertiles of 
calcium intake. These data are graphed in figure 5.6. Lumbar spine densities were 
lower at every time point measured, but were not statistically significant from 
baseline values. The changes were also not statistically significant between tertiles of 




Figure 5.6. Change in lumbar spine bone density over time in each tertile of calcium 
intake. T1 = lowest tertile, T2 =  middle tertile, T3 = highest tertile of calcium intake 
 
5.3.3.2 Changes in the femoral neck bone density 
The baseline femoral neck bone density between the 3 tertiles of Ca intake were not 
statistically different. The mean change in bone density at the femoral neck at each 
time point after baseline, for each tertile of calcium intake is shown in figure 5.7. 
Except at 6 months for tertile 1, femoral neck density decreased at each measured 
time point compared to baseline for all tertiles of calcium intake. There was no 
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Figure 5.7. Changes in the femoral neck bone density over time within each tertile of 
calcium intake. T1 = lowest tertile, T2 = middle tertile, T3 = highest tertile of 
calcium intake  
 
5.3.3.3 Changes in the total hip bone density  
There was no significant difference in baseline total hip densities between tertiles. 
Total hip bone density decreased after baseline on all measurements in all 3 tertiles 
and there was no significant difference between the rates of decrease between the 









Figure 5.8. Changes in the total hip bone density over time within each tertile of 
calcium intake. T1 = lowest tertile, T2 = middle tertile, T3 = highest tertile of 
calcium intake  
 
5.3.3.4 Changes in the proximal forearm bone density 
The baseline proximal forearm densities were not different between the tertiles. Bone 
density declined in all tertiles in the proximal forearm and was lower than baseline at 








Figure 5.9. Change in bone density in the proximal forearm in the 3 tertiles of 
calcium intake at each time point. T1 – lowest tertile, T2 – middle tertile, T3 – 
highest tertile. 
 
5.3.3.5 Changes in the ultradistal forearm bone density 
The difference between the baseline ultradistal forearm (UDFA) densities between 
the tertiles was not significant. At 6 months, the mean UDFA density appear to rise 
in the middle tertile. All other measurements were lower than baseline. The rate of 
fall in UDFA bone density was significantly greater in the first tertile compared to 






Figure 5.10. Changes in the ultradistal forearm bone density in each tertile of calcium 
intake at each time point. (T1 = lowest tertile, T2= middle tertile, T3 = highest 
tertile); * P<0.05 
 
5.3.4 Calcium intakes and annual percentage loss of bone 
Table 6.5 lists the annual percentage bone loss for each site for each tertile of 
calcium intake. The only significant difference between the rates of losses was 
between T1 and T2 in the ultradistal forearm where the rate of loss was greater in the 
lowest calcium intake group (P=0.01). 
 
Table 5.5. Mean (SD) and SE annual percent loss of bone at each site within each 
tertile 
 
site T1 T2 T3 
 mean (SD), SE mean (SD), SE mean (SD), SE 
LS -1.7 (3.8), 0.6 -2.1 (3.5), 0.5 -1.8 (4.0), 0.6 
FN -1.7 (4.0), 0.6 -1.9 (3.1), 0.4 -1.7 (2.6), 0.4 
TH -1.5 (2.8), 0.4 -2.2 (2.5), 0.4 -2.2 (1.5), 0.3 
PFA -1.9 (1.8), 0.3 -1.7 (1.9), 0.3 -1.9 (1.9), 0.3 
UDFA -2.3 (2.5), 0.4 -1.1 (2.6), 0.4 -1.7 (2.6), 0.4 
LS=lumbar spine, FN=femoral neck, TH= total hip, PFA= proximal forearm, 
UDFA=ultradistal forearm. 
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There was no significant difference in 25OHD status between tertiles of calcium 
intake. Vitamin D status in the subjects is discussed in detail Chapter 4. In  tertiles 1 
and 3, there was at least one subject with vitamin D deficiency. Vitamin D deficiency 
was most prevalent in the lowest tertile of calcium intake. When annual percentage 
loss of bone density for each site was regressed against serum 25OHD within each 
tertile of calcium intake, only the rate of loss at the femoral neck and total hip  in the 
middle tertile of calcium intake were significantly related to 25OHD (P=0.03 and 
P=0.02 respectively). 
 
There were 53 women who met the RDI for calcium intake with levels >1200mg/d 
and completed bone density measurements. Ten of these women had a serum 
25OHD of <60 nmol/L. The effect of vitamin D on the rate of loss was most 
pronounced at the lumbar spine (P=0.04) and femoral neck (P=0.009) in this group. 
Within this group the percentage of women who gained bone (had a positive rate of 
annual bone ‘loss’) for each site during the 2 years of observation are shown in table 
6.5. 
 
Table 5.6. Percentage of women who gained bone when RDI for calcium intake was 
met, according to 25OHD status 
 
Site /25OHD status <60  nmol/L > 60 nmol/L 
LS 2 28 
FN 1 30 
TH 1 23 
PFA 0 19 
UDFA 2 21 
LS=lumbar spine, FN=femoral neck, TH=total hip, PFA= proximal forearm, 
UDFA=ultradistal forearm 
 
More women gained bone when calcium intake met RDI, and serum 25OHD level 
was >60 nmol/L, than when RDI for calcium was met but serum 25OHD was 
insufficient (<60 nmol/L). A level of 60nmol/L was chosen for serum 25OHD used 
as a categorical variable because at the time of analysis the laboratory reference 
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interval was 60 to 160 nmol/L.  Other cut offs were not compared prior to this 
subgroup analysis. The rate of loss was significant at the femoral neck and the total 
hip in the women who met RDI for calcium but were vitamin D insufficient (P=0.05 
and 0.03 respectively). 
 
When corrected for age, calcium intake and serum 25OHD, BMI demonstrated a 
strong positive relationship with all measured sites (lumbar spine P = 0.0002, 
femoral neck P = 0.01, total hip P = 0.0003, proximal forearm P = 0.04 and 
ultradistal forearm P = 0.004). Only the ultradistal forearm showed a positive 
relationship to age when corrected for BMI, calcium intake and 25OHD (P = 0.001). 
 
5.4 Discussion and Conclusions 
There was no significant difference in mean baseline bone densities between the 
tertiles at any site. The rate of fall in the lumbar spine, femoral neck, total hip and 
proximal forearm were not significantly different between the tertiles at any of the 
time points measured. UDFA density fell significantly at the 6, 12 and 24 month 
measurements in the lowest tertile of calcium intake compared to the highest tertile 
of intake. However the strongest relationship between calcium intake and loss of 
bone was observed in the highest tertile of calcium intake at this site. 
 
The baseline bone density at any of the sites measured did not show a relationship to 
baseline habitual calcium intake. This may be because there were factors other than 
calcium intake affecting bone density such as vitamin D status, exercise, body weight 
and genetic factors. In fact, the women with the lowest calcium intake were heavier 
as discussed in Chapter 4, and strong positive relationships were observed between 
BMI and bone density at all sites. Therefore the positive impact of body weight or 
BMI on bone density in women with lower calcium intakes may have mitigated the 
negative effects of low calcium intakes to some extent. It is also possible that the 
estimated calcium intakes may not accurately reflect the actual usual calcium intake 
in these women.  
The mean serum 25OHD level did not differ significantly between tertiles of calcium 
intake however vitamin D deficiency was most prevalent in the lowest tertile of 
calcium intake. This may be due to the fact that those in the higher tertiles of calcium 
intake were taking calcium supplements that included vitamin D. The women in the 
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lowest tertile of intake were also heavier, suggesting that greater amounts of adipose 
tissue may have sequestered 25OHD and reduced the circulating 25OHD levels 
(306). Although there were more subjects with vitamin D deficiency in the lowest 
tertile, their rate of bone loss at the lumbar spine and hip did not differ significantly 
from those in the other tertiles. Those in the middle tertile of calcium intake 
demonstrated the strongest relationship between rate of bone loss at the hip and 
serum 25OHD. It may be that a higher intake of calcium (tertile 3, levels above 
1800mg/d) protects against effects of low vitamin D. These data suggest that, in 
addition to meeting the RDI for calcium, vitamin D sufficiency (serum levels >60 
nmol/L) is required to gain bone at the lumbar spine, hip and forearem, and to 
significantly reduce the rate of bone loss (at least at the femoral neck and total hip). 
 
Only the rate of bone loss at the ultradistal forearm was significantly greater in the 
lowest tertile of calcium intake compared to the highest tertile. This may be due to 
the greater proportion of trabecular bone at this site (326) and the resultant higher 
metabolic rate, responding to calcium intake and vitamin D status during the 
measurement intervals. However the bone density at this site was not lower in the 
subjects taking the lowest amount of calcium at baseline. This may be because, after 
completing the calcium intake questionnaire, the subjects did not change their diet 
significantly during the study, whereas the diet prior to recruitment may have not 
been reflected accurately in the estimate of calcium intake. When calcium intake was 
adequate then the rate of loss at the UDFA was strongly related to the amount of 
calcium ingested. The International Society of Clinical Densitometrists Adult 
Official Position Statement does not recommend using forearm measurements other 
than the 33% radius (1/3 radius, proximal forearm) (327), possibly due to the rapid 














Osteoporosis is the most prevalent metabolic bone disease in the developed world, 
placing considerable health, economic and social burden on society. In addition to 
the impact of morbidity of fragility fractures, the risk of re-fracturing following an 
osteoporotic fracture rises, also increasing mortality (8).  Therefore both primary and 
secondary prevention of osteoporosis are important aspects of public health. 
Increasing calcium intake and maintaining adequate vitamin D have been proven to 
prevent bone loss and reduce fracture risk. There are several community based 
campaigns that promote increased dietary calcium. 
 
Despite public education campaigns drawing attention to the increased requirement 
of Ca (38), studies show that the Ca intake in postmenopausal women falls well short 
of the recommended daily intake (RDI) (103,127,328) and adherence to Ca 
supplements is poor (165). There is evidence that, when given feedback on their 
calcium intake (295) or fracture risk and bone density result (329,330) women 
increased their Ca intake. 
 
The following study aims to investigate the influence of DXA results on the self-
reported calcium intake in community dwelling postmenopausal women in South 
Australia. 
 
6.2 Materials and Methods 
Community dwelling healthy postmenopausal women with no history of bone disease 
or other chronic disease were invited to participate as discussed in detail in Chapter 
2.  Bone density measurements at the lumbar spine (L1 to L4), total hip, femoral 
neck, proximal and ultradistal forearm were obtained using a Norland (USA) scanner. 
Copies of results were provided to the subjects and a verbal explanation of results, 
including the diagnosis (osteoporosis, osteopenia or normal bone density for each 
site) (208) and the fracture risk were given to each subject by a certified clinical 
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densitometrist. The calcium questionnaire was administered again 12 months 
following recruitment. Feedback on calcium intakes were not given to the subjects. 
Daily calcium intakes were calculated from the baseline and 12 month 
questionnaires.  A change in calcium intake of 50mg or more a day was considered to 
be significant. 
 
6.3 Results:  
Out of 175 women eligible, 129 women completed the calcium intake questionnaires 
and the bone density measurements. The dietary questionnaire was completed by 112 
subjects 12 months later. The mean age, BMI and years since menopause were 61 
years, 25 and 10 years respectively. Demographic data is given in table 6.1.  
 
Table 6.1 Demographic data 
Variable  mean SD range 
Age (y)  61 5 51 – 73 
Height (m) 1.62 0.06 1.48 – 1.81 
Weight (kg) 66 12 45 – 108 
BMI kg/m2 25.2 4.2 17.8 – 42.2 
 
The baseline total Ca intake was 1193mg/day and 40% were on Ca supplements. 
Only 45% met their daily recommended Ca intake of 1300mg. These data are 
presented in figure 6.1.  Ca intakes at baseline and after 12 months are recorded in 
table 6.2. The number and percentage of women meeting the RDI for calcium at 
baseline and at 12 months, with dietary sources alone and with supplementation are 
depicted in figure 6.1. The mean total Ca intakes do not equal the mean dietary and 









Table 6.2. Calcium intakes at baseline and at 12 months 
 
Ca mg/d    mean  SD range 
Baseline total   1193  508 300 – 2581 
Baseline dietary   666  305 300 – 1790 
Baseline supplemental  584  313 17 – 1200 
12 months total intake  1102  500 300 – 2845  
12 months dietary Ca  860  295 300 – 1719 




Figure 6.1.  Number and percentage of women meeting the recommended daily 
intake (RDI) of calcium with and without supplements, at baseline and 12 months 
after bone density scanning. 









Table 6.3. Types of supplements taken by subjects at baseline and 12 months. 
Supplement type  baseline (%)  12 months (%) 
Carbonate   31 (61)  30 (67) 
Citrate    8 (16)   8 (18) 
Citrate + hydroxyapatite 4 (8)   2 (5) 
Hydroxyapatite   2 (4)   1 (2) 
PO4 + citrate   1 (2)   2 (5) 
Oxide + hydroxide  1 (2)   1 (2) 
PO4    1 (2)   1 (2) 
Unknown   3 (6)   0 (0) 
Total    51 (100)  45 (100) 
 
Fifteen women had osteoporosis in at least one measured site (11.6%), while 60 
(46.5%) women had osteoporosis or osteopenia in at least one site. Normal bone 
density for all measured sites were reported in 69 (53.5%) of women. The prevalence 
of osteoporosis and osteopenia in this group was lower than that reported in our 
community (see table 6.4) (127). 
 
Table 6.4. Prevalence of osteoporosis and osteopenia at each measured site 
Number (%) LS FN TH PFA UDFA 
Osteoporosis 11 (8.5) 7 (5.4) 4 (3) 1 (2) 0 (0) 
Osteopenia 18 (14) 40 (31) 19 (15) 8 (17) 4 (8) 
Normal 100 (77.5) 82 (63.5) 106 (82) 39 (81) 44 (92) 
Total 129 129 129 48 48 
Osteoporosis (GOS) 13% 13% 13%   
Osteopenia (GOS) 49% 49% 49%   
 
LS = lumbar spine (L1 – L4), FN = femoral neck; TH = total hip; PFA = proximal 
forearm, UDFA = ultradistal forearm. Reported prevalence quoted here are from the 
Geelong Osteoporosis Study (127). 
The changes in calcium intakes between the baseline estimates and the estimates at 
the end of 12 months were calculated for each subject in terms of total intakes, 
dietary sources and supplements in order to ascertain if subjects increased their Ca 
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intake overall and if they did, whether it was by a higher intake of dietary sources or 
by increasing Ca supplement intake. Figure 6.2 shows the changes in supplements, 
dietary sources and total intakes in subjects. 
 
  
Figure 6.2. Change in total calcium intake 12 months after feedback on baseline bone 
density scan and fracture risk (change of at least 50mg/day)  
 
Overall there was no significant difference between the baseline and 12 month total 
Ca intake.  Total Ca intake increased by at least 50mg a day in 46% and 35% of 
women diagnosed with osteoporosis and osteopenia respectively. However 23% and 
40% diagnosed with osteoporosis and osteopenia decreased their total Ca intake. 
 
There was no significant change in supplement intake after bone density feedback, 
regardless of the bone density result. However 10 women decreased their 
supplemental Ca when normal bone density was reported. Most women who were 
given the diagnosis of osteoporosis and increased their calcium intake did so by 
increasing dietary sources of calcium rather than taking a calcium supplement (14 out 







The prevalence of osteoporosis in this group is consistent with that reported for 
healthy Australian postmenopausal women (299, 331) but lower than that reported by 
the Geelong Osteoporosis Study, which did not exclude subjects with chronic disease 
(127). The women in the current study are active, healthy women with no history of 
chronic disease that may impact on bone, therefore are representative of the healthy 
Australian community.  
 
Calcium intakes in this group of women fell short of the RDI, also consistent with 
reported data for Australian women (127). It is noteworthy that when given the 
diagnosis of osteoporosis, about half of women increased their calcium intake and 
this was done mainly by increasing dietary sources of calcium rather than taking a 
supplement. Despite commercial campaigns encouraging women to take calcium 
supplements, the preference for dietary sources of calcium over supplementation may 
be because of the media attention on the negative effects of calcium, namely 
cardiovascular effects attributed to supplemental calcium intake.  
 
Overall, in this group the mean Ca intake fell following bone density result feedback. 
Although some women increased their intake, an equal number of women decreased 
their Ca intake. These results suggest that at least strong feedback on Ca intakes is 
needed, including educational material on dietary Ca sources and Ca supplements, 
for subjects to increase their intakes considerably (299). Feedback on DXA result is a 
potential tool in educating women in prevention and management of osteoporosis and 














Acute effects of calcium with or without vitamin D 




Vitamin D deficiency, as defined by serum levels <60 nmol/L is common 
among the elderly. Hip fractures in this group have been attributed to 
vitamin D deficiency, likely due to low bone mineral density and mass, 
low muscle mass and propensity to fall. In addition, secondary 
hyperparathyroidism is a consequence of low vitamin D which leads to 
an increased rate of bone turnover and low bone mass. 
Low vitamin D is generally treated with oral vitamin D supplementation. 
This study was designed to investigate the effects of short term 
supplementation of calcium with or without vitamin D on the rate of 
bone resorption in vitamin D deficient postmenopausal women. Twenty 
two postmenopausal women (59 to 75 years, mean 66) were randomly 
allocated to receive either 7 days of 1000mg of Calcium (as carbonate) 
and then 1000 IU of vitamin D3 for a further 7 weeks or to received 1000 
IU vitamin D3 only for 7 weeks and then 1000mg added Ca (as carbonate 
for another week. All subjects were instructed to continue with their 
usual diet and activity, and to take the doses of Ca and vitamin D at 9 pm 
at night daily. Fasting blood samples for routine biochemistry, C terminal 
telopeptides (CTX), PTH and vitamin D were collected at 9 am before 
the commencement of the regimens, and after 7 days of Ca alone and 
after 7 weeks of Ca and vitamin D (for group 1) and in reverse order for 
group 2. There was no significant difference in any biochemical 
parameter measured between the 2 groups at the start of the study. The 
effect of calcium and vitamin D on PTH was more significant and 
consistent than with either supplement alone. However calcium alone 
was more effective in causing a significant reduction in CTX than 
vitamin D alone. When combined, the fall in CTX was even greater and 
more significant.  
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An interesting observation was a significant positive effect of calcium 
alone on serum 25OHD.  A significant rise in serum 25OHD in deficient 
women was noted after 7 days of 1000mg Ca/d. We propose that 
adequate calcium supplementation may inhibit the metabolism of 
25OHD, effectively prolonging the half-life of circulating 25OHD. 
 122 
Statement of Authorship 
Title of Paper Suppression of C-terminal telopeptide in 
hypovitaminosis D requires calcium as well 
as vitamin D 
Publication Status Published 
Publication Details Thomas SDC, Need AG, Nordin BEC. 
(2010). Suppression of C-terminal 
telopeptide in hypovitaminosis D requires 
calcium as well as vitamin D. Calcified 
Tissue International, 86:367-374. 
 
Principal Author 
Name of Principal 
Author (candidate) 
Sunethra Devika Chin Thomas 
Contribution to the 
Paper 
Contributed to the design of the study, 
recruitment of subjects, analysis of samples, 
interpretation of data, wrote the manuscript, 
corresponding author. 
Overall percentage (%) 85% 
Signature  Date  
 
Co-Author Contributions 
Name of Co-Author Allan G. Need 
Contribution to the 
Paper 
Contributed to the design of the study, 
supervised the project, contributed to data 
interpretation and manuscript evaluation. 
Signature  Date  
 
Name of Co-Author B.E.C. Nordin 
Contribution to the 
Paper 
Contributed to the design of the study, 
supervised the project, contributed to data 
interpretation and edited the manuscript. 









































Influence of supplement type – carbonate or citrate on 
bone resorption in post-menopausal women 
Introduction 
With the majority of postmenopausal women not meeting their RDI of 
calcium through dietary sources alone, there is a public health interest in 
promoting calcium supplements to prevent osteoporosis. Commonly 
marketed calcium supplements are carbonate, citrate and hydroxyapatite. 
Absorption of carbonate preparations require stomach acid while citrates 
do not. Therefore in achlorhydria citrate is preferred. In addition, if the 
patient is at risk of renal calculi, calcium citrate is preferred because 
citrate is an inhibitory factor in urine calcium oxalate precipitation. 
Calcium carbonate contains 40% elemental calcium, while citrate 
contains 21% by weight. However calcium citrate has a bioavailability 
25% greater than that of calcium carbonate. 
Calcium supplements are commonly prescribed to postmenopausal 
women in order to prevent osteoporosis and also as adjunctive therapy 
for those on anti-resorptive treatment. Bone turnover markers CTX and 
PTH can be measured to monitor the effectiveness of calcium given. The 
following study is a double blind crossover study designed to assess the 
effects of calcium carbonate and calcium citrate in suppressing CTX and 
PTH in healthy postmenopausal women. Briefly, 22 subjects were 
randomly assigned to receive either 1000mg of calcium carbonate or 
500mg calcium citrate once at night. The alternate dose was given 1 
week later. Fasting samples were collected for biochemistry each 
morning after the calcium dose. ANOVA suggested no difference 
between the variables measured after each calcium salt. Bioequivalence 
studies suggested that calcium citrate was superior to calcium carbonate 
in raising serum total and ionised Ca, and at least as effective as the 
carbonate in suppressing PTH and CTX. Therefore calcium citrate 
appears to be as effective as calcium carbonate in suppressing bone 
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Effects of obesity and metabolic syndrome on bone 
Introduction 
Osteoporosis is a multifactorial complex condition with up to 80% of the 
bone strength (quality and density) determined by genetics (332) with 
other factors such as nutrition, lifestyle and physiology (age, hormonal 
status) playing a significant role. The effects of energy metabolism, as 
expressed by weight, body mass index, visceral fat and the metabolic 
syndrome (insulin resistance, glucose intolerance) on bone is an evolving 
field. 
 
Traditionally, nutrients such as protein, calcium and vitamin D as well as 
other minerals have been the most studied nutritional factors in the 
context of bone metabolism. However there is a growing body of 
evidence linking energy metabolism and glucose and fat with bone 
metabolism, with the hypothalamus centrally mediating adipose tissue 
and bone metabolism (333). It has been demonstrated that leptin secreted 
by adipose tissue influence bone formation by osteoblasts. Higher 
circulating levels of leptin inhibit bone formation while removing leptin 
from the circulation using a soluble leptin receptor led to increased bone 
mass in a mouse model (190). This suggests that the amount of adipose 
tissue may influence bone turnover in an individual. Several studies have 
shown that obesity or overweight is associated with higher bone density 
and afford some protection against osteoporosis. 
 
There have been several publications that suggest an inverse relationship 
between calcium intake and body weight (132, 334, 144). A strong 
inverse relationship between relative risk of obesity and calcium intake 
was reported for the participants of NHANES III (132). The proposed 
mechanism is accelerated lipogenesis in adipocytes with rising 
intracellular calcium under the influence of PTH and 1,25(OH)2D (132, 
335). If this was the case, then habitual low calcium intakes will lead to 
higher circulating PTH and in turn, the rate of lipogenesis will rise 
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leading to triglyceride deposition. In fact, PTH and 1,25(OH)2D were 
reported to be positively associated with BMI (336). Conversely, higher 
calcium intakes will suppress PTH, resulting in a lower rate of 
lipogenesis. Indeed, low calcium intake has been recognised as a non-
traditional risk factor for overweight and obesity (337,338).  
 
The association between body weight and BMI and BMD in older 
women has been shown to explain a large proportion of variance in BMD 
(8.9 – 20% of total variance) (339,340). Given the evidence supporting 
higher BMD associated with higher body weight, it may follow that 
fracture incidence, at least to some extent, may depend on body weight or 
composition. In fact, epidemiological evidence from large studies such as 
Study of Osteoporotic Fractures EPIDOS and European Vertebral 
Osteoporosis Study show that a higher incidence of hip and vertebral 
fractures in women with lower body weight than those with higher 
weights (341,342,343,344). Similar results have been obtained for 
forearm fractures (345). A study in 3500 Australian men and women 
showed that the observed association between BMI and fracture risk is 
mediated by femoral neck BMD (346). 
 
The majority of these studies assessed the contribution of body weight, 
BMI or weight gain on BMD and some assessed the whole body 
composition and percentage whole body fat and their association with 
BMD. The following study was undertaken to determine if BMD was 
influenced by the overweight or obese state in postmenopausal women. 
In addition, this study aims to investigate if waist circumference has the 
same associations with BMD as visceral fat and BMI, and if the rate of 
bone loss is influenced by visceral fat. 
 
Materials and Methods 
Postmenopausal women (n=117) in the observational study of the 
relationship between calcium intakes and bone density had the visceral 
adipose tissue measured by DXA in the lumbar region, using 
manufacturer’s instructions (Norland XR 36, Swissray) at a scan speed of 
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25cm/s. The instrument was calibrated daily with the manufacturer’s 
phantom for bone. The software provided by the manufacturer assumes a 
weighted linear fat distribution model. Truncal obesity, a predominant 
feature of metabolic syndrome was measured as the visceral fat mass in 
the lumbar region (L2 to L4). In addition, other anthropometric measures 
such as height, weight and BMI, biochemical variables in serum and 
calcium intake were collated as described in chapter 2. Associations 
between BMI, Ca intake, VF (visceral fat mass) and waist circumference 
(WC) were explored using linear regression analysis. Subjects were 
categorised into overweight and obese (OW/O) (BMI ≥ 25) or non-obese 
(NO) (BMI < 25) groups. Measured variables for the 2 groups were 
compared using a Student’s T test. The effects of age, weight, BMI and 
visceral fat mass on baseline BMD at each measured site was assessed by 
linear regression analysis. Bone loss at each site was calculated using the 
difference between the final BMD and baseline BMD. This measurement 
was then used to estimate the annual loss by dividing it by the number of 
months between measurements and multiplying by 12. Pearson’s product 
moment correlation coefficient was used to assess the strength of the 
relationship between annual bone loss (g/cm2) at each site and other 
measured variables. The variables that showed a significant relationship 
with annual bone loss for each site were used in multivariate regression 
analysis (SPSS Statistical Package, IBM, USA) to correct for these 
factors so that the effect of BMI on bone loss can be assessed.  
  
Results 
In this group of women, the estimated daily Ca intake was not related to 
BMI or VF. BMI, VF and WC were significantly correlated to each other 
(P=0.000). Variables significantly related to baseline BMD for each site 
are listed in table 9.1. Age was associated only with forearm BMD while 
BMI was strongly related to all sites.  
 
Table 9.2 lists the mean (SD) for measured variables for OW/O and NO 
groups with the level of significance (P) for differences between the 
groups.  Bone density was significantly higher at all measured sites in the 
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OW/O individuals while calcium intakes were not significantly different. 
Predictably OW/O individuals also had significantly higher fasting 
glucose levels. In addition, higher levels of PTH were found in OW/O 
subjects but lower levels of 25OHD compared to NO subjects.  
 
Table 9.1. Variables correlated with baseline BMD at each site and level 
of significance (P)  
 
Measured site variable P 
Lumbar spine BMI 0.000 
WC 0.007 
VF 0.004 
Femoral neck BMI 0.03 
WC 0.006 
VF 0.006 
Standard hip BMI 0.001 
WC 0.003 
VF 0.004 
Proximal forearm Age 0.04 
BMI 0.01 
WC 0.03 
Ultradistal forearm Age 0.001 
BMI 0.003 
 
BMI = body mass index, WC = waist circumference, VF = visceral fat 
mass.  
 
The Perason’s r correlation coefficient between the annual bone loss for 
each site and other variables suggested those listed in table 9.3 to have a 
significant correlation with the rate of bone loss. In addition, fasting 
glucose and total cholesterol were strongly related to visceral fat mass (P 
= 0.01 and 0.05 respectively). CTX and PTH were correlated with a P of 
0.05. 
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Table 9.2. Mean (SD) for measured parameters for the overweight or 
obese vs non-obese subjects 
 
 
Variable  Non-obese (n = 66) OW/Obese(n=63) P 
Age (yr)   60.1 (4.6)  61.1 (5.3) 0.12 
Weight (kg)  57.6 (9.1)  74.8 (9.9) 0.000 
Height (m)  1.67 (0.43)  1.62 (0.06) 0.15 
WC (cm)   77.4 (6.9)  90.9 (10.9) 0.000 
Visceral fat (g)  669.1 (237.4)  1141.4 (298.5) 0.000 
Lean mass (g)  1521.8 (181.9)  1484.2 (191.0) 0.13 
BMD (g/cm2)  0.9249 (0.1709)  1.0189 (.1675) 0.001 
BMC (g)   40.198 (8.025)  46.572 (9.424) 0.000 
LS BMD (g/cm2)  0.9865 (0.1963)  1.0941 (0.1904) 0.001 
FN BMD (g/cm2)  0.7789 (0.1078)  0.8406 (0.1353) 0.002 
Hip BMD (g/cm2)  0.8383 (0.1176)  0.9243 (0.1211) 0.000 
PFA BMD (g/cm2 ) 0.6406 (0.0962)  0.7320 (0.0756) 0.000 
UDFA BMD (g/cm2) 0.3095 (0.060)  0.3542 (0.0514) 0.003 
Ca intake (mg/d)  1142.8 (523.4)  1058.3 (485.2) 0.17 
Creatinine  (μmol/L) 59.5 (10.7)  61.6 (11.5) 0.42 
Fasting glucose (mmol/L) 4.4 (0.6)   4.8 (0.9)  0.002 
Total cholesterol (mmol/L) 5.4 (0.9)   5.5 (1.0)  0.38 
iCa (mmol/L)  1.22 (0.04)  1.23 (0.03) 0.08 
total Ca (mmol/L)  2.37 (0.09)  2.39 (0.08) 0.35 
PO4 (mmol/L)  1.15 (0.12)  1.14 (0.13) 0.25 
ALP (U/L)  79 (22)   87 (25)  0.03 
CTX (ng/L)  465.5 (179.5)  429.2 (187.1) 0.13 
PTH (pmol/L)  4.08 (1.09)  4.68 (1.99) 0.01 
25OHD (nmol/L)  78.7 (27.6)  69.2 (21.6) 0.01 
UCa/Cr (mmol/mol) 0.25 (0.13)  0.23 (0.15) 0.27 
Ca absorption  0.59 (0.26)  0.59 (0.17) 0.49 
 
OW = overweight; WC = waist circumference; BMC = bone mineral 
content (L2 – L4), LS = lumbar spine (L1 – L4), FN = femoral neck, 
PFA = proximal forearm, UDFA = ultradistal forearm, BMD = bone 
mineral density, iCa = calculated ionised calcium; UCa/Cr = urine 
calcium to creatinine ratio on fasting spot urine sample. 
Table 9.3. Variables correlated with rate of bone loss and level of 
significance (n=98) 
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Site variable P (<) 
Lumbar spine Age 0.05 
Femoral neck Ca absorption 0.05 
Proximal forearm 
 
Ca intake 0.001 
PTH  0.05 
VF 0.01 
Ultradistal forearm Ca intake 0.05 
 
Multiple linear regression analysis between the rate of loss and BMI was 
performed for each site, taking into consideration those variables that 
showed a significant relationship to the rate of bone loss at that specific 
site. Tables 9.4, 9.5, 9.6 and 9.7 show the regression analysis for lumbar 
spine, proximal forearm and ultradistal forearm respectively.  
 
Table 9.4. Multiple linear regression of rate of bone loss 
(g/cm2/year) at the lumbar spine (ALLS) on age and BMI 
(n=117) 
      SE  P 
ALLS  = 0.0015 x age   0.001  0.03 
  -0.0032 x BMI  0.001  0.67 
  -0.0109 g/cm2/year 
R2 = 0.040; adjusted R2 = 0.024; P = 0.09 
 
Table 9.5. Multiple linear regression of rate of bone loss 
(g/cm2/year) at the femoral neck (ALFN) on intestinal calcium 
absorption and BMI (n=117) 
      SE  P 
ALFN  = 0.0200 x abs   0.014  0.05 
  -0.0007 x BMI  0.000  0.18 
  -0.0096 g/cm2/year 
R2 = 0.043; adjusted R2 = 0.027; P = 0.07 
 144 
Table 9.6. Multiple linear regression of rate of bone loss 
(g/cm2/year) at the proximal forearm (ALPFA) on age, baseline 
PTH, calcium intake and BMI (n=113) 
      SE  P 
ALPFA  =-0.0014 x PTH  0.000  0.09 
   +1.728x10-6 x Ca intake 2.69x10-6 0.52 
   +5.166x10-6- x visceral fat 4.67x10-6 0.27 
  -0.0002 x BMI  0.000  0.48 
  -0.0072 g/cm2/year 
R2 = 0.049; adjusted R2 = 0.007; P = 0.33 
 
Table 9.7. Multiple linear regression of rate of bone loss 
(g/cm2/year) at the ultradistal forearm (ALUDFA) on calcium 
intake and BMI (n=116) 
      SE  P 
ALUDFA  =+4.5442x10-6 x Ca intake 1.84x10-6 0.01 
      -0.0002 x BMI  0.000  0.47 
     -0.0107 g/cm2/year 
R2 = 0.076; adjusted R2 = 0.046; P =0.062 
 
When corrected for variables that were significantly related to the rate of 
bone loss at each site, BMI was not associated with the rate of loss at any 
site. VF was not related to age or calcium intake when corrected for 
fasting glucose and total cholesterol. These results are shown in table 9.8.  
Table 9.8. Multiple linear regression of visceral fat mass (g) on 
age, fasting glucose, total cholesterol and calcium intake 
(n=114) 
       SE  P 
Visceral fat mass  =+2.117 X age  6.88  0.75 
           +145.5 X glucose  43.39  0.001 
       +56.71  cholesterol  34.46  0.10 
       -0.1099 X Ca intake 0.068  0.11 
         -68.8 g 
R2 = 0.135; adjusted R2 = 0.103; P = 0.889  
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Discussion 
Consistent with published data BMI was positively associated with BMD 
at all measured sites at baseline. An association between BMD and age 
was only observed at the forearm sites, suggesting that the effect of 
weight or BMI is stronger than that of age on BMD at the hip and spine. 
Data from the Framingham study group support this with their finding of 
greater impact of weight on weight bearing sites such as the hip and spine 
(340). VF and WC were also significantly related to BMD at weight 
bearing sites, suggesting that WC, an easily obtained measurement to 
diagnose metabolic syndrome, can be used as a surrogate marker for 
factors such as BMI and VF in predicting the effects on BMD. 
 
When the subjects were divided into OW/O and NO groups based on 
BMI, BMD at all measured sites were significantly higher in the OW/O 
group, while there was no difference in daily Ca intake, intestinal Ca 
absorption or urinary Ca excretion, suggesting that the effect of adiposity 
may be more significant than calcium intake in this group. There was no 
difference in CTX between the groups, suggesting a similar rate of bone 
turnover in the 2 groups. An explanation is that, the skeletal response of 
OW/O women to the same amount of dietary Ca is more significant than 
the response of NO women, as demonstrated in chapter 10 (347).  
Consistent with published data, OW/O women had higher PTH and 
lower 25OHD. It appears that OW/O women maintained a higher BMD 
despite higher levels of serum PTH and lower 25OHD compared to NO 
women. In addition, ALP was higher in OW/O women suggesting some 
element of fatty liver or a contribution from bone formation. 
 
The rate of bone loss was not associated with BMI. The rate of loss at the 
forearm was associated with Ca intake as described in chapter 5. PTH 
was strongly associated with the proximal forearm bone loss consistent 
with the widely accepted position that forearm bone (cortical bone) 
losses are more pronounced in primary hyperparathyroidism. However 
VF was also associated with bone loss at this site. 
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When factors significantly associated with bone loss at each site were 
corrected for, there was no significant relationship between the rate of 
bone loss and BMI. Although not significant, the rate of loss for all sites 
was negatively associated with BMI suggesting that a higher BMI may 
be related to a lower rate of bone loss.  
 
In contrast to published data, this study failed to show a significant 
association between Ca intake and BMI or VF. Notable is the analysis of 
NHANES III data set (1988 – 1994, 380 women and 7114 men) that 
found an inverse relationship between dietary Ca intake and the risk of 
greater body fat (348, 349). The weak association between Ca intake and 
VF in this study was however negative suggesting that a higher Ca intake 
tends to reduce VF. VF was strongly associated with fasting glucose.  
 
These findings suggest that there is an interaction between fat cells and 
bone metabolism, and this may be more pronounced in overweight or 
obese women, who maintain a higher BMD than non-obese women at 
similar intakes of Ca. This chapter and the following chapter strongly 
suggest that women with a greater amount of visceral fat utilise dietary 
Ca more efficiently. The physiological process involved in this ‘Calcium 
thrift’ in women with more fat cells may involve incretins, leptin and 













Acute effect of a supplemented milk drink on bone 
metabolism in healthy post-menopausal women is 
influenced by the metabolic syndrome 
Introduction 
Ingested calcium exerts a suppressive effect on bone resorption as 
demonstrated by a suppression of markers such as PTH and CTX 
following a dose of calcium. When a mixed meal including calcium is 
ingested, other nutrients in the meal may exert effects on skeletal 
metabolism. In addition, a dysregulation of metabolism of other 
nutrients, as in the metabolic syndrome (Met S), may impact on calcium 
metabolism and bone metabolism. In Met S, energy metabolism is 
thought to be dysregulated with impaired glucose metabolism as a key 
feature. High energy nutrient intake or caloric intake plays a role in the 
development of Met S. The concept of gut-brain-bone axis postulates that 
nutrient intake has feedback and feed forward effects on the 
hypothalamus that then exerts effects on skeletal metabolism. 
Osteocalcin secreted by osteoblasts has been shown to exert effects on 
pancreatic beta cells and regulate insulin secretion, which has a feed 
forward action on osteoblast metabolism. 
 
The following study was designed to investigate whether Met S had an 
impact on the suppressive effects of bone turnover exerted by calcium in 
postmenopausal women.  Briefly, 25 postmenopausal women were given 
200 mL of milk supplemented with 560mg additional calcium (Milo) 
once prior to bedtime. Fasting blood was collected for biochemistry 12 
hours after the drink. The baseline CTX level declined with rising 
abdominal fat mass as measured by DXA (P=0.04). While there was no 
significant drop in CTX after the drink in the group as a whole. When the 
women were divided to lean women and women with Met S (waist 
circumference ≥ 88cm) there was a significant fall in CTX in women 
with Met S after the supplemented milk drink. This suggests that bone 
turnover in overweight or obese women with Met S is more sensitive to 
 148 
dietary calcium intake. These findings are consistent with previous 
proposed theories of obesity protecting against osteoporosis, with close 
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Osteoporosis remains one of the most important public health concerns in 
the world. The burden of osteoporosis on society and economy is likely to 
rise with an aging population. Post-menopausal women are affected by 
osteoporosis due to oestrogen deficiency and other factors including genetic 
inheritance. Prevention of osteoporosis in this group is likely to increase 
their quality of life and productivity.  
The most inexpensive and accessible preventative measures of osteoporosis 
are adequate calcium, vitamin D and exercise. There is strong evidence that 
calcium supplementation with or without vitamin D is effective in the 
prevention of fractures albeit more effective with vitamin D. The evidence 
for dietary calcium preventing fractures is not as strong. Additionally 
shorter term studies investigating the effects of calcium supplementation in 
increasing bone density or preventing loss of bone report variable results. 
 
The data obtained from this study suggest that, despite public health 
campaigns promoting higher calcium intakes for post-menopausal women, 
most community dwelling women did not meet their daily requirement of 
calcium, consistent with published data for Australian women. However, the 
majority of them were vitamin D sufficient, consistent with reports for 
Australians over the age of 50 years.  
 
The major finding from this study suggest that higher intakes of calcium 
(dietary sources with or without supplemental calcium) in the short term (ie: 
in 2 years) does not increase or prevent the loss of bone at the lumbar spine 
and the hip. The ultradistal forearm, with a greater proportion of trabecular 
bone may respond to higher calcium intakes and the changes may be 
detectable by bone density.  
 
Two of the main findings of this study are that women with higher BMI and 
more visceral fat had higher bone densities compared to those with lower 
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BMI, and women with metabolic syndrome (higher waist circumference and 
more visceral fat) demonstrated a greater impact on bone resorption from a 
dietary calcium load. This is despite similar calcium intakes, lower 25OHD 
and higher PTH than women with lower BMI. They suggest that women 
with more visceral fat may require less calcium than lean women to 
maintain bone. Overall these results suggest that there is an important 
interaction between fat, bone metabolism and dietary calcium which may 
have implications on the calcium requirement. The biochemical processes 
involved in the gut-brain-bone axis require further investigation with PTH 
as a key hormone. The effect on weight gain and weight loss on PTH, and 
the effect on and response of PTH in anorexia and other catabolic states that 
lead to loss of fat as well as bone requires further investigation.  
 
The findings of this study suggest links between bone and energy 
metabolism, consistent with a growing body of evidence. Firstly, from a 
biochemical point of view, hormones affecting bone also affect fat cells. 
PTH has consistently been shown to be higher in men and women with 
greater body weight or BMI. Likewise hormones such as leptin and 
adiponectin traditionally assigned to adipocyte metabolism are now believed 
to be involved in bone metabolism. Secondly, women with higher BMI 
consistently demonstrate a greater bone density independent of their 
reported calcium intakes. Thirdly, as shown in Chapter 10, women with 
metabolic syndrome appeared to respond to a dietary calcium load more 
favourably than those without, in that, the rate of bone turnover showed a 
greater degree of suppression as a response to a calcium load in these 
women compared to lean women. This may be due to the link between 
energy and bone metabolism, and also suggests that adipocytes may play a 
role in the response to dietary calcium. The theoretical gut-brain-bone axis 
suggests that incretins released in response to certain nutrients may have an 
impact on bone turnover. Thus dietary loads of calcium when given together 
with carbohydrate, protein and fat, may lead to the release of incretins that 
have an influence on calcium homeostasis. 
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The women recruited to this study were healthy, independently living 
individuals. They enrolled in the study because they were ‘health conscious’ 
and wanted to be informed of their bone density. Although no feedback was 
given to them about their dietary calcium intakes, the baseline bone density 
was reported to them with an explanation of their fracture risk. Their 
calcium intake did not change significantly. Less than half of the women 
diagnosed with osteoporosis increased their calcium intake by increasing 
dietary intake rather than adding a supplement. This may be due to the 
negative publicity calcium supplements received at the time, due to the 
publication of cardiovascular effects of calcium.  
 
There are several limitations of this study. Firstly, at baseline, there was no 
significant difference between bone densities of women with adequate or 
lower calcium intakes. This suggests either the dietary calcium estimation 
may not be adequate or does not reflect the long term diet, or that dietary 
calcium may not have played a major role. However, when the effects of 
obesity and metabolic syndrome on bone are considered  the role of dietary 
calcium may become clear. Secondly, only the bone density at the ultradistal 
forearm showed any difference between high and low calcium intake 
women after 2 years. Technical issues such as positioning of the patient 
affects the femoral neck and total hip density measurements and may have 
introduced variability to the serial measurements, and osteoarthritis and 
other factors may have affected the lumbar spine measurement. The forearm 
is the least affected by positioning and may have been the most consistent 
measurement taken. In addition, 2 years may not be a sufficiently long time 
to detect major changes in bone density, and had the study continued for a 
longer period changes may have been detected at other sites. 
 
Thirdly the dietary calcium estimate may not be accurate due to the 
exclusion of a number of common food items. The online questionnaire was 
very extensive and many of the participants reported that it was difficult to 
complete in one sitting. There may have been instances when they ‘glossed 
over’ some questions which may have led to an over- or under-estimation of 
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their intakes, which also introduced inconsistency between the 2 
questionnaires. 
 
In conclusion, the ultradistal forearm density is more likely to show shorter-
term changes in response to calcium intakes, however this site is not 
recommended for the diagnosis of osteoporosis by the International Society 
of Clinical Densitometrists (ISCD). The response to dietary calcium by bone 
is modulated by energy metabolism, those with metabolic syndrome 
demonstrating more benefit in terms of reduced bone turnover. Women with 
lower calcium in the diet appeared to be more likely to be overweight or 
obese, suggesting an overall poorer diet, lifestyle or suggesting a role for 
calcium in the maintenance of healthy weight. 
 
The prevalence of osteoporosis in the study subjects was consistent with that 
published by a self-reported survey but much lower than the prevalence 
reported for an unselected Australian population. The average calcium 
intake in the women in the current study is higher than reported for the 
unselected Australian population therefore may not reflect the average 
calcium intake of Australian post-menopausal women. This suggests that 
the conclusions drawn from this study may be relevant to the community 
dwelling post-menopausal women who are health conscious and free of 
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APPENDIX 1 -  Information to Volunteers  
      
 
 
INFORMATION SHEET  
Protocol Name: Study of the relationship between dietary 
calcium and the rate of bone loss in postmenopausal women 
 
Investigators:  
 Dr S. Devika Thomas 
 Trainee Medical Officer 
 Division of Chemical Pathology, SA Pathology 
 
 Prof B.E. Christopher Nordin 
 Consultant Physician, Endocrine and Metabolic Unit 
 
 Professor Michael Horowitz 
 Director, Endocrine and Metabolic Unit 
 
 A/Prof Peter M. Clifton 
 Physiology Associate  
 School of Molecular and Biomedical Science, University of Adelaide 
 
 Dr Jennifer B. Keogh 
 Research Scientist, CSIRO Human Nutrition 
 
 Dr Penelope S. Coates 
 Clinical Director, Consultant Endocrinologist 
 Division of Chemical Pathology, SA Pathology 
 
1. Voluntary Study  
 
 You have been invited to join in a study of the relationship between 
dietary calcium and bone loss after the menopause.  This is a research 
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project and you do not have to be involved.  If you do not wish to 




 The evidence for a relation between calcium in the diet and the rate of 
bone loss after menopause is inconsistent. In this study, we will attempt 
to establish the relation between dietary calcium and the rate of bone loss 
in women like you.   
We will estimate your dietary calcium from a questionnaire which is 
enclosed. If you decide to participate in this study we will ask you to 
come back one morning without breakfast for a full blood and urine test 
and measurement of your calcium absorption with radiocalcium. We will 
then measure your bone density either on the same day or another day. If 
the bone density is too low you can withdraw from the study to have 
treatment. Otherwise we will ask you to stay on your usual diet and your 
bone density will be checked every 6 months for 2 years. Another blood 
test (without the calcium absorption or the urine test) will be performed 
between 12 months and 24 months from the start of the study. 
 
3. Possible benefits from the study 
 
 This study will be of benefit to you because it provides you with a bone 
density assessment and a lot of information about yourself.   Copies of the 
report can be sent to your General Practitioner if you wish.  If the initial 
bone density measurement shows that you have osteoporosis then you 
will be withdrawn from the study and given the option of attending the 
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Osteoporosis Clinic in the Royal Adelaide Hospital if you and your 
doctor wish it.  Any abnormalities in the blood tests will also be 
communicated to you and your doctor so that you can be treated. If your 
bone density below expected values during the course of this trial this 
will be communicated to your General Practitioner. 
 
4. What you will be asked to do 
(1) If, after reading the Information sheet you decide to take part 
in the study you will be asked to complete a food questionnaire either 
online or by mail. After this you will be given an appointment to attend 
the Endocrine Test Unit at the Royal Adelaide Hospital for an 
information session (45 minutes) during which you can ask questions 
and also sign a consent form.  You will then be given an appointment to 
attend the test unit after an overnight fast,   blood and urine specimens 
will then be taken.  You will then be given a drink (about 1 cup) 
containing radiolabelled calcium.  Another blood sample will be taken 1 
hour later to assess the amount of calcium you absorb.  The bone density 
measurement may be done on the same day (or on another day 
convenient to you).   
(2) After this initial visit, you will be contacted by telephone to 
arrange the next visit, which will only a bone density measurement and 
a food questionnaire (6 months).   
 The following table explains what is involved in each visit after you 
have consented to take part in the study.  
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   1st visit 2nd visit 3rd visit 4th visit Final visit 
  Timing: start 6 months 12 months 18 months 2 years 
  Blood test: Yes No Yes No No 
  Urine test: Yes No No No No 
  Calcium drink: Yes No  No No No 
  Bone density: Yes Yes  Yes Yes Yes 
  Food Yes Yes Yes Yes Yes 
  questionnaire:  
 
 
(3) It is important that you do not change your diet during this 
study. However, you can continue medication if it does not affect your 
bones.  If you start any new medication please let us know as soon as 
possible. 
5. Payment 
 We will cover your travel and parking expenses.  No further payment is 
available for the participation in this study but you will be provided with 
information gained from the tests.  
 
 
6. Possible risks from the Study 
 i. Blood samples are drawn from the vein on the inside of your 
elbow. Some bruising and swelling can occasionally occur and will be 
treated at the test unit.         
 
 ii. This research study involves exposure to a very small amount of 
radiation.  As part of every day living everyone is exposed to naturally 
occurring background radiation and receives a dose of about 2 
millisieverts (mSv) each year.  The effective dose from this study is 
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about 0.33 mSv. At this dose level no harmful effects of radiation have 
been demonstrated as any effect is too small to measure. The risks are 
believed to be very small. You should not be pregnant at the time of any 
radiation test (absorption study and the bone density measurements). If 
you are pregnant or planning to become pregnant please let us know as 
soon as possible. 
 iii. You will receive dietary advice and other information regarding 
prevention of osteoporosis at the end of the study. 
 
7.   Confidentiality 
 The data gathered in the trial will be securely stored for 15 years. All 
data points will be deidentified (ie given a number or symbol rather than 
your name). If the results are published in a scientific journal all data will 
be similarly deidentified and your identities will be kept confidential. 
 
8. Further information  
 If you have any concerns or need further information about this study, 
please contact Dr Thomas (telephone 8222 3611 or 0401120720).  
 If you wish to speak to someone not directly involved in the study 
about your rights as a volunteer, or about the conduct of the study, you 
may also contact the Chairman of the Human Ethics Committee, Royal 







    APPENDIX 2 – letter to volunteers 
 
Dr Devika Thomas 
Chemical Pathology 








Dear Mrs Smith 
 
Re: Diet and Bone Density Study 
 
Thank you for your interest in our study looking at the link between 
your diet and your bone density. I have enclosed an information sheet 
and 2 questionnaires. Please read the information carefully and if you 
would like to participate in our study, fill out the diet and general health 
questionnaires. Please return these 2 questionnaires in the stamped 
envelope.  
 Upon receipt of the questionnaires I will contact you to make 
appointments for your bone density scans and blood test. 










     APPENDIX 3 – Brief Health Questionnaie 
 
ROYAL ADELAIDE HOSPITAL 
Comparison of the effects of calcium tablets alone with effects of 








Date of birth………………………………………………… 
 
 
Date of last menstrual period…………………………………… 
 
 
Was your menopause surgical or natural?……………………… 
 
 






Have you had any treatment for bone loss?………………… 
 
 
If yes, when did it stop?………………………………………… 
 
 
Have you any current illnesses?………………………………… 
 
 
Have you had any hormone replacement therapy?…………… 
 
If yes, when did it stop?………………………………………… 
 
 
Please place this completed questionnaire in the envelope supplied 
together with the completed “Dietary Calcium and Physical Activity 




 APPENDIX 4  Short Questionnaire for estimating daily calcium 
intake 
 
DIETARY CALCIUM QUESTIONNAIRE 
 
Name:………………………………………….    
Date:………………………   Date of Birth:……………………  Sex:F/M 
 
This questionnaire has been designed to assist in estimating your dietary 
calcium intake. While your food intake may vary from time to time, try to 
give answers that reflect your normal, ‘yearly average (summer/winter)’ 
intake to the questions asked. If the ‘standard serve’ size given in some of 
the questions does not reflect your usual normal serve size, adjust your 
normal serve size to reflect the standard serve size (eg. Two of your 
‘normal’ large (300mL) glasses of milk per week would become three 
‘standard’ serve sizes (200mL) of milk), or please make a comment near 
the question. 
 
Please read carefully before answering the questions. Then be as accurate 
as you can be and give an answer to every question on both sides of the 
paper.  
 
For office use only 
 
1. Do you have an intolerance or allergy to any foods?   
Yes  /  No 
 (Please circle the correct answer) 
         If ‘Yes’, what foods? 
 
2. What type of milk do you usually buy? 
(eg: wholemilk, skimmer, tone, Goats’ milk, soy milk) 
 
3. How many of the following beverages do you have 
during One Day? 
a) Tea      _______                      c) Herbal Tea      _________ 
b) Coffee ____                           d) Coffee substitute _ 
 
4. Do you have milk in the following beverages? 
         (please circle the correct answer) 
a) Tea        Yes  /  No            c) Herbal Tea         Yes  /  No                            





5. How many days of the week do you have breakfast 
cereal, porridge or muesli?  _____________ days per week 
 
 
6. How many cups of milk do you usually add to your 
breakfast cereal, porridge or muesli?  (please circle the 
correct answer) 
 






7. How many of the following drinks do you have in One  
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Week? 
a) Glass of milk (200 mL)_________________ 
b) Glass of milk based drinks (200 mL)_______ 
(eg: flavoured milk, milkshake, hot cocoa, Milo) 
8. How many serves of the following foods do you have in 
One Week? 
a) Cheese  (all types) - 1 slice (30 gram) ______________ 
b) Yoghurt – 1 carton (200 gram) ____________________ 
c) Custard or milk based puddings – ½ cup 
(eg: Blancmange, junket, mousse, cheese cake) ________ 
d) salmon, mackerel, sardine – ‘1 serve’ ____________ 
 
9. Do you add salt: 
a) when cooking and preparing meal ?  Yes  /  No 
b) to your meal at the table ?                  Yes  /  No 
 
10. Do you take any calcium supplements ?        Yes  /  No 




For Office Use 
#. Baseline for regular, balanced diet = 300mg calcium 
Q3./Q4. – Milk in each beverage = 35mg Ca.  
Q6. ½ cup = 150mg Ca. 1 cup = 300mg Ca. 
Q8. a) 30gram = 200mg Ca 
      b) 200gram = 350mg Ca 
        c) ½ cup = 125mg Ca 
       d) 1 serve = 200mg Ca 
Q7. 200mL = 240 mg Ca.                        





APPENDIX 5 – letter to volunteers after completion of Brief 
Health Questionnaire  
Study of the relationship between bone density and diet. 
Thank you for completing the surveys for the above project. Your 
personal details will be stored for the purposes of contacting you for 
future appointments. All results obtained will be numbered so your 
identity will remain confidential. 
 
The blood tests (includes a urine test) take 1 hour and are done at the 
RAH. They can be done any day of the week (except Thursdays), They 
are done first thing in the morning, starting anytime from 0800. You 
need to fast from the night before from about 10 pm. You are allowed 
water until about 7am on the day of the test. If you take multivitamins or 
calcium tablets please hold off on them the day before and the day of the 
test.  All other medication is OK. 
 
The tests are done on level 9. You need to come in via the Main 
Entrance on North Terrace, and walk past the escalators and take the 
yellow Out Patient Lift (located behind and to the left of the escalators) 
to level 9. As you exit the lift turn left and you will see a small sign to 
the Endocrine Test Unit. The tests are done there and I will meet you 
there. 
You can directly book the blood test at the Royal Adelaide hospital by 
ringing 82225505. Alternately if you wish to have your tests done at 
your local IMVS collection centre, let me know via email and I can post 
you a blood test request form and contact information for them. Please 
tell them you are coming for the calcium absorption as well as part of 
the research study, so that they can have the drink prepared for you. 
(they will need a few days’ notice). Let me know when you have made 
the appointment for (if coming to RAH).  
 
If you prefer, you can have your blood tests done at a local IMVS 
centre. You need to ring them and make the appointment quoting 
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calcium absorption test, with 2 days notice. There is also a urine test, 
and a container will be provided to you when you arrive for the test. I 
have enclosed the phone numbers for IMVS collection centres. 
 
For Bone density scans you need to ring the bone density unit directly 
on 82225520 and speak to Jody or Fiona so that you can make that 
appointment at a time convenient for you. It takes about half an hour 
and they are done on level 7 in the RAH. They are located in the 
Emergency block and you will be given direction. When you have done 
your bone density scan  please make sure that you make another 
appointment to come back in 6 months for your second appointment. 
There are a total of 5 bone densities, one every 6 months. 
You may be able to book the blood tests and the bone density on the 
same day. 
When you have made the bookings, please let me know when you are 
coming in for them. 
If you have any difficulties with the appointments, let me know and I 
will try and sort them out. 
Alternately, I can book these for you. This may involve phone calls and 
emails back and forth because I will be liaising between you and the 
respective departments. 
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